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ABSTRACT: The cost of discovering a new drug has doubled every 9 years since the 1950s. 
This can change by using machine learning to guide experimentation. The idea I have developed 
over the course of my PhD is that using latent factor modeling (LFM) of the drug-target 
interaction network, we can guide drug repurposable efforts to achieve transformative 
improvements. By better characterizing the drug-target interaction network, it is possible to use 
currently approved drugs to achieve therapies for diseases that currently are not optimally treated. 
These drugs might be directly used through repurposing, or they can serve as a starting point for 
new drug discovery efforts where they are optimized through medicinal chemistry methods. To 
achieve this goal, I have developed LFM-based techniques applicable to existing databases of 
drug-target interaction networks. Specifically, I have started out by establishing that probabilistic 
matrix factorization (PMF; one type of LFM algorithm) can be used as descriptors by showing 
they capture therapeutic function similarities that state-of-the-art 3D chemical similarity methods 
could not capture. Then I have shown that PMF can effectively predict unknown drug-target 
interactions. Furthermore, I have used newly developed computational techniques for discovering 
repurposable drugs for two diseases, α1 antitrypsin (1-AT) deficiency (ATD) and Huntington’s 
disease (HD) leading to successful discoveries in both. For ATD, two sets of data generated by 
the David Perlmutter and Gary Silverman laboratories have been used as input to deduce 
potential targets and repurposable drugs: (i) a high throughput screening data from a genome-
wide RNAi knockdown in a C. elegans model for studying ATZ (Z-allele of 1-AT), and (ii) 
data from Prestwick library screen for the same model. We have predicted that the antidiabetic 
drug glibenclamide would be beneficial against ATZ aggregation, and data collected to date in 
Mus musculus models are promising. We have worked on HD with the Robert Friedlander lab, 
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by examining the potential drugs and implicated pathways for 15 neuroprotective (repurposable) 
drugs that they have identified in a two-stage screening study. Based on LFM-based analysis of 
the targets of these drugs, we have developed a number of hypotheses to be tested. Among them, 
the antihypertensive drug sodium nitroprusside appears to be effective against HD based on 
neuronal cell death inhibition experiments that were conducted at the University of Pittsburgh 
Drug Discovery Institute as well as the Friedlander lab. Finally, we have built a web server, 
named BalestraWeb, for facilitating the use of PMF in repurposable drug identification by the 
broader community. BalestraWeb enables users to extract information on known and potential 
targets (or drugs) for any approved drug (or target), simply by entering the name of the query 
drug (or target). I have also laid out the framework for developing an integrated resource for 
quantitative systems pharmacology, Balestra toolkit (BalestraTK), which would take advantage 
of existing databases such as STITCH, UniProt, and PubChem.  Collectively, our results provide 
firm evidence for the potential utility of machine learning techniques for assisting in drug 
discovery. 
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1.0  INTRODUCTION 
The pharmaceutical industry is in a crisis: for every one dollar’s worth of patent-protected 
therapeutic revenue expiring, the industry can generate only 26 cents of revenue through new 
patented therapeutics [1]; bringing a new molecular entity to the market is estimated to cost 
around $1.8 billion [2]; the rate of new drug discovery per billion dollars of research and 
development spending has steadily halved every 9 years for the last 60 years giving credence to 
the so-called “Eroom’s Law” which is “Moore’s Law” read backwards [3]; and the success rate 
in the present drug discovery and development process (from beginning to end) is only 4% [2]. 
Moreover, we are witnessing a major shift in the pharmaceutical industry financial landscape, 
with major companies being driven toward mergers in order to create a larger “pipeline” of 
potential drugs to supplement the low R&D productivity with this trend having started more than 
a decade ago [4]. However even these merged giants could deliver only eleven FDA approved 
drugs out of the thirty approved in 2011 [5]. The culmination of these difficulties is that 
traditional pharma companies are reported to have lost 2% sales and 2.5% earnings in the first 
half of 2014 compared to their reported sales and earnings from one year ago [6]. 
The main causes of this crisis have been debated for a long time. The arguments put 
forward range from the perceived lack of managerial success [7] to the improper structuring of 
R&D divisions [3]. Yet, there is another set of arguments that suggest that the problem at the 
heart of the matter is more scientific than managerial: Hopkins and Overington have been 
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pioneering of the idea of multiple-target modulation and the replacement of the high affinity 
binding of a single peptide paradigm by polypharmacology paradigm for years [8-10]. Many 
other scientists have also emphasized the need for a paradigm shift, as there has been a mounting 
evidence on  the promiscuity of drugs as well as targets [11-15].  
The efficiency of drug discovery and development might be improved by adopting a 
systemic approach that takes into consideration the interaction of existing drugs and candidate 
compounds with the entire network of proteins and other biomolecules in a cell [16]. This 
approach can either be used for repurposing, or it can be used to inform de novo drug discovery. 
To give a specific example about the latter use, we can make inferences on the drugs that share a 
common therapeutic activity with other drugs and use such inferences for hit diversification. 
Alternatively, we can identify the targets that are similar in their interaction patterns with known 
drugs, despite being dissimilar in structure or sequence and uncover novel biochemical 
properties, or potentially even biological pathways. Therefore there is a multitude of ways in 
which a systematic analysis of the interactome can reveal novel, useful insights. 
The often-cited scientific justification for the paradigm shift is the observation that most 
single-target manipulations do not perturb biological systems: a pioneering work by Hillenmeyer 
et al. reports that only 34% of gene deletions result in disease or lethality, however 97% of the 
gene knockouts results in a phenotypic catastrophe when the gene deletion is combined with one 
or more small molecules under a specific environmental condition [17]. Moreover, the early 
work of Barabasi and Oltvai has established that most biological networks are essentially scale-
free [18], which further corroborates the observation that single-target modulation of biological 
networks can have limited effect due to the fact that in a scale-free network most single-target 
perturbations will have minimal effect whereas those that fall on ‘hubs’ will have too strong an 
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effect which in turn would make it hard to use as a therapeutic intervention. The relatively high 
ratio of drug failures due to safety concerns, reported as accounting for more than half of all 
failed projects in one recent review [19] and accounting for 20% of all phase II failures in 
another review [20] can be arguably be attributed, among other reasons, to the toxicity impact of 
modulating the so-called hub nodes of the scale-free biological network that comprises the cell. 
Furthermore the observation that the topological organization of the biological networks strongly 
reflects the underlying functional relationships [21] also helps develop an appreciation of 
pharmacological therapy as the modulation of a biological network instead of a simple ‘lock-
and-key’ problem. Indeed, the “one gene, one drug, one disease” paradigm is now widely 
recognized to fail in describing experimental observations [8]. Many drugs act on multiple 
targets, and many targets are themselves involved in multiple pathways. For example, -lactam 
antibiotics and most antipsychotic drugs exert their effect through interactions with multiple 
proteins [10;22]. Biological networks are highly robust to single-gene knockouts, as recently 
shown for yeast where 80% of the gene knockouts did not affect cell survival [17]. Similarly, a 
recent study showed that 81% of the 1,500 genes knocked out in mice would not cause 
embryonic lethality, further corroborating the robustness of biological networks against single 
target perturbagens [23].  
These results suggest that quantitative systems pharmacology (QSP) strategies that take 
account of target (and drug) promiscuities can present attractive alternative routes to drug 
discovery.  QSP approaches take into account complex biomolecular interactions in their cellular 
context. They combine computational and experimental studies in order to develop new 
compounds [22]. This requires a systems-level understanding of the biological process of 
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interest, with detailed higher resolution modeling of the specific biochemical pathways of 
interest; along with supporting experimental data to help inform the entire effort.  
The dissertation contains work that requires a broad base of understanding in both 
computational and biological disciplines. A major contribution to the field is the adoption of 
latent factor modeling (LFM) methods for analyzing the bipartite network of drug-target 
interactions and making predictions on potential new drug-target association.  Therefore, I 
present below the background for different methods of computational drug-target interaction 
prediction. Furthermore, I also briefly present the background on two specific diseases, α-1 
antitrypsin deficiency (ATD) and Huntington’s disease (HD), which have been examined as two 
application areas of biological significance within the scope of this dissertation. 
1.1 BACKGROUND ON COMPUTATIONAL METHODS 
Recent years have seen many network-based models adopted to reduce the complexity of, and 
efficiently explore, drug-target interaction systems [10;22;24;25]. In particular, the development 
of computational methods that can efficiently assess potential new interactions became an 
important goal. Computational approaches used to predict unknown drug-target interactions can 
be divided into roughly four categories:  
I. Chemical-similarity-based methods [26-28], 
II. Integrative (both target- and chemical-similarity-based) methods [29-35], 
III. Holistic approaches [36-41], 
IV. Target-similarity-based methods [42-44]. 
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The first two posit that if two entities are chemically or structurally similar they will share 
interactions – which is an assumption that may hold in multiple cases. However it is not 
guaranteed to hold universally as dissimilar chemicals can bind to different sites on the same 
protein and/or have allosteric effects. Furthermore the utility of different methods may depend on 
the size of the dataset being analyzed, e.g. computing chemical-chemical and target-target 
similarity matrices can be problematic for large databases like STITCH [45] (STITCH v3.1 has 
210 million interactions between 2.6 million proteins and 300,000 chemicals). To overcome 
these limitations, holistic methods have been introduced, which utilize a number of different data 
sources such as gene expression perturbation [37;38] or high-throughput screening [40].  
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Figure 1: Summary categorization of current computational methods for polypharmacology predictions  
One representative study from each main category is shown, along with figure(s) from the cited work to illustrate the 
results. The bar chart for ligand-centric methods shows that the interaction between DMT and 5-HT2A predicted by 
the method has been experimentally validated [28]. The figure in the holistic methods section shows that the 
validation of the prediction that topiramate would be useful in inflammatory bowel disease [37]. On the target-
centric methods, the inset figure shows the ligand-binding site similarity between two target proteins, COMT and 
InhA, which serves as the basis for their subsequently validated prediction that comtan, an inhibitor of the COMT, 
would also inhibit InhA [42]. (see text for details). 
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1.1.1 Ligand-Centric Approaches 
Among the ligand centric methods, the most significant is the Similarity Ensemble Approach 
(SEA) [26-28]. The SEA method was introduced by the Shoichet laboratory, in an article where 
they first used the method to relate protein pairs through similarities between their known ligands 
[26]. Later, this idea was adapted to drug repurposing predictions by comparing a single query 
chemical to all the known binders of each known protein [28]. More recently, predictions made 
by this method on a side effect target set were tested in a high throughput scheme by Novartis, in 
order to provide an unbiased assessment of the capabilities of the method: about 22% of the 
experimentally tested predictions turned out to be true predictions [27]. 
The SEA method is based on the calculation of the chemical similarity between the two 
sets of ligands known to interact with two different targets. Shoichet and coworkers have used 
the MDDR database [46] to retrieve data on the chemicals and their targets. They have used the 
2D fingerprint similarity method (also known as Tanimoto similarity) to calculate the pairwise 
similarity between chemicals. This method entails the conversion of a chemical structure into a 
binary vector where each element of the vector indicates the presence/absence of a specific 
chemical feature. The similarity between two chemicals is then calculated by dividing the 
number of shared features by the total number of unique features present in both molecule 
vectors [47]. They have adapted the BLAST algorithm [48] to calculate the expectation that the 
chemical similarity between a set of chemicals and a specific query chemical of interest can be 
observed by chance. Using SEA, the authors have calculated the chemical similarity between a 
query chemical and all chemicals known to interact with a particular target. If a particular 
chemical is statistically significantly similar to all the drugs that are known to share a particular 
target, then it is predicted that this chemical would also work against that target.  
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The advantages of this method are that it can be easily applied to novel chemicals with no 
previously known interactions, and that it is rapid since it relies on chemical fingerprint based 
vector operations (which are efficient). The disadvantages are that it requires the target to have a 
large set of known and validated interaction partners (i.e. drugs).  
1.1.2 Integrative Approaches 
The methods that integrate chemical and biological information to generate polypharmacology 
predictions are termed here “integrative methods”. Encapsulating as much information as 
possible to boost performance is an attractive idea. Consequently there is a significant body of 
research that focuses on the use of integrative approaches for polypharmacology prediction. 
There are multiple such methods: the kernel regression method [29], bipartite local models [31], 
integrated bipartite graph inference [32],  SITAR [33], the unified probabilistic framework [35] 
and the Bayesian Matrix Factorization method [34].  
The bipartite graph learning method of Yamanishi et al. is a good example of an 
integrative approach since it fundamentally describes a way of mapping drugs and proteins into 
the integrated ‘pharmacological space’ to then use proximity in this space to be indicative of 
interaction [29]. Moreover, this approach has been shown to work better than related studies [41] 
and has been the foundation for further techniques.  Therefore I will discuss this method in some 
detail.  
The authors employ three methods of generating polypharmacology predictions; all 
relying on calculating the similarity among chemicals, and likewise among proteins. The 
similarity between drugs is computed using the Tanimoto score for chemical fingerprints; the 
similarity between the targets is computed as the normalized Smith-Waterman score between the 
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two sequences. The first method they describe is the nearest profile method, where they assign 
each new compound the interaction profile of the compound which has the highest similarity to 
the query. The second method is the weighted profile method where they weigh the interaction of 
each compound to compute the final interaction vector assigned to a query as the weighted sum 
of all the interaction vectors for all compounds with the weights being the similarity between the 
compounds. All the above described operations can also be applied for proteins to predict the 
drugs that would interact, since drugs and proteins are interchangeable with this methodology. 
Finally, they describe a novel method called the bipartite graph learning method, which employs 
a kernel regression model.  
The bipartite graph learning method first entails the construction of a distance matrix K 
of size N + M between all compounds and proteins, where N is the number of compounds, M is 
the number of proteins. The element Ki,j is the similarity between elements i,j if they are of the 
same type (i.e. both drugs or both proteins) or the shortest distance in the bipartite connectivity 
graph if they are of different types (i.e. one drug and the other protein, or vice versa). The matrix 
K is then decomposed into its eigenvalues and eigenvectors: 
T
UUΓΛΓΛK  2121  (1)  
where Λ  is the diagonal matrix of the  eigenvalues and the columns of matrix Γ  are the 
eigenvectors and 21ΓΛU  . The row vectors of U are then used to represent each drug and 
protein in the training set in an integrated ‘unified feature space’. Then a weight is learned for 
each compound and protein in the training set using kernel regression model, which entails 
finding the set of weights that minimize the loss function: 
2
F
TTT
SSWWUUL   (2)  
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where S is the similarity matrix and W is the weight matrix and 
F
.  is the Frobenius norm. To 
map a new compound to the integrated space, the vector corresponding to the new compound in 
the pharmacological space must be computed. This vector is computed as follows: 
 


c
inew
n
i
cinewcinewcc ccsccf
1
,),( wu  (3)  
where 
ic
w  is a weight vector and  .  ,  .cs  is a chemical structure similarity score. Likewise for 
proteins,  
 


g
jnew
n
j
gjnewgjnewgg ggsggf
1
,),( wu  (4)  
where 
jg
w  is a weight vector and  .  ,  .gs  is a sequence similarity score. Finally, when a drug-
target pair is queried for interaction, the drug and target are both mapped to the integrated space, 
and the dot product between their coordinate vectors in the integrated space is used as a measure 
of closeness between the query drug and target. If the drug and target are closer than a set 
threshold, they are declared to be interacting. The most important strength of this method is that 
it requires only the sequence of the proteins and just the chemical structure of the small-
molecules (both of which are always available) therefore it is broadly applicable. The method 
has been later improved upon addition of pharmacological information [32].  
The later work of Bleakley and Yamanishi treats polypharmacology predictions as a 
supervised learning problem [31]. Given a drug-target pair (di, tj), the method entails labeling all 
proteins known to interact with di as one class (labeled +1) and all other proteins as another class 
(labeled -1), with a classifier trained to distinguish the interactors from the rest based on protein 
sequence. Then this classifier is used to predict the label of tj. The same procedure is repeated to 
train a classifier that distinguishes drugs interacting with tj (labeled +1) from the rest (labeled -1) 
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based on the chemical structure of the drugs. Perlman et al. proposed to integrate many different 
similarity measures for comparing drugs and targets to define numerous features, which are then 
used to train classifiers for making polypharmacology predictions [33]. Five sources of 
information are used to compare a pair of drugs: chemical structure, side effect, perturbation of 
gene expression, ATC
1
 code and finally ligand similarity. The ligand similarity is the overlap 
between the sets of SEA-predicted targets for each chemical [28]. The proteins are compared 
using sequence similarity, proximity in a protein-protein interaction network and overlap of 
Gene Ontology annotations [49]. The features are defined as one (out of five) chemical-chemical 
comparison method and one (out of three) protein-protein comparison method, for a total of 15 
features. Then given a query drug-target pair, the similarity score of a feature is computed as: 
10 ,),(),(max),( 121,',' 

 rttSddStdScore
rr
tdtd  (5)  
                              
          
            where S1 is the feature’s drug-drug 
comparison method and S2 is the feature’s protein-protein comparison method, with r optimized 
through cross-validation. The authors then use forward-propagation feature selection (initially no 
features, most useful feature is added at each step) and backward-elimination (initially all 
features, most useless feature is dropped) to select 10 features that both techniques identified as 
useful. They then trained a logistic regression classifier on this feature set to separate the 
interacting pairs from the non-interacting ones. The authors report a classification performance 
of AUC
2
 = 0.935 for their method, SITAR; whereas the kernel regression method of [29] is 
reported to have AUC=0.884 and the bipartite local models method [31] yields AUC=0.814. 
                                                 
1
 ATC: Anatomical, Therapeutic and Chemical classification system 
2AUC: Area under the Receiver-Operator Characteristic curve; a classifier performance metric where the best 
possible classifier scores 1 and the worst possible classifier (random classification) scores 0.5. 
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SITAR is an excellent example of the utility of integrating multiple techniques for comparative 
analysis of drugs/proteins.  
In the same spirit, Swann and coworkers suggested a method for integrating many diverse 
structure- and ligand-based comparison results to predict protein-chemical interactions in a 
robust manner [35]. Their method requires knowledge of actives and decoys
3
 for each target. 
Given the actives / decoys for a target and a particular comparison technique they bin the range 
of scores computed by the method, then divide the number of actives in each bin by the total 
number of compounds (actives and decoys) in that bin to assign the probability of activity for the 
bin. They call this probability the ‘belief’ that the result from this technique is true. They assign 
such defined activity probabilities for the docking score computed by the FRED [50] and GLIDE 
[51] docking programs with four different force fields; the ECFP6 chemical fingerprint [52] 
overlap (Tanimoto score, computed as described when discussing the ligand-centric approaches) 
and ROCS three-dimensional spatial and physicochemical property overlap. They integrate the 
entire set of activity probabilities (which they term ‘beliefs’) to get the cumulative belief score as 
follows:  



N
i
iPbeliefcumulative
1
)1(1   (6)  
where    is the belief from the i
th
 technique and N is the total number of techniques used. The 
authors argue that the strength of the method is in its capability to incorporate new scoring 
functions. The orthogonality of the data sources that they integrate is a strong advantage. 
However their assignment of ‘beliefs’ is dependent on the presence on actives and decoys for a 
given target, which restricts their method only to targets that are already well-characterized.  
                                                 
3 Decoys are compounds with no known activity against the target of interest. 
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Finally, the first fully probabilistic formulation for drug-target interaction network 
inference is the Bayesian Matrix Factorization method proposed by Gonen [34]. This method 
entails projecting the drugs and proteins into the same (integrated) subspace, through the use of 
chemical and genomic kernels respectively. The study uses the same dataset as that of [29] 
described above, therefore the genomic and chemical kernels are exactly as described above: 
chemical fingerprint similarity for the chemical similarity kernel and Smith-Waterman based 
sequence similarity for the genomic kernel. The low-dimensional projections in the integrated 
space are then used to compute interaction scores between drugs and targets using a factorization 
of the interaction matrix. Any given new drug or target can be mapped to the integrated space 
through the use of the relevant kernel and once it is projected onto the integrated space, its 
interaction scores can be computed as well. This way, the interaction between a new compound 
and known targets, a new target and known drugs or a new drug and a new target can be 
estimated. For automatic complexity control, the probabilistic representation has been applied 
Bayesian treatment by the introduction of priors and therefore exact and optimal inference of the 
posterior is very hard. There are two techniques that can be applied: variational approximation or 
sampling procedures. Gonen opted to adopt variational approximation which entails using a 
factorized version of the posterior distribution of the probabilistic representation as a lower 
bound on the marginal likelihood and then optimizing that bound. The author reports better AUC 
values than those acquired earlier [32]. However an earlier study [33] reported higher AUC 
values for all four types of targets. Secondly, others have reported that sampling-based inference 
procedures have advantages over variational approximations for Bayesian matrix factorization 
[53]. Nevertheless, this work is valuable as a first fully probabilistic formulation of the 
polypharmacology prediction problem. 
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The main advantage of integrative approaches is that they can utilize drug and target 
similarity calculation methods in making predictions. This can be beneficial when making 
predictions on drugs and targets with no other previously known interactions (either newly 
synthesized chemicals, or newly characterized genes). Furthermore after learning is completed, 
making a new prediction can be quite efficient. However the reliance on the similarity 
calculation methods (chemical or genomic) is also a major disadvantage: chemical or genomic 
similarity does not necessarily imply interaction similarity. Drugs with different chemical 
moeities can bind different sites on the same protein, thus sharing the same target. Alternatively 
two targets with similar sequences can have major differences in the ligand recognition site, 
thereby having different interaction characteristics despite being highly similar in sequence.  
1.1.3 Holistic Approaches 
Holistic approaches are distinguished by their being independent from information on individual 
targets. Their advantage is that they allow for a broader assessment of the activity of a compound 
and they can be used when there is not enough data for using one of the other approaches. Most 
of these methods take advantage of the high-throughput screening (HTS) methodologies 
developed in the last two decades. The significant methods that can be categorized under this 
umbrella are the following: connectivity map (CMap) [36-38], guilt-by-association (GBA) [39], 
the Bioactivity Profile Similarity Search (BASS) [40], and PREDICT [41]. A comprehensive 
review of these methods can be found in [16]. Cancer has been highlighted as being a disease 
where these holistic methods can play a particularly important role in the development of novel 
therapies [54]. Finally, multi-scale holistic models that integrate data spanning across multiple 
levels of biological organizations have been described [55]. 
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The CMap approach is a pioneering work that established the idea of anti-correlating the 
effect of a perturbagen with the impact of a disease for predicting activity [36]. To measure the 
phenotypic response to different perturbagens and diseases, the authors used a microarray 
mRNA expression assay and computed the up/down-regulation patterns. The perturbagens that 
correlate positively mimic the effect of the disease while those that correlate negatively have the 
potential to restore the normal phenotype. The authors have studied 164 small molecule 
perturbagens in 4 cell lines (with most of their results in the breast cancer epithelial cell line 
MCF7). They showed that their method can capture the anti-estrogenic activity of fulvestrant 
because the response to this perturbagen and that to treatment with estrogen anti-correlate; 
among other success stories. This work has established the idea behind holistic approaches to 
polypharmacological predictions.  
CMap has been successfully applied to repurpose the anticonvulsant topiramate for 
inflammatory bowel disease [37] and the antiulcer drug cimetidine as a therapeutic for lung 
adenocarcinoma (LA) [38]. In these studies, the authors have downloaded gene expression 
signatures characterizing 100 diseases from the Gene Expression Omnibus [56] and then anti-
correlated these signatures with the 164 drug signatures in CMap, as described above. The two 
images in the lower part of the middle section in Figure 1 are reproduced from [37] and they 
show the clinical endoscopy of mice that were treated with TNBS to induce inflammatory bowel 
disease with and without treatment with topiramate. The therapeutic impact of topiramate can be 
clearly seen. Similarly, the authors of [38] showed that tumors treated with cimetidine shrunk in 
size. These results serve to illustrate that computational strategies are viable methods for 
assessing polypharmacology and drug repurposable possibilities. At the very least, these 
strategies give good starting points at a favorable cost/benefit ratio. The major advantage of 
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CMap is that it can make clinically relevant predictions without requiring a detailed 
understanding of the mechanism. However, the major disadvantage is that it requires 
transcriptomic profiling of the entire chemical library.  
The guilt-by-association method was first introduced by Chiang and Butte [39]. 
Fundamentally this method is based on the idea that when two diseases share a therapy, then the 
therapies that are known to work for only one of them might also work for the other. With this 
starting point, the authors investigated 726 diseases and 2,022 drugs for pairs of diseases that 
share at least one therapeutic using the data in the DRUGDEX system (Thomson Healthcare, 
Greenwood Village, CO) and the Drug-Disease Knowledge Base (DrDKB). They then predicted 
that the drugs known to work for one disease but not the other, would work for both diseases. 
They found that their drug use suggestions were 12 times more likely to be undergoing clinical 
trials than a random drug-disease pair not within their suggestion set. The main disadvantage of 
this approach is the high false positive rate. 
Predicting drug-disease associations directly has been a direction that the developers of 
SITAR have also taken with their development of PREDICT [41]. PREDICT compares the drugs 
using their targets  in addition to chemical structure similarity and side effect similarity. The 
diseases are compared with the text-mining based semantic similarity of disease phenotype 
information and overlap between human phenotype ontology entries. They used a total of 593 
drugs and 313 diseases by merging data from DrugBank [57], KEGG Drug [58], Matador [59], 
OMIM [60] and UMLS [61] to create the list of drug-disease associations. Each feature consists 
of one drug-drug comparison method and one disease-disease comparison method. For a given 
drug-disease pair, the value of each feature is computed using the scoring scheme in SITAR. 
Then a logistic regression classifier is trained on these features using the known drug-disease 
 17   
associations (from the databases listed above) as training data to classify a given drug-disease 
association as true or false (this is also highly similar to SITAR). The authors report an AUC 
performance of 0.9 in 10-fold cross-validation (i.e. 10% of the drugs are hidden, and their 
associations are predicted using a model trained on the remaining 90%; repeated 10 times each 
time hiding a different set of drugs). PREDICT compares favorably with the guilt-by-association 
[39] and CMap [36]. This method stitches together drug-target interactions and target-disease 
associations to directly make predictions on drug-disease associations. While useful for 
elucidating more practical predictions, the lack of validation, the lack of mechanistic insight and 
the use of a small dataset makes it hard to assess the utility of the method. 
Cheng et al. have developed a new direction, where they use similarity between the 
bioactivity profiles of compounds to predict unknown targets of known drugs, using a method 
called bioactivity profile similarity search [40]. Their study is based on the bioactivity data of 
4,296 compounds tested in the US National Cancer Institute 60 human tumor cell line anticancer 
drug screen (NCI-60). For each compound, a bioactivity vector of length 60 is generated, where 
the i
th
 entry corresponds to the log(GI50)
4
 value of the compound against the i
th
 cell line. Each 
drug di is compared against every other drug dj in the dataset by computing the Pearson 
coefficient between their bioactivity profile vectors. Whenever the similarity between di and dj is 
75% or higher, the targets of dj are assumed to be targeted by di as well and vice versa. The 
authors claim that 44.8% of their predictions were verified against publicly available databases. 
The one criticism of the method is that compounds with more than 75% similarity in their 
bioactivities are likely to be highly similar in chemistry and the authors do not establish that their 
                                                 
4 GI50: The concentration required for 50% growth inhibition of tumor cells. 
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similarity assessments are not easily discoverable through simple chemoinformatics methods 
(such as Tanimoto scores) that do not require expensive HTS data.  
The abundance of data, the increasingly cheaper computational resources and the success 
of the previously discussed methods have led to increasingly ambitious projects. Bai and 
Abernethy describe the use of computational data and resources to attempt new therapeutic 
discovery ranging from the small chemicals and individual biochemical reactions all the way to 
organism-level responses [55]. They describe a quintipartite (5-compartment) approach for 
determination of toxicity of drug candidates. They describe the data as being composed of 
chemicals, proteins, pathways, organs, and phenotypes where the interactions between these 
parts are in that order: chemical-protein interactions, protein-pathway associations, pathway-
organ interactions and finally organ-phenotype mapping. They unify multiple methods that have 
been used as predictors based on subcategories of this high-level approach and present it as a 
possible unified approach to predicting toxicity arguing that the integration across scales is going 
to achieve what individual models cannot.  
Finally, Du and Elemento argue that the advent of holistic systems biology approaches 
present unique opportunities for the advancement of cancer therapeutics [54]. They argue for the 
use of an integrated approach for cancer that has been recently enabled by the advent of modern 
technologies, where cancer is probed at the genomic level, protein/post-translational level and 
tissue level in an iterative and integrated manner is necessary for realizing more effective 
treatment. They argue that the interplay between the highly person-specific nature of cancer as a 
disease, the interplay between the tumor microenvironment and the disease, as well as the 
Darwinian evolution that the cancer cells undergo create unique challenges that can only be 
overcome by holistic approaches that combine all of these factors together. They argue for the 
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need to develop an approach that involves experimentally characterizing the genome, 
transcriptome, proteome and the microenvironment whose output are evaluated in a holistic 
computational model to select optimal treatment strategy as the necessary road for the future.  
1.1.4 Target-Centric Approaches 
Possibly the most straightforward way of building a target-centric, systems-wide 
polypharmacology prediction scheme is to dock all drugs to all proteins. Li and colleagues have 
attempted to do that, by collecting 252 human drug targets, 4,854 small molecule compounds 
from DrugBank and docking all-to-all [43]. They first identified 13,156 binding pockets in 678 
protein drug targets. Then they docked the known drugs for these targets into these binding 
pockets and evaluated how good the fit was. If their docking software ICM (Molsoft LLC, San 
Diego, CA) was able to recover the already-known interaction between a drug and its target, then 
the target was deemed to be ‘reliable-for-docking’ [62]. They identified 252 targets and 2,923 
binding pockets to be fit for docking. Then they docked all 4,854 drugs to each pocket and 
examined the results. They reported that they were able to correctly predict 10 of 14 known 
interactors of the protein kinase MAPK14, as well as all 4 targets of chemical BIM-8 that were 
not in the original dataset (DrugBank v1). They also gave a list of 31 interaction predictions that 
were not in DrugBank v1 but supported by literature. The major drawback of this approach is 
that it requires protein structure, which is not available for all proteins. Another is the need for 
extensive computational resources and time if rigorous simulations that take account of the 
conformational flexibility of the targets are to be carried out.  
Another target-centric polypharmacology prediction paradigm is to consider binding 
pocket similarity. The idea is that when two proteins share similar features in their binding 
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pockets, they will interact with the same ligand. One example of such an approach is the 
sequence order-independent profile-profile alignment (SOIPPA) method [44]. The idea behind 
SOIPPA is that the structure and fold might be similar between two proteins, with the same 
domains in roughly the same three-dimensional arrangement, while their order in the sequence 
might be different. Since the tertiary structure of the protein is more relevant to the ligand-
protein interaction than the primary structure, SOIPPA aims to capture these domain similarities 
irrespective of sequence properties. This method has later been used to capture binding site 
similarities and enable proteome-wide polypharmacology screens [42]. The authors first 
extracted the binding site of a drug from a known structure, then used SOIPPA to screen for 
other proteins with similar binding sites, and finally performed docking to evaluate the fit. They 
were able to demonstrate similarity between the binding sites of human catechol-O-
methyltransferase (COMT) and the M. tuberculosis enoyl-acyl carrier protein reductase (InhA). 
COMT is targeted by entacapone and tolcapone while InhA is reportedly targeted by isoniazid 
and ethionamide. The authors postulated then that entacapone would interact with InhA too –
which would mean that entacapone could treat multi-drug resistant (MDR) tuberculosis. Their 
preliminary experiments have shown that Comtan tablets (which contain entacapone as the active 
ingredient) have slowed the growth of M. tuberculosis in culture. The advantage of this method 
is the mechanistic and rational basis for the predictions. However the requirement of structural 
data limits applicability to only structurally resolved proteins. It also does not take account of the 
conformational flexibility of proteins. 
Finally, recent developments in sequencing technology have given rise to a new approach 
called phenome-wide association studies (PheWAS) where the diseases that are of interest for a 
particular genetic variant are searched in addition to the more-established genome-wide 
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association studies (GWAS) where the genes of importance for a particular disease are searched 
[63]. The central idea with these methods is to find links between genes and the diseases (or 
more broadly, phenotypes) of interest and then use the information on known drugs targeting 
these genes to make new drug repurposing predictions.  
1.2 BIOMEDICAL BACKGROUND 
1.2.1 α-1 Antitrypsin Deficiency 
1-Antitrypsin (1-AT) is a member of the serine protease inhibitor superfamily, also called 
serpins, which regulates the activity of trypsins (in the digestive system) and neutrophil elastase 
(in the lungs). AT deficiency (ATD, also known as A1AD) is an inherited autosomal co-
dominant disorder that causes lung and liver diseases. It affects 1 in 2,000 to 5,000 individuals of 
Northern European descent [64;65]. It is one of the most common genetic cause of liver disease 
in children, and causes cirrhosis and hepatic fibrosis and carcinoma in adults [66;67]. 
Furthermore the aggregation phenotype in ATD has been recognized as a model for 
conformational diseases, including many common neurodegenerative diseases such as 
Alzheimer’s disease [68]  
The primary cause for ATD is the E342K mutation in the SERPINA1 gene that encodes 
AT, which causes the production of the aggregation-prone Z variant of AT, called ATZ, that 
accumulates in the endoplasmic reticulum (ER) of the liver cells. AT/SERPINΑ1 is the 
prototypical member of the serpin superfamily and a major anti-protease in the circulation and 
extracellular fluids [69]. The function of AT is to protect tissues from collateral damage by 
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neutralizing leukocyte-derived peptidases [70;71]. A structural depiction of the work of the 
serpins, as reported in the PDB [72], is shown in Figure 2. On the left, the serpin is shown 
immediately after its interaction with the trypsin molecule, with the serpin shown in blue and the 
proteinase shown in green (PDB:1K9O) [73]. Upon cleavage by trypsin, the serpin’s recruiting 
arm quickly undergoes a structural reorganization, embedding the recruiting arm in a sheet of β-
strands; which is being shown in the structure on the right [74]. The structural reorganization 
prevents the trypsin from completing its reaction and releasing itself, thereby trapping the protein 
in a mouse-trap fashion.  
Hepatocytes are the major biosynthetic source of AT, where the protein normally enters 
the constitutive secretory pathway [75]. However, the Z-mutation delays native folding and 
impairs secretion, which leads to polymerization and aggregation of ATZ by a domain swapping 
mechanism [76]. Consequently, ATZ is retained within the endoplasmic reticulum (ER) as large 
inclusions that cause fibrosis/cirrhosis and hepatocellular carcinoma [77-79]. In ATD patients, 
therefore, a loss of serpin inhibitory activity underlies the lung disease, whereas a gain-of-toxic-
function triggers liver disease. 
ATZ aggregation induces a reduction in circulating AT, and predisposes adults to 
developing emphysema and chronic obstructive pulmonary disease [80-82] because of the lack 
of the proteinase inhibitory function in the lungs. In addition, ATD patients homozygous for the 
most common mutation, Z (E342K), are at increased risk of developing liver disease throughout 
their lifetime due to the ATZ aggregation in the hepatocytes [66;67]. Simply stated, ATZ leads to 
two major disease phenotypes (i) the gain-of-toxic-function due to ATZ aggregation causes liver 
damage; (ii) the loss-of-function due to reduced secretion of AT from the liver leads to lung 
diseases. The marked accumulation of mutant ATZ has been demonstrated in the PiZ transgenic 
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mouse to lead to liver damage, closely resembling that  in human disease [83;84]. As known 
from earlier studies, only a subpopulation of ATD patients develop liver disease [85], suggesting 
that genetic and/or environmental modifiers determine the susceptibility of an ATD individual to 
liver disease [83].  
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Figure 2: The ‘mouse-trap’ mechanism of serpins 
Serpins operate as proteinase inhibitors by recruiting and trapping the proteinases as reported and shown in the 
figure above adopted from the PDB [72]. The structure on the left (PDB:1K9O) [73] shows the serpin-trypsin 
complex (serpin shown in purple, proteinase shown in green) immediately after binding; whereas the structure on 
the right (PDB:1EZX) [74] shows the trypsin after the serpin has stabilized, inactivating the serpin. Upon cleavage, 
the serpin undergoes a structural reorganization, embedding the recruiting arm in a sheet of β-strands, with this 
change preventing the proteinase from dissociation thus trapping the proteinase. 
 
1.2.2 Huntington’s Disease 
Huntington’s disease (HD) is an autosomal dominant genetic neurodegenerative disease, caused 
by an expanded CAG repeat in the huntingtin gene, that affects 4-10 out of 100,000 people in the 
western world with many others at the risk of disease [86]. Higher than 40 CAG repeats cause 
nearly full penetrance at about 65 years of age, while the average onset of disease is at the age of 
40 [87]. Disease onset usually occurs during the fourth or fifth decade in life and mean survival 
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of onset being 15 to 20 years after onset; furthermore the disease is universally fatal, and despite 
best efforts, there is currently no known cure for HD [88]. The clinical phenotypes the disease 
presents involve characteristic movement disorder (Huntington’s chorea), cognitive disorders, 
and psychiatric symptoms. The etiology of the disease is described as selective regional neuron 
loss and gliosis in striatum, cerebral cortex, thalamus, subthalamus and hippocampus [89]. 
Owing to the discovery of the causal mutation of the disease, transgenic mouse models of the 
disease have been made possible [90]. In these mice models of disease, selective regional 
neuronal loss accompanying motor symptoms has been demonstrated as observed in the human 
disease [89].  
The Friedlander lab has screened the library of the Neurodegeneration Drug Screening 
Consortium [91] in isolated mitochondria for cytochrome c release inhibition, and tested the hits 
resulting from this first screening for their neuroprotective activities in ST14A cell lines [92]. 
These were immortalized striatal cells stably expressing a mutant huntingtin fragment to serve as 
a model of HD [92].  In total they have identified 21 drugs that inhibit cytochrome c release, 15 
of which subsequently demonstrated neuronal cell death inhibition activity in ST14A HD model 
cell lines serum deprivation and heat insult assays. Among them methazolamide also showed a 
dose-dependent delay in HD progression in vivo, in a mice model of HD (specifically R6/2) [90]. 
 
1.3 SCOPE OF CONTRIBUTION  
Most computational methods for predicting drug-target interactions rely on similarity. However, 
there are multiple shortcomings with basing interaction inferences mostly on chemical and/or 
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genomic similarity; primarily that global similarity is not always a good predictor of specific 
binding behaviour. There can be proteins with highly similar sequence (and even structure) but 
with a very small, varible ligand-binding region (such as membrane-bound receptors) that give 
rise to critically different interaction patterns. Since small-molecule compounds used as drugs 
are usually much smaller, the converse is harder yet there are cases where minor modifications 
can lead to widely different physiological phenotypic differences. A good example can be found 
in steroidogenesis in humans: Testesterone and Estradiol have 74% chemical similarity based on 
the MACCS fingerprints, calculated using Pybel [93], despite having radically different 
phenotypic effects. The contribution presented in this paper is completely independent of any 
chemical/protein similarity methods and relies on the interaction network therefore bringing a 
novel and complementary approach that avoids the pitfalls of other methods relying on 
similarity.  
I have demonstrated that a latent factor based drug-target interaction prediction method 
has successful descriptive and predictive power. I have validated the predictive characteristics 
with many different cross-validation setups. I have also tested the descriptive characteristics by 
comparing the drug-drug similarities calculated by the latent variables to those calculated by 3D 
chemical similarities. Finally, I have shown that such a method can perform remarkably well in 
directing experimentation in an active learning setting. 
I performed both computational and experimental studies towards elucidating the 
mechanism of action of these drugs and designing new, more potent inhibitors or HD. 
Specifically, I helped develop a neuronal cell death inhibition assay using the Q7/Q111 striatal 
neurons derived from murine cell lines which respectively express 7- and the 111-CAG-repeat 
human huntingtin protein. I characterized the apoptotic response under heat and serum 
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deprivation induced stress conditions, and helped develop a high content screening (HCS) based 
workflow for assessing the level of neuroprotection through neuronal cell death inhibition in 
response to chemical intervention. Computationally, I have used the descriptive function of latent 
variables within the context of HD in order to discover other drugs that can work effectively. I 
developed a method for analyzing the drugs that were observed by the Friedlander lab to be 
preventing cytochrome c release from the mitochondria and/or to be neuroprotective, and 
identified other drugs that could potentially be helpful in this disease. This work has given rise to 
the discovery of a novel repurposable candidate sodium nitroprusside (SNP). SNP is traditionally 
used as an antihypertensive owing to the fact that it breaks down in circulation and releases nitric 
oxide (NO), which results in vascular smooth muscle relaxation and vessel dilation. SNP has 
been experimentally shown to be an effective inhibitor of neuronal cell death in the Q111 HD 
model cell line, initially in the experiments done in the Friedlander lab by Hossein Mousavi. This 
phenotype was later reproduced in the University of Pittsburgh Drug Discovery Institute using 
the assays developed under the guidance of Lans Taylor, Andrew Stern, Mark Schurdak and with 
the work of Celeste Reese, Laura Vollmer and myself.  
I have also analyzed the whole-genome RNAi knockdown data in a C. elegans model of 
ATD to identify the genes that significantly impact disease progression, matched those nematode 
genes to the druggable human genome, and identified the best candidate drug for modulating the 
disease, glibenclamide (traditionally used as an antidiabetic), as a potential repurposable drug 
against ATD. Building on this central idea, we identified a set of 104 known proteostasis 
network (PN) modifier genes, and mapped them onto their human orthologs using two different 
databases/compendia available for C. elegans genes: Wormbase and Ortholist [94;95]. We 
mapped the human orthologs to interacting drugs, and filtered for targets of drugs that occur in 
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the Library of Pharmaceutically Active Compounds (LOPAC™) for feasibility. There were four 
such targets: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform 
(PIK3CA), Transthyretin (TTR), ATP-binding cassette (ABC), and Nociceptin receptor 
(OPRL1) and we tested two drugs for each of these targets identifying four that were shown to 
reduce ATZ aggregation. 
Furthermore there is a need for user-friendly tools that an experimental scientist could 
use to rapidly search for known and predicted protein/targets using as query a given drug or a 
target of interest. These tools need to be easy-to-use, accessible, efficient, yet highly robust and 
low in false positives in order to help build reasonable hypotheses for further experimentation. 
This is important because the experimental scientists are an important audience, if not the key 
audience, to which these methods are addressed to. Yet they cannot be expected to possess the 
technical expertise required to develop and implement algorithms, neither download or 
implement existing tools, and then to run the code simply to get one prediction of interest. I 
contributed a new web server, BalestraWeb, to facilitate the broad dissemination and usage of 
the PMF-based computational prediction tools developed within the scope of this doctoral 
studies where the execution of the complicated machine learning is abstracted from the user who 
simply enters the query of interest (drug and/or target) and clicks one ‘Predict’ button. Finally, 
my work on laying the foundations of BalestraTK can help other scientists conduct research 
easier by allowing them to easily integrate multiple datasources. 
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1.4 SPECIFIC AIMS 
Below is a summary of the specific aims proposed to be accomplished during the course of my 
doctoral research studies. 
 
 Specific Aim 1: Predicting drug-target interactions using probabilistic latent factor models 
and validating their use as descriptors of therapeutic effects. The drug-target interaction 
network can be used to learn probabilistic latent factor models (LFM) about drugs and targets. 
These latent factor models can be used as (i) descriptors of drugs/targets for therapeutic function 
similarity comparison, clustering, distance calculation purposes; and (ii) predictors of drug-target 
interaction likelihood.  
Sub Aim 1: Latent variables as descriptors. We will demonstrate the use of LFM as 
descriptors of drug-target interactions by showing that the LVs can capture therapeutic functional 
similarity between compounds in cases missed by state-of-the-art similarity based comparison.  
Sub Aim 2: Latent variables as predictors. We will validate the use of LFM as 
predictors by comparing them against state-of-the-art methods on benchmark datasets, in 
addition to an active learning setting where LFM directs interaction experimentation in silico.  
 
Specific Aim 2: Identification of repurposable candidates for α-1 antitrypsin deficiency and 
Huntington’s disease. New drugs that can be repurposed against ATD will be identified using 
the experimental high content screening data collected on C. elegans model of the disease. 
Furthermore I will diversify previously identified hits against Huntington’s disease to identify 
more effective neuroprotectives using latent factor modeling based methods. 
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Sub Aim 1: Predict repurposable candidates for A1AD. I will identify potential 
targets in humans using the genome-wide RNAi screen, and a chemical library screen performed 
on a C.elegans model of ATZ aggregation. The genes that significantly alter ATZ accumulation 
will be mapped to their human orthologs. The drugs interacting with the human targets will be 
reported, for experimental verification. The data from an additional chemical screen, Prestwick 
library [96], for their ATZ elimination activities will be analyzed to identify potential targets, as 
well as the common chemical patterns that led to anti-aggregation activity, toward identifying 
new repurposable candidates. 
 
Sub Aim 2: Describe mechanism of action of neuroprotective drugs. Drugs that share 
one common target with neuroprotective drugs but otherwise have as diverse a target profile as 
possible will be identified, where diversity is defined as distance within the latent variable space, 
These drugs will then be tested in a neuroprotection assay, whose development I will assist. The 
hypothesis therein is that other, more effective drugs can be identified by exploiting the 
information we have about our currently known active drugs.  
 
Specific Aim 3: Development of new tools to integrate existing data sources and enable fast, 
efficient prediction of drug-target interactions to expedite drug discovery process. The 
algorithms, software and tools developed during the course of the doctoral studies will be  made 
available to the larger community of biomedical researchers with the help of user-friendly 
interfaces.  
Sub Aim 1: Website for drug-target interaction prediction. We will build 
BalestraWeb, (http://balestra.csb.pitt.edu/) a website for latent factor based interaction 
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predictions. The user will be able to acquire predictions for (i) a specific drug-target pair; (ii) the 
most likely interaction partners of a drug, (iii) the drugs most likely to interact with a given 
target.  
Sub Aim 2: Development of a toolkit, BalestraTK, for chemical, protein and 
interaction data integration and analysis.  We will develop a Python toolkit 
(https://github.com/mcc-/balestraTK) for interaction information access and prediction. The 
users of the toolkit will be able to integrate and easily access data stored in the public databases 
DrugBank, STITCH, UniProt, and PubChem.  
 
1.5 SUMMARY OF FINDINGS 
Within the scope of aim 1, subaim 1, I have shown that latent factor based models can accurately 
describe the interaction profiles of drugs by assessing the similarity of the drugs with known 
similar therapeutic functions in latent variable space. I have also compared the similarity of these 
molecules in latent variable space to the results acquired by using state-of-the-art 
chemoinformatic 3D chemical similarity methods and shown that latent variable methods 
actually discover therapeutic function similarity better. For aim 1, subaim 2, I have validated the 
use of LFM based methods for predictive drug-target interaction assessment in two ways: (i) I 
assessed the recapitulation rate of known interactions after randomly removing 70% of the 
interactions, (ii) de novo prediction performance by assessing the presence of direct and indirect 
evidence for predictions made after including all the available data [97].  
 32   
Within the scope of aim 2, subaim 1, I have analyzed the whole-genome RNAi 
knockdown data from the Perlmutter lab’s C. elegans model of ATD. Based on these data, I 
devised a logistic regression based classifier to distinguish the genes that reduce aggregation, 
mapped these genes to human drug-target orthologs using WormBase and DrugBank and thus 
identified human drugs. Selecting for maximal match performance at every step, I predicted that 
the antidiabetic glibenclamide would be effective in A1AD, and this prediction has subsequently 
been validated by the Perlmutter lab in vivo in a murine model of the disease. The same central 
idea has been applied using more data sources: OrthoList in addition to WormBase; STITCH and 
MetaCore instead of DrugBank [45;94;95]. This approach has yielded eight other predictions 
that were tested, four of which have turned out to be active [65]. Finally, I have analyzed the data 
from the chemical screening and identified three new predictions. One of these has been 
validated by our collaborators so far, with the other two to be tested. Within the scope of aim 2, 
subaim 2, I have analyzed the results of a two-stage screen previously conducted by the 
Friedlander lab [92]. After implementing a novel computational method for computationally 
selecting new compounds to test, I have identified a set of experimentally feasible compounds to 
test. Then I have participated in the experiments to build a neuroprotection assay based on the 
Q7/Q111 HD model cell lines. Our experiments suggest that the antihypertensive SNP is a 
promising potential repurposable candidate. SNP has shown statistically significantly more 
neuroprotective activity than the glaucoma medicine methazolamide, which had been shown to 
be highly neuroprotective in HD in vitro and in vivo thus being used by the Friedlander lab as a 
positive control. 
Within the scope of aim 3, subaim 1, I have built BalestraWeb [98] which is a publicly 
accessible website that allows any user to be able to access predictions made by our methods and 
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thus allows us to facilitate the dissemination of the results of our work to a wider audience. 
Making a prediction is simplified to the point that the user only needs to input the name of the 
drug and/or target of interest, and click the ‘Predict’ button. The website automatically retrieves 
the proper prediction made by our latent factor based method and then visualizes the 
prediction(s) within the context of known interactions; as well as providing the user with links to 
more information about any drug/target that is either predicted to interact or known to interact. 
Within the scope of aim 3, subaim 2, I have built BalestraTK, which is open-source and publicly 
available (https://github.com/mcc-/balestraTK). This toolkit allows the users to easily parse, 
analyze and integrate publicly available datasets for use in computational systems pharmacology 
projects. 
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2.0  LATENT FACTOR MODELING BASED ANALYSIS OF DRUG TARGET 
INTERACTIONS 
In this section, I will describe the various methods used or developed during the course of my 
doctoral studies.  First, I describe the various latent factor based probabilistic modeling 
techniques that I have adapted to QSP studies. Secondly, I describe the computational techniques 
we used and implemented for data analysis and new predictions within the scope of the ATD 
project. Third, I present the algorithms developed for new compound identification within the 
scope of the HD project. Finally, I describe the methodology behind BalestraWeb and 
BalestraTK.  
2.1 METHODOLOGY 
2.1.1 Problem Definition 
The drug-target interaction network is a bipartite graph with two types of nodes; drugs, and 
targets (Figure 4). Each edge represents an interaction between a drug and a target. The drug-
target interaction identification problem is to determine the missing edges that are likely to exist 
given all nodes and some of the edges in the network.  
 35   
2.1.2 Dataset 
We used DrugBank (version of September 20, 2011) as the database [99].  All drugs annotated 
therein as approved, along with their annotated targets, are included in our dataset (i.e., we 
excluded compounds annotated as withdrawn or nutraceuticals), resulting in N = 1,413 drugs and 
M = 1,050 targets with 4,731 interactions among them. The interaction network displays small-
world characteristics: many nodes have low degree and a few, very high degree, as illustrated in 
the panels b and c of Figure 4, in line with previous studies on drug-target networks [100]. On 
average, there are 3.35 interactions per drug, and 4.50 interactions per target.  
2.1.3 Probabilistic Matrix Factorization (PMF) 
PMF is a member of the LFM subtype of collaborative filtering family of machine learning 
algorithms that decomposes the connectivity matrix, RN x M, of a bipartite graph of N drugs and M 
targets as a product of two matrices of latent variables (LVs) [53;101].  RN x M is defined as: 
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The matrix RN x M is modeled as the product of two matrices U
T
N x D and VD x M, that 
express each drug/target in terms of D LVs. Our objective is to find the best approximation for 
LVs, while avoiding over-fitting. The predicted connectivity matrix Rˆ N x M is then expressed as: 
 
MD
T
DNMN   VURˆ  (8)  ( 
 
 36   
where U
T
 and V are composed of N rows ui
T
 and M columns vj, respectively, each being D-
dimensional. The PMF adopts a probabilistic linear model with Gaussian noise to model the 
interaction. Therefore, the conditional probability over observed interactions is represented as 
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where f((x | )  is the Gaussianly distributed probability density function for x, with mean  
and variance , and Iij is the indicator function equal to 1 if the entry Rij is known, and 0 
otherwise. Therefore, p(R | U, V, 2) gives us a probabilistic representation of the connectivity 
matrix, R [101]. Using zero-mean, spherical Gaussian priors on LVs, we can write 
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which leads to the log-likelihood of U and V given by 
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where C is a term that does not depend on LVs; the first term on the right-hand side is the 
squared error function to be minimized; and the two summations over the square magnitudes of 
ui and vj  are regularization terms that favor simpler solutions and penalize overfitting. The above 
log-likelihood directly follows from the Bayes’ rule where R stands for data, and U and V 
represent the model. If we assume that the variance of the prior for the drugs and targets are 
equal, i.e. 
222    UU , and if we define 
21    then we can write this optimization 
function with a single hyper-parameter, λ. Furthermore, maximizing this log-likelihood can be 
 37   
shown to be equivalent to minimizing a squared-loss error function, regularized with the 
Frobenius norm of the latent variable vectors, as shown in the following equation: 
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To learn an optimal model means to find the U and V matrices, or the D-dimensional LV 
vectors, ui (1 ≤ i ≤ N) and vj  (1 ≤ j ≤ M), that maximize the log-likelihood function, together with 
the identification of the hyper-parameters (λ and D) that yield the optimal learning performance. 
To identify the best hyper-parameters, we use cross-validation. Specifically, we hid 70% of the 
data and looked at performance in recapturing the missing interactions. Figure 13 demonstrates 
the results with D = 30 and D = 50 when predicting 100 and 1000 interactions, using the active 
learner as well as the passive learner (discussed in more detail below, in the next subsection). We 
chose D=50 and λ=0.01 based on our cross-validation runs. The PMF code distributed by the 
authors of [53] can be freely downloaded at http://www.utstat.toronto.edu/~rsalakhu/BPMF.html 
whereas our code that is partially built on top of that can be freely accessed at 
http://www.csb.pitt.edu/Faculty/bahar/QSP_PMF_code/ along with all the data we used to run 
these analyses. A detailed description of the contents of the two files provided in the link to our 
files is provided in Appendix A. 
The PMF method yields the optimal ui and vj vectors corresponding to each drug, di, and 
each target tj, respectively.  The basic idea is that the model is forced towards making a ‘no-
interaction’ prediction by the regularization – i.e. there is a penalty associated with any non-zero 
value in the LV matrices. However, there is also a penalty for failing to capture known 
interactions– i.e., if the dot product of the LV vectors corresponding to an interacting drug-target 
pair is close to zero. Therefore learning a model means to optimally balance out two objectives: 
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developing a sufficiently complex model to describe the known interactions, but not overly 
complex to end up in over-fitting.  In this study, we use gradient descent for minimizing the 
objective (error) function.  The adoption of higher D values usually yields more accurate results, 
although beyond a certain limit the increase in complexity and decrease in efficiency may not 
warrant the marginal improvement, if any, in prediction accuracy. D = 50 is adopted here as an 
optimal dimensionality for prediction runs. The method is highly efficient: a 50-dimensional 
model is trained on the entire DrugBank in approximately 2 seconds using a 2.00 GHz AMD 
Opteron processor. Moreover, the computing time to learn a PMF model scales linearly with the 
number of interactions, and as such, the method can be advantageously used for much larger 
datasets.  
2.1.4 Methodology for Active Learning On Drug-Target Interactions Using PMF 
The active learning (AL) strategy adopted in the present study is, in part, motivated by the 
success reported by Warmuth et al.[102]
  
who demonstrated that hit maximization is a viable AL 
strategy applicable to predicting drug-target interactions. The AL strategy adopted here also 
prioritizes the discovery of unknown interactions. Our method differs in that we aim at capturing 
the interactions between all drugs and targets, as opposed to predicting activity against a single 
target.  
The procedure is the following: We begin with the set of N drugs and M targets, and 
known associations, schematically shown in Figure 3 by black connectors. The purpose is to 
identify new associations, indicated by red connectors. For each candidate interaction, say the 
possible interaction between di and tj, we compute the model’s estimate, by calculating the dot 
product ui 
T
vj which serves as a weight ij for the edge/connector between di and tj. Clearly, ij, 
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or the likelihood of association between di and tj, is high when ui and vj have both large values of 
the same sign at the same dimension(s).  For example, a relatively large weight may originate 
from the 2
nd
 component of both ui and vj, which means that the predicted association is mainly 
due to latent variable 2. We evaluated the statistical weights ij(di, tj) for the N x M pairs of drug-
targets for two purposes: (i) benchmarking the methodology via an iterative AL scheme, and (ii) 
making de novo predictions. In the former case, the method is benchmarked by hiding 70% of 
known interactions and examining whether the top-ranking prediction is a ‘hit’, i.e., whether it 
corresponds to a known (but hidden) interaction. The outcome from this test is fed back to the 
model, to repeat the calculation for the next prediction. Therefore, the AL model is updated at 
each iteration using the newly acquired ‘hit’ or ‘miss’ data until a predetermined number (m) of 
predictions are made. The passive learner (PL) makes the m predictions simultaneously without 
updating its model.  
In the case of de novo predictions, all DrugBank data were used as input. De novo 
predictions also lend themselves to an AL scheme provided that the top-ranking prediction is 
experimentally tested and then the new hit or miss data are incorporated in the model to perform 
a new prediction, and so on, until the experimentation budget is exhausted.  
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Figure 3: Qualitative illustration of the method for identifying drug-target interactions.  
The known interactions between drugs and targets (indicated by the black lines) are used to learn the LV vectors 
(shown adjacent to each node) that describe each drug and target. The dot product ui 
T
vj of the LVs for each pair of 
drug di and target tj define the predicted statistical weight ij of corresponding connection.  Example predictions are 
shown in red. (From [97]) 
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Figure 4: Drug-target interaction network  
(a) Network representation of the drug target interaction dataset used in this study. The drugs are shown in blue, 
protein targets, in red.  Data retrieved from DrugBank [99], Cytoscape used for visualization [103] (b) Distribution 
of drugs with respect to the number of targets they interact with (i.e. as a function of the number of edges around 
each drug node). (c) The distribution of targets with respect to the number of distinct drugs they interact with. (From 
[97]) 
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2.2 RESULTS 
Below I am going to discuss the results that demonstrate the power of LFM in descriptive 
function, predictive function, and in active learning. 
2.2.1 Descriptive Power of LFM 
To assess whether the LVs provide us with a pharmacologically meaningful metric, we examined 
the clustering of drugs in the D-dimensional space of the latent vectors. The number of clusters 
was chosen to be 30 as that was the value that gave the lowest Akaike information criterion 
[104], and using as basis the drug-drug distance L1(di, dj) = k |uik  - ujk | where uik designates the 
k
th
 component of ui, and the summation is performed over D components. 
Inasmuch as our method evaluates drugs based on their interaction profiles with targets, 
which in turn refer to specific therapeutic or phenotypic actions, the similarity of a pair of drugs 
should be high when their therapeutic effects are comparable and vice versa. Thus, the method 
will tend to cluster drugs that exhibit similar patterns of interactions (with target proteins), which 
we term as functionally similar drugs. The heatmap in Figure 5a displays the resulting 
organization of drugs in 30 clusters (indicated by different colors and indices along the axes). 
Table 1 lists the dominant therapeutic action associated with each cluster. The dark regions on 
the map indicate high functional similarity. The dark blocks along the diagonal show that most 
clusters include highly similar members, except for two (clusters 29 and 30), which apparently 
combine the outliers.  
Given that (promiscuous) proteins present more than one site for ligand-binding, different 
functionalities may be modulated by chemical-structurally different drugs, depending on the 
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binding site on the target (e.g. catalysis, substrate recognition, or allosteric signaling). 
Furthermore, a shared phenotype may arise from the targeting of different proteins along a given 
pathway. In order to make a better assessment of the properties of drugs grouped in those 
clusters, we examined their 3D structural similarities. High similarities would suggest that they 
bind similar epitopes, if not similar (or identical) structural domains or proteins.  If, on the 
contrary, they are structurally dissimilar, this might indicate a different site on the same protein, 
or a different target on the same pathway, or other indirect effect due to drug-target network 
connectivity. 
The extent of 3D structure similarity between pairs of drugs was computed using a 
multitude of the OpenEye™ scientific software products as described below 
(http://www.eyesopen.com/). We chose 3D similarity because it was reported to be a better 
predictor than 2D methods for off-target interactions, and to perform equally well in on-target 
interactions [105]. However 3D methods may suffer from more noise due to the conformational 
flexibility of the small molecule therefore we generated all possible stereoisomers using 
OpenEye FLIPPER [106], and up to 200 conformers per stereoisomer using OpenEye OMEGA 
[106] for every drug. All combinations of conformers accessible to the examined pair of drugs 
were examined using OpenEye Shape [35] toolkit; and the best matching pair was adopted to 
assign a 3D similarity score. This computationally expensive task led to the heat map presented 
in panel b of Figure 5. The drugs (along the axes) are ordered as in panel a to enable visual 
comparison.  
The comparison of Figure 5 shows that some clusters of functionally similar drugs (panel 
a) also exhibit some 3D similarities (panel b), whereas others display little structural similarity. 
We examined more closely the individual clusters to see if shared therapeutic functions were 
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captured even when 3D similarities were absent. Figure 6 illustrates the results for cluster 14. 
This cluster essentially consists of anti-anxiety drugs, the majority of which are both functionally 
(panel b) and structurally (panel c) similar. However, the cluster also includes a structurally 
dissimilar drug, ethchlorvynol (panel a), which shares the same type of phenotypic action (as a 
sedative) as the majority of the cluster membership (mostly targeting GABA receptors). The 
present approach thus detects chemically or structurally distinctive drugs that share common 
activities, which would have been missed by methods based on ligand fingerprint similarities. 
Another interesting observation concerns the cross-correlations between different clusters 
(i.e. the off-diagonal regions of the heat maps). We note for example that cluster 11 also contains 
a set of sedatives. LVs are able to capture the commonality between the clusters 11 and 14 as 
may be seen by the strong signal (dark region) at the off-diagonal region enlarged in Figure 6b. 
The 3D similarity, on the other hand, cannot recognize the functional similarity and potential 
interference/side effects between these drugs in these two clusters (Figure 6c). Figure 8 
illustrates the same behavior for another cluster, whose members are mostly antineoplastic 
agents, albeit with various 3D structures. The LVs thus provide information on drug groups that 
potentially share pathways or exhibit similar activity patterns despite their distinct 
physicochemical properties.  
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Figure 5: Comparison of pairwise similarities of drugs, based on their therapeutic targets compiled in 
DrugBank and 3D structure 
Panel a displays the 30 clusters of drugs (color-coded along the axes; see Table 1 for their dominant therapeutic 
indication) deduced from the PMF of 1,413 approved drugs and corresponding 1,050 targets compiled in DrugBank. 
By definition, drugs belonging to a given cluster share similar interaction patterns with respect to targets. Panel b 
displays their 3D similarities, with the drugs being ordered as in panel a. Dark regions indicate high similarity based 
on LVs (panel a) or 3D similarities (panel b). Comparison of the panels shows that close proximity in LV space 
(which indicates functional similarity) does not necessarily imply 3D-structure similarity. LV distances were 
distributed in the range [0, 1] whereas the 3D distances were distributed in the range [0, 2] ([0-1] from spatial 
overlap, [0-1] from physicochemical property overlap); with the distribution of values also skewed in different ways. 
To render the two sets comparable, we performed rank normalization on both the LV similarities and 3D 
similarities. Selected boxes are enlarged in Figure 6 (white), Figure 7 (yellow), and Figure 8 (green). (From [97]) 
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Figure 6: Latent variables can capture therapeutic action similarities when 3D similarity metrics cannot 
Closer examination of the similarities between the members of the cluster 14 in Table 1 (enclosed in white boxes in 
Figure 5, enlarged in panels b and c here) shows that the cluster contains a series of anti-anxiety drugs. A few 
members of this cluster (indicated by orange boxes along the abscissa of panels b and c) are displayed in panel a, to 
illustrate their shared structural features, also indicated by the panel c that reflects their 3D similarities. The same 
cluster however contains ethchlorvynol, also used as a sedative, which would have been missed if we had used 
exclusively used 3D similarity to identify functionally similar drugs. (From [97]) 
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Figure 7: Strong cross-correlations between different clusters of drugs are consistent with their similar 
therapeutic functions 
Cluster 11, color-coded cyan, is essentially composed of hypnotics and sedatives. Cluster 14 (dark gray) contains 
anti-anxiety drugs. The drugs in these two clusters are located very closely on the drug-target interaction network, as 
shown in panel a, consistent with their similar actions. The LV-derived heat maps capture the functional similarity 
between these two clusters (as indicated by strong signals, or the dark region, in panel b); the maps based on 3D 
similarity (panel c) do not. In panel a drugs are shown in blue, protein targets in red. Most drugs and targets are part 
of a single connected component. Data are retrieved from DrugBank [99]. Cytoscape is used for visualization [103]. 
(From [97]) 
 48   
 
 
 
Figure 8: Latent variables capture functional similarity 
The figure illustrates how the drugs clustered based on their PMF-derived latent vectors share functional similarity, 
while their 3-dimensional (3D) structures may vary.  The cluster shown in this case is dominated by antineoplastic 
agents, and they show significant latent variable similarity. The color code in the maps varies from red (no 
similarity) to black (high similarity). The corresponding 51 drug structures and DrugBank identifiers are presented 
on the right. (From [97]) 
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Table 1: The most dominant therapeutic function in each cluster 
Cluster Number Most Dominant Therapeutic Function Number of Drugs 
1 Antineoplastic Agents 1 
2 Gastrointestinal Agents 4 
3 Nucleic Acid Synthesis Inhibitors 6 
4 Quinolones 11 
5 Calcium Channel Blockers 12 
6 Anti-Bacterial Agents 13 
7 Androgens 15 
8 Anti-Bacterial Agents 16 
9 Anti-HIV Agents 19 
10 Anti-Arrhythmia Agents 21 
11 Hypnotics and Sedatives 21 
12 Antipsychotic Agents 22 
13 Diuretics 22 
14 Anti-anxiety Agents 22 
15 Adrenergic Uptake Inhibitors 27 
16 Analgesics, Opioid 27 
17 Anti-inflammatory Agents 32 
18 Anti-Bacterial Agents 33 
19 Cyclooxygenase Inhibitors 34 
20 Antihistamines 34 
21 Adrenergic beta-Antagonists 35 
22 Sympathomimetics 39 
23 Contraceptives, Oral, Synthetic 42 
24 Anti-Bacterial Agents 49 
25 Antineoplastic Agents 51 
26 Cholinesterase Inhibitors 53 
27 Muscarinic Antagonists 55 
28 Antipsychotic Agents 59 
29 Antineoplastic Agents 201 
30 Antihypertensive Agents 258 
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2.2.2 Predictive Power of LFM 
To evaluate the performance of the method in comparison to previous work, we considered three 
important studies in this area, one recently published by Gonen [34] and two by Yamanishi et al. 
[29;32]. Gonen used a kernel based matrix factorization (KBMF) with chemical and genomic 
similarities to predict multiple targets. Yamanishi et al., on the other hand, integrated chemical, 
genomic and pharmacological data to map all drugs and targets to the same unified feature space 
where each protein-compound pair closer than a predefined threshold was predicted to interact. 
Our approach differs from both studies, in that PMF assumes an independent LV for each row 
and column with Gaussian priors; whereas KBMF employs LVs spanning all rows and columns 
with Gaussian process priors, and Yamanishi et al project drugs and targets into a 
pharmacological space based on the eigenvalue decomposition of the graph-based similarity 
matrix. 
The benchmarking procedure that we adopted is a five-fold cross-validation of drugs on 
four target classes: Enzymes, Ion channels, G-protein coupled receptors (GPCRs) and Nuclear 
Receptors. In order to achieve comparable results, we used the same protocol as that adopted 
earlier, i.e., we divided our dataset into five subsets, and each was used as a test set, and the 
others, as training sets. Due to the randomness involved in the selection of subsets, we repeated 
the cross-validation experiments 100 times with randomly selected subsets and evaluated the 
average AUC (area under the receiver operating curve) for each subset. The first four rows in 
Table 2 compare the results (columns 6-10) for the four classes, and the 5
th
 row lists the average 
performances weighted by the size of the interaction space. Our method performs best when 
applied to large datasets (e.g. enzymes and ion channels); whereas Gonen’s performs best in the 
case of GPCRs, and Yamanishi et al. (2010) exhibits the highest performance for nuclear 
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receptors, where the present method yields a relatively low (0.642) AUC value.  Examination of 
the statistical significance of our results (Figure 9 panel a) indicates that the mean AUC values 
obtained for all four sets are highly robust. Their variances vary from 2% (Enzymes and Ion 
Channels) to 11% (Nuclear Receptors). Finally, the application of the same benchmarking 
protocol to DrugBank yielded an accuracy rate of 79.4 ± 0.01% (Table 2, last row), supporting 
the utility of the method when applied to large datasets. 
In principle, it might be intrinsically harder to make accurate predictions for larger 
datasets as the size of the potential interaction space N x M grows quadratically when the number 
of drugs and targets grow linearly, particularly if the number of known interactions is small. The 
occupancy of the N x M interaction matrix is only 1.5% in the Enzyme class, which could make 
it difficult to learn an informative model. The present PMF technique, however, successfully 
learned an informative model and handled the complexity of interactions in this space of 
interactions, apparently due to the availability of a sufficiently large (absolute) number of known 
interactions (Figure 10 panel b). 
The drug class that targets ion channels has the second largest number of known 
interactions among the four. Although the size of interaction space is one order of magnitude 
smaller than Enzyme class, there are 776 known interactions leading to a percent occupancy of 
5.37% of all possible ion channel-drug associations.  The success of our method in this case may 
be attributed to both the relatively large number of known interactions and the rich annotation of 
that class of interactions. The two other classes, GPCRs and Nuclear Receptors, are significantly 
smaller in terms of their interaction space and/or occupancy of that space. Nuclear Receptors 
comprise only 27 drugs and 22 targets, and 44 interactions. A method that relies solely on 
connectivity, like ours, cannot presumably formulate an informative model when the set of 
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‘edges’ to construct the network connectivity matrix is incomplete. In those cases, the data that 
come from other sources, e.g. chemical similarity and genomic patterns, amend this lack of 
information. Consequently, methods that incorporate such features [32;34] outperform ours.  
To further examine the effect of scarcity of known interactions on the performance of the 
present method, we performed additional tests by varying the fraction of hidden interactions.  
The results are presented in Figure 10. Panels a-d show the performance on Ion Channels, 
Enzymes, GPCRs and Nuclear Receptors, respectively. These results show that the performance 
depends on the fraction of known interactions. To put the results into perspective, we indicated 
by a vertical dashed line in each panel the fraction of data (80%) used in previous studies [32;34] 
for training purposes. Consistent with the above findings, Ion Channels yield the best result: 
previous AUC values [34] (of 0.799; Table 2) are matched with about only 35% of the data. On 
the Enzyme group, we match the performance of Yamanishi et al. [32]  (AUC of 0.845) with 
roughly 70% of the data used for training. GPCRs and Nuclear Receptors yield AUC values 
lower than those previously attained, [32;34]  irrespective of the fraction of hidden interactions.  
Table 2: Properties of the examined space of proteins-drugs, and performance of the 
present method in comparison to others 
Target 
type 
# of 
known 
inter-
actions 
# of 
drugs 
(N) 
# of 
targets 
(M) 
Size of 
interaction 
space 
(N M) 
Percent 
occupancy 
of the 
space 
Yamanishi   (pred 
pharmacol effects) 
Gonen, 
2012
(a)
Present 
method 
(D = 50) 2008
(a)
2010
(a)
Enzymes 1,515 212 478 101,336 1.50% 0.821 0.845 0.832 0.861 ± 0.02 
Ion 
Channels 776 99 146 14,454 5.37% 0.692 0.731 0.799 0.904 ± 0.02 
GPCRs 314 105 84 8,820 3.56% 0.811 0.812 0.857 0.771 ± 0.04 
Nuclear 
Receptors 44 27 22 594 7.41% 0.814 0.830 0.824 0.650 ± 0.11 
All
(b)
2,649 443 730 - - 0.782 0.807 0.825 
0.859 ± 0.03  
DrugBank 4,731 1,413 1,050 1,483,650 0.32% - - - 0.794 ± 0.01 
(a)
The last four columns present the comparison with Yamanishi’s [29;32] and Gonen’s [34] for the same 
dataset. 
(b)
weighted-average mean and covariances, evaluated using the number of interactions as weights
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In summary, the PMF method is particularly suitable for screening and inferring 
repurposable drugs or potential side effects from large datasets where computational assessment 
of structure similarity kernels become prohibitively expensive. In cases where the dataset of 
known interactions is too small, on the other hand, 2D or 3D similarity metrics provide more 
accurate assessments.  
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Figure 9: Closer examination of the statistical distribution and robustness of the results obtained for four 
classes of drug-targets and for the entire DrugBank 
Five-fold cross-validation runs were repeated for 500 iterations with different selections of hidden/known subsets to 
examine the robustness of the results. Panel a displays the running averages obtained for the AUC values as we 
performed 500 iterations. Results for Enzymes (green), Ion Channels (red), as well as the entire DrugBank (blue) 
exhibit small fluctuations (see histograms on the right ordinate), GPCRs exhibit moderate fluctuations (orange); 
whereas, the nuclear receptors (black) show significant variations. The running averages converge after ~ 100 
iterations and are robustly maintained to yield values listed in Table 2 (last column). The dependence of the final 
AUC values on the number of known drug-target interactions in the examined dataset is shown in panel b. A 
correlation coefficient of 0.73 is obtained, upon logarithmic fitting of the data.  When the number of known 
interactions is sufficiently large (e.g. N x M > 500), the occupancy of the full interaction space appears to affect the 
overall performance. (From [97]) 
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Figure 10: Evaluation of method performance as a function of dataset size on DrugBank v3 data.  
We evaluated [97] the method’s performance as a function of the training dataset size, displayed for the four subsets 
of targets listed in Table 2. The fraction of the dataset used for training the model was changed from 20% to 90% 
and the resulting AUC was recorded. Since there is randomness in assigning data points to the train/test datasets, 
each step was repeated 100 times. The solid curves show the average and the dotted curves showing one standard 
deviation above/below the average.  The dashed vertical bar indicates the fraction (80%) used for generating the 
AUC values listed in Table 2. The two horizontal lines indicate the AUC values attained by Gonen (2012) (red) and 
Yamanishi et al (2010) (black). (From [97]) 
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2.2.3 LFM Based Predictive Active Learning on Drug-Target Interactions 
As a more stringent test, 3,318 (70%) of the known 4,731 interactions in DrugBank v3 were 
randomly hidden, reducing the average number of interactions per drug from 3.35 to 1. The 
resulting ‘incomplete’ interaction matrix was then used to predict the hidden interactions, one at 
a time (rank-ordered by statistical weights ij(di, tj)) as described in the methodology section. 
The outcome was checked in a simulated experiment to assess whether the predicted interaction 
is a true positive (TP) or a false positive (FP). If the prediction is an existing, but hidden, 
interaction, the result is considered a TP (or hit), otherwise a FP (or miss). Then the model is 
updated in line with our AL scheme, and this loop is repeated until the completion of m = 1,000 
predictions. At that point, the simulation is halted and the overall performance of the model, or 
the hit ratio, is evaluated. Note that this method gives us a lower bound for hit ratio because the 
predictions are labeled as hits only if they are annotated in DrugBank, although they can be true 
but not yet observed experimentally or annotated in DrugBank. 
The results are presented in Figure 11. The figure displays the number of hits as a 
function of the number of predictions, obtained with three approaches: active learning (dark blue 
curves), passive learning (dark red curves) and random (green). The approach is able to achieve, 
on average, 587 hits out of 1,000 predictions via AL, 407 hits, via PL; and the corresponding 
variances (indicated by the dashed curves) are 35 and 46, respectively. Compared to the random 
probability of 2.23 hits per 1,000 predictions, the AL result is a 263-fold improvement over 
random.  The improvement of AL over PL is 1.44 fold. The AL improvement over random was 
reported to be up to 3.19-fold in a previous SVM-based study for predicting the activity of 1,316 
drugs against a single target [102]. The same study also reported 1.59-fold improvement between 
passive and active learners. Closer examination of the results from the top 100 predictions 
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(enlarged in the inset) further shows that hit ratios of 88.0 ± 4.7% and 82.2 ± 6.4% are obtained 
by the respective AL and PL protocols. The results are obtained with D = 50, which yields 
optimal results, as can be seen from Figure 12 and Figure 13. 
These results permit us to draw two conclusions. First, a hit ratio of 88% is attainable in 
the top 100 predictions (and 59% in top 1,000) upon adopting a PMF-based AL strategy for 
identifying hidden/unknown interactions in a sparse (0.32% occupancy) dataset of about 1.5 
million potential interactions. Second, the AL method outperforms random by two orders of 
magnitude and PL by a ratio of 1.5 approximately, in support of AL strategy for predicting new 
interactions.  
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(A)  
(B)      
 
Figure 11: Active learning hidden drug-target interaction prediction performance.  
(A) The number of drug-target interactions per drug was reduced from 3.35 (average) to 1 by hiding 70% of known 
interactions, selected randomly. Simulations were repeated n = 96 times for each of the 1 < m < 1,000 predictions 
(abscissa) and the number of hits (correctly identified hidden interactions) is plotted for each run, along the ordinate. 
The dark blue and dark red solid curves refer to the average performance obtained by active learning and passive 
learning protocols, respectively, using D = 50,  = 3,  = 0.01, and  = 0.9 in the adopted PMF algorithm. Dashed 
curves show the corresponding variances (by one standard deviation) above and below the mean value. The green 
curves (practically overlapping with the abscissa) refer to results from random predictions. The inset shows a close-
up of the first 100 predictions. AL reaches an accuracy rate (hit ratio) of 88.0 ± 4.7% and 58.7± 3.5 % in the 
respective cases of m = 100 and 1,000 predictions. These results are on DrugBank v3 data. (From [97]) (B) The 
same results reproduced on DrugBank v4 [107] data.  
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Figure 12: Improvement in prediction accuracy by AL over random and over PL 
Random selection of experiments is used as a representative of the performance of the brute force strategies 
commonly employed in screening based drug discovery efforts. Improvement over random allows the comparison of 
the various active learning paradigms. Fold-improvement is based on hit ratios obtained at the end of 1,000 
predictions, using same parameters as Figure 11. The AL performance levels off at about D = 50 in panel a. The last 
bar in each panel refers to the work of Warmuth et al. (2003). (From [97]) 
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Figure 13: Comparison of the predictive performance of the active and passive learners (AL and PL), and 
random model as a function of latent variable space dimensionality 
In each plot, the ordinate shows the number of hits (accurately predicted hidden interactions) as a function of the 
number of predicted drug-target associations (abscissa). Blue, red and green solid curves refer to AL, PL, and 
random results and dashed curves indicate the standard deviation (see caption for Figure 11). The dashed orange line 
indicates the 100% performance limit for comparative purposes. 70% of the interactions were hidden/removed 
randomly at the beginning of each simulation, and computations were repeated 48 times with different selections of 
hidden associations. The upper panels display the results for the top-ranking 100 predictions, and the lower, for the 
top-ranking 1,000.  Overall the AL accuracy rate increases from 50.4% to 58.7%, as we increase the dimensionality 
from D = 30 to 50, for m = 1,000 predictions, and the respective variances are 2.7 and 3.5%. In the case of N = 100 
predictions, the AL accuracy rate increase from 70.1% to 88.0%, and the respective variances are 5.1 and 4.7%. 
(From [97]) 
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2.3 EFFICIENT & ONLINE LATENT FACTOR MODEL BASED DRUG-TARGET 
INTERACTION PREDICTIONS 
BalestraWeb is built by training a latent factor model, as described in our previous work [97], on 
approved drugs and their interactions data from DrugBank v3 [99]. To build the latent factor 
model we use the GraphLab collaborative filtering toolkit implementation [108]. We mapped all 
the known names, brand names and synonyms of the drugs and targets to the relevant latent 
factor using a precomputed hash table that allows constant time access and enables maximal 
efficiency. 
 
The server allows users to submit three types of queries: drug-target interaction, drug-
drug similarity and target-target similarity. In the former case ( Figure 14), the input is mapped to 
the corresponding drug latent vector (LV) and target LV, and the dot product of these vectors 
yields a score for the probabilistic occurrence of the queried drug-target interaction. In the 
current version, there is an update compared to the original version where this operation is 
repeated across 128 models the results of which are averaged to reach the reported final value. 
Alternatively, the user can enter a single type of input, either a drug or a target. If a single drug is 
entered, the server retrieves the LV for that drug and screens it against the entire set of LVs 
corresponding to all targets, so as to identify known and newly predicted targets reporting the 
targets with the maximal predicted interaction scores. Drug-drug and target-target similarity 
queries provide information on drugs (or targets) similar to the query drug (or target) based on 
the cosine similarity of their LVs where the average cosine similarity across all models is 
reported to the user. The use of model averaging enables robust model learning since it prevents 
the random initialization of the model training stage from playing a role in the reported results. 
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The output is an interactive graph (which can be downloaded in JSON format) and a table 
displaying both the known drug-target interactions for the query drug (target) and the top N 
predicted targets (drugs), rank-ordered by their score. This interactive graph is rendered using 
scalable vector graphics, which is a widely used tool for displaying graphics on the Web as it is 
highly efficient in terms of network bandwith use as well as being highly communicative and, if 
preferred, interactive [109-112]. It enables the transmission of the network using only about 5% 
of the bandwith that would be required to communicate a static bitmap representation of the 
same graph, while also enabling interactive use. Furthermore, users can select to view a second 
layer of interactions beyond the immediate neighbors of the query drug/target in the bipartite 
network of drugs and targets. The resulting subnet of interactions thus provides a more complete 
picture of the investigated drug/target in the context of the interactions of their known 
targets/drugs. 
In addition to providing information on the distribution of scores in general, in the 
tutorial, we provide query-specific histograms in the output files:  the distribution of predicted 
confidence score (for each member of the drug-target pairs) or the histogram of cosine 
similarities (for each member of the drug-drug or target-target pairs). These histograms facilitate 
the interpretation of the specific score released for the query pair in the context of the complete 
distribution of scores for the investigated drug/target, and help make a better assessment of the 
significance of the outputted score.   
BalestraWeb has been significantly updated as of May 7, 2015. Multiple 
updates/improvements have been made compared to the version published last year. The new 
BalestraWeb v2 uses the average of 128 models to do all calculations in order to learn a robust 
model that does not become affected by the random initialization of the latent factor learning 
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process. This is important because during the model learning stage, the optimization landscape is 
tremendous because the number of parameters to be learned is high (the exact number of 
parameters to learn are N*D+M*D; which is 1313*50 + 1455*50 = 138,400 for DrugBank v4 
[107]). Consequently the algorithms that can learn a model in a reasonable time almost always 
converge to a local optimum. Therefore depending on where in the parameter manifold the 
random initialization places the model, the converged model (i.e. the learned model) can be 
different for different initialization seeds. This creates a high variability in the model outputs, 
which is undesirable. However averaging over a very high number of models all of which have 
been randomly initiated effectively removes/minimizes this problem because the optima that are 
frequently reached are all sampled. Instead of picking a single model which yields the first but 
not necessarily the best fitness, we take the average of all the trained models to minimize 
overfitting. As it currently exists, there are 11 newly predicted drug-target associations in the 
current version of BalestraWeb with a predicted interaction score above 90%. These are 
presented in Table 3. The list of all predictions above the threshold of 70% are reported in 
Appendix B. The code and all the auxiliary files that run BalestraWeb can be downloaded at 
http://balestra.csb.pitt.edu/static/balestraweb.zip and the explanation of the contents of this file is 
provided in Appendix C. 
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 Figure 14: BalestraWeb architecture and underlying methodology. 
 The user input (lower left) is mapped onto the latent factor vector(s) ui (for drugs) or vj (for targets), learned by 
minimizing squared error regularized by Frobenius norm  (see equation at top left). The output (right) contains  a 
score Rij representative of predicted interaction confidence along with a graphical representation of the close 
neighborhood of the query drug (red dots) and/or target (blue dots) in the drug-target association network, along 
with a table of known (grey bars) and predicted (red bars) interactions. Similar features hold for drug-drug and 
target-target similarity searches and outputs. (From [113]] 
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Table 3: The top predictions on BalestraWeb v2 
The table below shows the drug-target pairs with the highest predicted interaction likelihood scores among all 
possible BalestraWeb queries. In other words, these are the interactions that BalestraWeb considers most likely 
based on DrugBank v4. Therefore they represent the top candidates for experimental validation/ 
Drug ID Drug Name Target ID Target Name Score 
DB00116 Tetrahydrofolic acid BE0002176 Methylenetetrahydrofolate reductase 1 
DB00116 Tetrahydrofolic acid BE0000331 Serine hydroxymethyltransferase, cytosolic 1 
DB00145 Glycine BE0000331 Serine hydroxymethyltransferase, cytosolic 0.99971 
DB00116 Tetrahydrofolic acid BE0000292 Serine hydroxymethyltransferase, mitochondrial 0.99954 
DB00128 L-Aspartic Acid BE0000277 Calcium-binding mitochondrial carrier protein Aralar2 0.9993 
DB00145 Glycine BE0000292 Serine hydroxymethyltransferase, mitochondrial 0.99912 
DB00370 Mirtazapine BE0000291 5-hydroxytryptamine receptor 1A 0.92736 
DB00543 Amoxapine BE0000572 Alpha-2B adrenergic receptor 0.92068 
DB00408 Loxapine BE0000393 5-hydroxytryptamine receptor 2B 0.91003 
DB04946 Iloperidone BE0000533 5-hydroxytryptamine receptor 2C 0.9008 
DB00696 Ergotamine BE0000342 Alpha-2C adrenergic receptor 0.90057 
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2.4 METHODOLOGY FOR BUILDING EFFECTIVE MODEL-AVERAGED 
LATENT FACTOR BASED DRUG-TARGET INTERACTION PREDICTION MODELS 
In this section, I outline the steps needed to be taken in order to learn an effective LFM for 
predicting drug-target interactions, based on my experience during my PhD work.  
First, there are a multitude of different algorithms to learn LFM – even though I have 
started off with discussing PMF, it is important to realize that PMF is only one of the many 
competing latent factor learning algorithms. To mention a few, there is alternating least squares 
[114], ALS with parallel coordinate descent [115;116], stochastic gradient descent (SGD) [117], 
biased methods such as biased stochastic gradient descent [118] as well as many others published 
in the collaborative filtering literature. All of these models aim to accomplish the same objective 
at the core: to learn latent factor models that best characterize the nodes of a bipartite network 
based on their connections. ALS, SGD and PMF are highly similar in their objective functions, 
effectively minimizing squared loss regularized with the Frobenius norm of the latent variable 
vectors. The biased methods have a slight difference in that they include global and node-
specific bias terms designed to differentiate the nodes that are globally promiscuous from those 
that are not.  
The LFM learning methods have different hyperparameters that control some 
fundamental aspects of the learning process some of which we have seen above in our discussion 
of PMF. Specifically important hyperparameters are: the dimensionality of the latent variable 
space (D),  the regularization parameter governing how much to penalize complex models (λ),  
model update parameter that governs how much to update the model at each iteration (γ) whose 
larger values yield faster convergence but lower values yield more accurate convergence to local 
optima. Adaptive approaches where gamma is reduced by a certain rate at each iteration can also 
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be construed. This list is not exhaustive: depending on the type of learning algorithm, there can 
be other (or fewer) parameters to tune.  
There exist Bayesian treatments to these learning algorithms such as the Bayesian 
Probabilistic Matrix Factorization; BPMF [53] which aim to allow automatic complexity control 
by essentially integrating over all the hyperparameters. The problem is that after the Bayesian 
treatment, it is no longer possible to obtain a closed form expression of the gradient of the 
objective function, which necessitates approximating the posterior directly. This can be achieved 
through approaches such as Markov Chain Monte Carlo sampling, however sampling the 
posterior is usually computationally quite expensive, and also makes the method output harder to 
interpret.  
Therefore to build an effective non-Bayesian model, it is important to compare the 
performance of multiple hyperparameter combinations and algorithms. An example (results from 
the comparison I did on STITCH v3.1 in order to learn the LFM algorithm/ 
hyperparameterization to use for our work on HD) can be seen in Figure 15. The full list of 
results, acquired by testing each method and hyperparameter combination on 16 randomly 
partitioned train/test sets can be found in Appendix D. As best practice, I would recommend 
scanning these parameters in log-scale (i.e. 10
-12
, 10
-10
, etc) and in the following ranges: for 
latent variable dimensionality (D) the range 2
4
 to 2
7
 (which, in log-scale, is simply 4 values: 2
4
,
 
2
5
,
 
2
6
, and
 
2
7
); for λ/γ the range 10-12 to 100 (skipping every other entry, i.e. 10-12 then 10-10 and 
so on, might be performed to minimize computational resource use).  
If a non-Bayesian algorithm is used, there is a caveat that needs to be taken into account. 
The random initialization of the parameters that are being learned (note the nomenclature 
distinction: λ/γ are hyperparameters of the learning process, whereas the actual contents of the 
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latent variable matrices are the parameters that are being learned) can effect the final converged 
model. Therefore it is often a good idea to use the average of multiple (more than 100) models. 
Here it is important to take care that only the inner product of the latent variable matrices (i.e. 
predicted matrices) should be averaged. Averaging the latent variable matrices directly across 
models is an important mistake to be avoided as it can be algebraically shown to be different 
from the average of the predictions of the individual models.  
In order to test the quality of the models, one commonly used strategy is to evaluate the 
root mean squared error (RMSE) on held-out test data. I used RMSE for evaluation of the 
algorithms and hyperparameters to be used in modeling STITCH for the HD project, as shown in 
Figure 15. It is important to remember that whenever random train/test splits are used, the entire 
operation that involves this partition must be repeated many times in order to average out the 
effect of randomness in the train/test split.  
Depending on the objective to be accomplished, different performance metrics can also 
be devised. For example, to learn the model used in the current iteration of BalestraWeb (as of 
May 7, 2015) I have used rank-based performance evaluation, where the objective maximized is 
the median rank of the true-but-hidden interactions among all the predicted interaction partners 
of each drug. It is important to clarify the following point: When evaluating different model 
learning strategies, I optimize for the model that minimizes the median rank. Once that is 
completed, I use the best-performing hyperparameters to use the optimal model learning strategy 
to build the model underlying BalestraWeb. These parameters can be found in the code provided 
online at http://balestra.csb.pitt.edu/static/balestraweb.zip the contents of which are explained in 
Appendix C. The scores in Table 3, or anywhere in BalestraWeb for that matter, come from the 
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model that is learned with this optimal strategy. Hence the scores in Table 3, and the rank 
performance described here are from two entirely different approaches.  
Using a rank-based performance evaluation when training BalestraWeb makes the most 
sense because the most important aspect for the use case of BalestraWeb is to be able to rank the 
correct but unknown predictions as high as possible in the output predictions. Compared to the 
hyperparameters used to train the model used in Figure 13, the parameters identified through this 
scan achieve about 25% higher median rank for true but unknown (i.e. hidden) interactions, 
achieving a median rank of 20. This is quite impressive: 50% of the true but unknown 
interactions occur among the top 20 predictions.   
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Figure 15: Hyperparameter optimization results with four different latent factor model learning algorithms 
The figure shows results from hyperparameter optimization runs where the STITCH v3.1 is used to compare four 
LFM learning algorithms and their various hyperparameterizations. The panels (a), (b), (c), and (d) respectively 
show the results with the ALS, PMF, BiasSGD, and SGD algorithms. For the first two (i.e. ALS and PMF) the 
hyperparameters that are scanned here are the dimensionality of the latent variable space (D) and the regularization 
hyperparameter that determines how much to penalize complex models (λ). For the last two, the parameters that are 
scanned are λ as defined before, and γ which is the parameter that controls for how much to update the model at 
each iteration of the learning process. The vertical axis is always the root mean squared error (RMSE) on the held 
out test data, averaged over 16 iterations to minimize the effect of randomness in the data train/test split. ALS has 
performed the best at an RMSE of 4.7% when trained with λ=1.5 and D=100. Therefore I subsequently used ALS 
trained with these choices of parameter in our HD work to train the LFM on STITCH v3. 
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2.5 BALESTRATK: PYTHON TOOLKIT FOR DRUG TARGET INTERACTION 
DATA ACCESS AND INTEGRATION 
Programmatically accessing drug-target interaction data requires parsing and constructing data 
structures amenable for efficient storage and access. Specifically, O(1) time complexity
5
 in 
random access, O(1) name-based lookup operations, O(n) for iterations over all interactions of a 
particular protein or drug that is called by name are important requirements because these are 
commonly encountered operations when conducting computational drug repurposing research. 
Specifically, there are two main databases that I have used as the source of drug-target 
interactions in my research: DrugBank [99;107] and STITCH [45;119]. These two databases 
have different uses; DrugBank is a smaller but more richly annotated dataset of interactions with 
15,120 links between 7,740 drugs and 4,103 proteins whereas STITCH offers 4,523,609 
interactions between 141,799 drugs and 19,488 human proteins. In fact, STITCH is a superset of 
DrugBank data as it incorporates DrugBank among 14 databases in the latest version of STITCH 
(v4). Yet for the user who needs to programmatically access a set of specific drugs, the only 
method is to download these datasets in aggregate format and write purpose-specific scripts that 
access the relevant information. I have built a Python toolkit that obviates that need by collecting 
and packaging the code that I have had to write to conduct the research presented in this thesis: 
BalestraTK.  The open source code is hosted on GitHub, which is a commonly used open source 
code repository and is publicly accessible at: https://github.com/mcc-/balestraTK  
                                                 
5 O(.): The so-called big-O notation is commonly used in computer science to describe the complexity (often 
time complexity) of performing an operation in terms of the variable of interest; with constants eliminated 
from the inside of the parantheses. O(1) represents an operation that takes constant time and hence is the 
lowest time complexity that can be achieved, O(n) represents an operation that is linear in the number of 
inputs, O(n2) is quadratic, etc. 
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The mode of operation is such that there is a single one-time cost of parsing the data in 
these databases and constructing the data structures at the very first use of the toolkit, which 
leads to constant time access in every subsequent use of the toolkit as many times as desired. The 
data structures that are built are persistent (i.e. they are saved in the disk) and therefore they are 
used from one instantiation to the other. This means that once the data structures are constructed 
all subsequent uses also instantiate rapidly.  
When using BalestraTK, the user must point the toolkit to the folder where they keep the 
data downloaded from DrugBank; or in the case of STITCH simply where they intend to keep 
the data, and the code automatically downloads the required data there. The difference between 
these databases are due to differences in their license terms: DrugBank prohibits redistribution, 
thus I require that the user visit the DrugBank website to download the data and then point the 
toolkit to where the data is stored locally on his/her machine. STITCH license enables the 
sharing and redistribution of data thus I have coded the toolkit to automatically download the 
data when the toolkit is first used, if it is not already there. What this means is that if the user 
already has the STITCH files downloaded, he/she can simply point to the appropriate folder and 
the toolkit automatically uses them whereas in the absence of one or multiple required files, the 
toolkit will download the appropriate files to the directory specified by the user.  
When using STITCH, one important limitation is that the STITCH interaction file 
contains only PubChem compound identifiers for chemicals, and Ensembl/UniProt identifiers for 
proteins. In order to perform most repurposing and/or computational drug discovery efforts the 
names of both proteins and chemicals, as well as the structures of these chemicals and the 
sequences, GO identifiers, PFAM identifiers, etc of these proteins are also useful. In recognition 
of this fact, I automatically download the necessary information and integrate it into the 
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appropriate data structures. DrugBank already contains this information embedded in its data 
representation in an integrated manner, and I make them accessible programmatically as well. 
Detailed information as well as usage examples are provided on the public source code 
repository referenced above. 
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3.0  COMPUTATIONAL DISCOVERY OF THERAPEUTIC AGENTS AGAINST 
ALPHA-1 ANTITRYPSIN DEFICIENCY (ATD) 
In the following chapter, I will discuss the results of our study towards the identification of novel 
computational therapeutic agents. The data we analyzed have been acquired from two different 
studies, and therefore the results in the chapter are organized accordingly. In the first study, we 
have analyzed the data acquired from a whole genome RNAi knockdown study performed in a 
C. elegans model of ATD [65]. In the second study, we have analyzed the results from a high 
content screen conducted with the Prestwick library of approved small molecule chemicals. 
3.1 METHODOLOGY FOR DRUG REPURPOSING BASED ON MODEL 
ORGANISM GENE KNOCKDOWN DATA 
Model organisms are useful for interrogating different diseases in multiple contexts. Here we 
present a methodology for using model organism whole genome knockdown (RNAi) data to 
inform a drug repurposing approach. This methodology has been developed specifically with the 
intent to apply it to the aim 2, subaim 1 within the context of the A1AD project.  
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3.1.1 Whole Genome RNAi Knockdown Screen  
RNA interference screen was conducted to identify the genetic modulators that affect the 
accumulation of ATZ [120]. A transgenic C. elegans line expressing GFP tagged ATZ in the 
intestinal cells was derived. The intestinal cells were selected because these cells have the 
highest biological environment resemblance to the human liver cells. To simplify the 
identification of transgenic animals, the head muscle promoter myo-2 was tagged with mRFP to 
serve as co-injection marker. The successful injections led to the derivation of transgenic animals 
expressing mRFP in the head region and mGFP in the intestinal region.  
The transgenic animals were then used to knockdown each of the 16,256 known C. 
elegans genes by using RNAi fed to the worms through bacterial vector. Around 300 worms 
were exposed to each specific RNAi culture, followed by sorting them into three separate wells 
(100 worms per well) of a 96-well optical bottom plate. The worms were then anesthetized with 
4 mM Levamisole and imaged. In these images, ATZ accumulation manifests high GFP 
fluorescence and vice versa. The GFP signal is normalized with respect to the number of worms 
that are still alive – which can be quantified through the RFP signal.  
One or more plates were processed in separate batches. For every batch, two types of 
controls were setup: (i) GFP-quenching controls and (ii) empty vector feed controls. The GFP-
quenching controls (to be called GFP controls for brevity) allow for the quantification of the 
baseline signal that is measured even when there is minimal GFP fluorescence. Due to the 
instrumental variability, this minimal level of signal changes from batch to batch which is why 
these controls are important. The empty vector feed controls (to be simply called vector controls) 
are experiments where the bacterial vector was provided with no RNA. The objective of these 
controls was to determine the fluorescence readout in the absence of any alteration to the disease 
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progression. These controls allow elucidation of the impact of knocking out a particular gene on 
the disease progression.  
Knockouts that result in suppression of fluorescence intensity (i.e. ATZ accumulation) 
are called ‘suppressor knockouts’. For these types of knockouts, the signal level was similar to 
the GFP controls. If the gene knockout had no effect on ATZ accumulation, the readout was 
similar to the vector control readout. These knockouts can be termed ‘no-effect knockouts’. If the 
gene knockout caused excessive accumulation of ATZ, the fluorescence intensity was 
excessively high. These are called ‘enhancer knockouts’ and there are no controls that model 
higher than normal signal. The results of a typical experiment, along with the controls are shown 
in Figure 16a. 
Ideally, if there is ATZ accumulation in the cell (as in vector controls), the intensity of 
fluorescence should be high and if there are fluorescence quenchers present (as in GFP control 
experiments), it should be low. However the fluorescence intensity is not spread over a uniform 
range between different batches, as illustrated in Figure 16b. Therefore it became evident that the 
raw fluorescence values cannot be compared across batches. Moreover, there were some batches 
where fluorescence values were inconsistent with the controls, as illustrated in Figure 16c and 
these data were filtered out from the computational analysis.  
3.1.2 The Computational Methodology for Analyzing Whole Genome Knockdown Data 
Our computational method consists of two parts: (i) target identification based on suppressor 
knockouts, (ii) prediction of repurposable drugs inhibiting these targets. Suppressor knockouts 
identify the genes whose removal alleviates ATZ aggregation. Therefore inhibition of the 
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products of these genes by known drugs should also alleviate ATZ aggregation.  The steps in the 
procedure are enumerated and illustrated in Figure 17.  
To identify the suppressor knockouts, we made use of the observation that the GFP-
quenching controls model the readout from suppressor knockouts, while the vector controls 
model the readout of a no-effect knockout. Therefore we collected the control and gene knockout 
screen data (Step 1) and trained a logistic regression classifier (Step 2) to distinguish the gene 
knockout as suppressor knockout or not based on the reported fluorescence intensity after 
knockout. We trained a separate logistic regression classifier for each batch since only values in 
the same batch can be meaningfully compared.  
The logistic regression classifier was used to estimate the probability that a gene 
knockout was a suppressor knockout (based on the recorded fluorescence signal). If the 
probability that the gene suppresses ATZ clearance was more than 1 – 10-6, in other words if the 
probability of error was less than 10
-6
, the gene was classified as a suppressor (Step 3). There 
were 54 genes that were thus identified to cause ATZ accumulation (Step 4). We looked up the 
sequence of these 54 genes in the WormBase resource using the corresponding gene identifiers 
[94]. The full list of the 54 genes is provided in Appendix E. For 44 of these genes, WormBase 
delivered a known sequence (Step 5a).  
In parallel, we retrieved the sequences for the targets of all approved drugs in DrugBank 
[99], comprising step 5b in Figure 17. We then built a database using known drug target 
sequences, and compared each newly identified ATZ target against this database using the 
BLAST algorithm [121]. We used an E value cutoff of 1e-6 to select for high sequence similarity 
(Step 6). We identified three ATZ accumulating genes that were very similar (in sequence) to 
known drug targets (Step 7). These worm genes, along with the top three most similar drug 
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targets are shown in Figure 17. The list of drugs targeting these human proteins is provided in 
Table 4. The Tanimoto heatmap showing the level of similarity between these drugs is provided 
in Table 5.  
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Figure 16: Representative data samples from the RNAi knockdown data show the motivation of our batch-
specific classifier based computational workflow 
The data clearly shows that data across batches cannot be reliably compared and we have therefore analyzed each 
batch separately. (a) A typical experiment where the GFP controls model the signal of knockouts reducing ATZ 
aggregation and vector controls model the effect of no-change knockouts. (b) The range in which fluorescence 
values are distributed change significantly from one batch to another. (c) For some batches with an inherent 
measurement flaw, the control fluorescence values were distributed at a much different range than the knockout 
experiment readouts.   
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Figure 17: Visual representation of the computational workflow for whole genome knockdown data analysis 
The data used for this analysis is the whole genome RNAi knockdown data acquired on a C. elegans model of ATD 
by the Perlmutter lab. The data are initially analyzed using batch-specific machine learning tools to identify the 
important target genes in every batch, then these genes are mapped to human orthologs. These human proteins are 
then assessed to identify potential drugs that target the targets of interest. Three such drugs have been identified: 
Roxithromycin, Voacamine, and Glibenclamide. Glibenclamide has been identified as the best drug candidate 
among these three drugs because its target of interest, BSEP, is more specific (i.e. less promiscuous) than the target 
of the other two drugs, MRP1, based on the available data.  
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Table 4: Whole genome knockdown data analysis results 
Computational analysis of the human proteins with high sequence similarity to targets suppressing ATZ clearance, 
along with the structures of drugs targeting these human proteins are shown. The sequence similarity E-values are 
also reported. 
ATZ 
clearance 
suppressor 
Drug Targets 
with High 
Similarity 
Sequence 
Similarity 
(E Value) 
Targeting Drugs Drug Structure 
C05A9.1 
Multidrug 
resistance 
protein 1 
0 
Roxithromycin 
Voacamine 
Multidrug 
resistance 
protein 3 
0 – – 
Bile salt 
export pump 
0 
Glyburide (also 
called 
glibenclamide) 
T01G9.3 
Toll-like 
Receptor 9 
8e-15 
Chloroquine 
Hydroxychloroquine 
Toll-like 
Receptor 7 
3e-11 Imiquimod 
Toll-like 
Receptor 8 
2e-10 
Imiquimod Already shown 
Hydroxychloroquine Already shown 
F13D2.2 
Vasopressin 
1b Receptor 
3e-11 Desmopressin 
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Conivaptan 
 
Terlipressin 
 
Vasopressin 
1a Receptor 
9e-11 
Desmopressin Already shown 
Terlipressin Already shown 
Oxytocin 
Receptor 
3e-09 Carbetocin 
 
 
 
Table 5: The Tanimoto heatmap showing similarity between the drugs identified for ATD 
ChloroquineHydroxychloroquineImiquimodRoxithromycinVoa amineGlyburideDesmopressinT rlipressinCo ivaptanC rbetocin
Chloroquine 1 0.793 0.112 0.064 0.089 0.142 0.074 0.077 0.095 0.083
Hydroxychloroquine0.793 1 0.113 0.062 0.098 0.136 0.075 0.077 0.092 0.085
Imiquimod 0.112 0.113 1 0.049 0.123 0.065 0.065 0.064 0.095 0.066
Roxithromycin 0.064 0.062 0.049 1 0.126 0.068 0.097 0.09 0.07 0.114
Voacamine 0.089 0.098 0.123 0.126 1 0.098 0.11 0.11 0.118 0.126
Glyburide 0.142 0.136 0.065 0.068 0.098 1 0.101 0.092 0.137 0.123
Desmopressin 0.074 0.075 0.065 0.097 0.11 0.101 1 0.821 0.125 0.646
Terlipressin 0.077 0.077 0.064 0.09 0.11 0.092 0.821 1 0.124 0.628
Conivaptan 0.095 0.092 0.095 0.07 0.118 0.137 0.125 0.124 1 0.113
Carbetocin 0.083 0.085 0.066 0.114 0.126 0.123 0.646 0.628 0.113 1   
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3.1.3 Integration of Drug-Target Interaction and Drug Approval Status from Multiple 
Sources 
The NCGC Pharmaceutical Collection (NPC) [122] was used to download the complete list of 
7,793 drugs approved for human use (as of 11/20/2012). Of these, 1,426 were matched using 
their PubChem Compound Identifier (CID) to the chemicals collected in the STITCH chemical-
protein interaction database (DB) [45]. STITCH DB currently contains information on 
210,169,728 interactions between more than 300,000 chemicals and 2.6 million proteins from 
1,133 organisms. These 1,426 approved drugs (represented in both NCGC and STITCH DBs) are 
reported in STITCH to act as either activators or inhibitors of 5,373 human proteins (targets).  
Sequence information for 4,022 of these targets could be found among the 205,537 human 
protein sequences downloaded from the Ensembl DB [123] (as of 11/20/2012).  
3.1.4 Mapping Between H. sapiens and C. elegans Targets 
The sequences of these 4,022 human drug targets were screened against the sequences of the 
worm proteostasis network (PN) modifiers identified in the RNAi screening experiments, using 
BLASTP [121]. 29 worm (C. elegans) orthologs were identified, which represent 29.6% of the 
initial 98 RNAi hits. Of these, 24 (83%) are reported to be orthologs in Ortholist [95] as well.  
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3.1.5 Identification of Repurposable Drugs 
Having identified the human counterparts of the worm PN modifiers we scanned STITCH to 
determine whether any known drugs that target these human proteins could be repurposed 
against ATD. We mapped each of the original RNAi hits to their human orthologs. The human 
orthologs were chosen to be the target of an approved drug. This analysis of 29 RNAi hits 
yielded an ensemble of 244 human targets with 525 corresponding approved drugs. Since the 
Perlmutter lab previously ran the LOPAC library of compounds against ATD, we focused on the 
compounds that were dissimilar to the chemicals in LOPAC. Therefore we compared each drug 
to all the chemicals in LOPAC, and filtered out those with the highest similarity compound’s 
name and similarity score. This way, we extracted 30 approved drugs that targeted a human 
ortholog of a worm PN modifier gene, which were dissimilar to any previously investigated 
compound.  
3.2 GLIBENCLAMIDE AS A NOVEL REPURPOSABLE CANDIDATE AGAINST 
ATD 
All three of the C. elegans genes identified as ATD targets (C05A9.1, T01G9.3, and F13D2.2; 
shown in Figure 17) with high similarity to known drug targets are good leads for directing 
further experimentation. Yet the objective of the computational analysis was to deliver the single 
most promising lead. Therefore we concentrated on the gene with the highest sequence similarity 
to a known drug target: C05A9.1. This gene had an E value of 0 when compared against three 
out of all the known drug targets, these targets being multi-drug resistance protein 1 (MRP1), 
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MRP3 and the bile salt export pump (BSEP). We looked up the interaction partners of these 
three proteins in DrugBank (step 8 in Figure 17) and discovered that MRP1 is annotated as a 
target of roxithromycin and voacamine.  BSEP is targeted only by glibenclamide (MRP3 was not 
annotated as the target of any approved drugs). All three of these drugs are good candidates for 
experimental testing. However, we prioritized glibenclamide over the other two since 
glibenclamide’s target, BSEP, is annotated to be involved in the transport of 26 drugs while 
MRP1 is reportedly involved in the transport of 233 drugs. This ten-fold difference in the 
number of proteins they interact with suggested that BSEP is less promiscuous among the two 
targets. Therefore we prioritized the experimental testing of the corresponding drug, 
glibenclamide.   
3.3 ADDITIONAL REPURPOSABLE CANDIDATES AGAINST ATD 
Our computational approach (described in section 3.1.5) that aims to identify potentially 
repurposable drugs started with 104 C. elegans genes that were confirmed to be PN modifiers, 85 
of these were successfully mapped to human PN modifiers using OrthoList [95] and/or 
WormBase [94], and in turn these human orthologs were mapped to drugs acting on them 
through STITCH [45] and MetaCore [124] with 12 of the PN modifier C. elegans genes  being 
mapped to 48 distinct drugs. The results of the computational analysis were made available 
through an internet-accessible interactive tree-style visualization framework (at 
www.ccbb.pitt.edu/faculty/bahar/hitanalysis/) a screenshot of which is presented in Figure 18. 
Using this interactive visualization framework, one can see that the worm gene ‘ageing alteration 
1’ (abbreviated name: AGE-1, id: B0334.8) for example, is similar to the human protein 
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phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA). The user can click on the B0334.8’s 
name, see the WormBase page corresponding to this gene, and find out that this gene is named 
AGE-1 and that it is a central component of the C. elegans insulin-like signaling pathway. 
Likewise, more information about the homologue, PIK3CA, can be retrieved by clicking the 
name. PIK3CA is targeted by three drugs, caffeine, wortmannin and theophylline, according to 
MetaCore and STITCH. Both of these compounds have been tested by the Perlmutter Lab, with 
wortmannin showing activity. As illustrated over this single example, one can use the website to 
interrogate all the experimental results, and accompanying predictions.  
Based on the examination of our PN modifier set using comparative analysis to other 
RNAi screens, pathway analysis and ortholog searches, no PN master gene set emerged with 
exception of a few known PN modifiers such as AGE-1, inositol-requiring 1 protein kinase 
related (IRE-1) and abnormal DAuer Formation transcription factor (DAF-16). Rather than 
further investigate the biologic activity of each new PN modifier, we sought to utilize the gene 
set as whole to serve as potential drug target list and search for potential compounds that would 
be effective in decreasing sGFP::ATZ accumulation. The advantage of this approach is 1) prior 
knowledge of the gene function was not required, just whether the gene functioned as a PN 
enhancer or inhibitor in order to select an agonist or antagonistic compound, respectively, 2) the 
low cost and high processivity of screening and validation in C. elegans, 3) selection of 
druggable targets from a gene set based on phenotype, 4) the identification of drugs that could be 
tested rapidly for efficacy in other types of protein misfolding disorders, and 5) acceleration of 
the drug discovery process by re-purposing of FDA-approved drugs that also prove to be 
effective in vertebrate models of misfolded protein disorders.  
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Figure 18: The screenshot of our interactive visualization 
I have built a website to visualize the results of the analysis in order to facilitate the interrogation of our results by 
other scientists. The interactive visualization shows the C. elegans genes that were identified to be significant on the 
left column, the human orthologs that these genes map to in the center column, and the drugs known to be 
interacting with them on the right-hand side column. The service is accessible over the web at: 
www.ccbb.pitt.edu/faculty/bahar/hitanalysis/ 
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Figure 19: Human orthologs and drug-target interaction prediction 
Panel a shows a flow chart summarizing the in silico approach used to identify human drug targets from the 104 C. 
elegans PN modifiers. Panel b shows a Venn diagram showing the overlap between human orthologs identified by 
OrthoList and WormBase. Panel c shows DAVID analysis comparing the WormBase (outer ring) and OrthoList 
(inner ring) assigned orthologs to the original C. elegans protein profile (middle ring). Finally panel d shows the 
final list of targets and interacting drugs identified using STITCH and MetaCore. (From [65]) 
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In some instances, PN modifiers had multiple (>75) predicted drug interactions. 
Conversely, we found some drugs to have multiple predicted targets. For example, midostaurin, 
a synthetic indolocarbazole kinase inhibitor, was predicted to interact with several targets 
including tyrosine-protein kinase (ABL), vascular endothelial growth factor receptor 2 
(VEGFR2), platelet-derived growth factor receptor (PDGFR), RAC-alpha serine/threonine-
protein kinase (AKT-1), phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinase 10 
(MAPK10), serine/threonine-protein kinase/endoribonuclease (ERN1), receptor-type tyrosine-
protein kinase (FLT3) and AMP-activated protein kinase alpha 1 catalytic subunit (PRKAΑ1). 
To increase stringency, drugs with multiple or nonspecific target interactions were omitted from 
further analysis. Moreover, only drug-target interactions predicted by both STITCH and 
MetaCore were chosen for further investigation. Since some drugs were not readily available due 
to licensing restrictions or excessive cost, we tested only those compounds that were found in 
Library Of Pharmacologically Active Compounds (LOPAC). In total, 8 drugs targeting 4 PN 
modifiers namely, PI3K, Transthyretin (TTR), ATP-binding cassette (ABC) and opiate receptor-
like 1 (OPRL- 1) met our criteria for further investigation, as shown in Figure 19. To determine 
whether any of the 8 compounds were potentially therapeutic, sGFP::ATZ animals were treated 
for 24 hours and misfolded protein accumulation was measured using the ArrayScan VTI 
automated imaging machine. Fluphenazine was identified in a previous small molecule screen to 
reduce sGFP::ATZ accumulation and was included as a positive control [125]. Average results 
from three independent experiments showed that wortmannin, fluspirilene, fluoxetine and 
amiodarone significantly decreased sGFP::ATZ accumulation in a dosedependent fashion (12.5-
100 µM) compared to the DMSO control (Figure 200, panels A-B). Based on these findings, we 
selected one of these compounds, fluspirilene, and tested it on a mammalian cell line expressing 
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ATZ. As shown with C. elegans, fluspirilene showed a dose dependent decrease in ATZ 
accumulation in ATZ-inducible HeLa cell line, HTO/Z (Figure 200, panel C). 
We used a genetic approach to obtain insight into drug-target interactions. Wortmannin is 
a fungal steroid metabolite that inhibits mostly class I and III phosphatidylinositol 3-kinases 
(PI3Ks) [126]. In a C. elegans model of hypoxic injury, 100 µM wortmannin blocks autophagy 
by inhibition of the class III PI3K, VPS-34 [127]. Since autophagy inhibition enhances 
sGFP::ATZ accumulation, wortmannin was more likely to inhibit the class I PI3K, AGE-1, 
which would phenocopy the effects of reduced insulin/insulin-like signaling (IIS), rather than 
VPS-34 [128]. To determine whether AGE-1 was the target of wortmannin in this model, the 
Silverman lab first crossed sGFP::ATZ animals with AGE-1(hx546) mutants. As expected, the 
loss of AGE-1 activity resulted in a marked, but not complete, decrease in ATZ accumulation 
(Figure 21A). If the effects of wortmannin and AGE-1(hx546) on sGFP::ATZ accumulation 
were in the same or different pathways, then treatment of sGFP::ATZ; AGE-1(hx546) animals 
with an effective, but not maximal, dose of wortmannin (Figure 21B) would be expected to have 
no or an additive effect, respectively. No additive effect was detected (Figure 21C), despite 
GFP(RNAi) demonstrating that the sGFP::ATZ levels were not below the ArrayScan VTI level 
of detection (Figure 21B-C). Loss of AGE-1 activity, activates a downstream FOXO 
transcription factor, DAF- 16, which leads to decreased sGFP::ATZ accumulation (Figure 21A). 
Thus, if wortmannin inhibits AGE-1, a DAF-16 loss-of-function mutation should suppress the 
protective effects of the drug. This was the case as sGFP::ATZ; DAF-16(m26) animals were 
resistant to the effects of the drug, although sGFP::ATZ accumulation could still be modulated 
with GFP(RNAi) treatment (Figure 21D). Interestingly, the other three compounds isolated via 
the in silico screen, as well as the fluphenazine positive control, reduced sGFP::ATZ 
 91   
accumulation in sGFP::ATZ; DAF-16(m26) animals (Figure 21E). Taken together, these studies 
strongly suggested that wortmannin inhibited the class I PI3K, AGE-1 and that the other 
compounds were active on other target pathways. If this were the case, than combination therapy 
between wortmannin and one of the other compounds should be feasible. To test this hypothesis, 
we treated sGFP::ATZ animals with equal amounts of wortmannin and fluphenazine at three 
different concentrations. In all cases, combination therapy decreased sGFP::ATZ accumulation 
more than either monotherapy (Figure 21F).  
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Figure 20: Experimental testing of drugs predicted against ATD 
Panel a shows the fluorescence on L4 GFP::ATZ animals that were treated with 100 µM of each drug for 24 h, and 
analyzed using the ArrayScan VTI. Panel b shows the drug dose response curves. The experiment was repeated 3 
times, and a representative experiment shown. The error bars represent the SD of 5 replicate wells (n>150 
animals/treatment). Statistical significance was determined by using a Student’s t-test (*** P < 0.001, **P < 0.01). 
Panel c shows the effect of fluspirilene on steady state levels of ATZ in a cell line model of ATZ. HeLa cells 
engineered to express ATZ (HTO/Z) were treated with DMSO, carbamazepine (CBZ) (positive control) or 
fluspirilene for 48 h. Lysates were prepared and separated into soluble and insoluble fractions. Samples were 
analyzed by immunoblotting with antibodies against AT (top), and GAPDH (middle). GAPDH is cytosolic marker 
and its absence in the insoluble fraction indicates correct fractionation. The blots were also stained with GelCode 
Blue (bottom) to demonstrate equal sample loading in each well. (From [65]) 
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Figure 21: Validating AGE-1 as the target of wortmannin action 
Panel a shows the steady state expression levels of sGFP::ATZ in the N2, AGE-1(hx546) and DAF-16(m26) 
backgrounds. Data is normalized to N2;sGFP::ATZ worms. Panels b through d show the effect of wortmannin on 
steady state levels of sGFP::ATZ. N2;sGFP::ATZ (B), sGFP::ATZ;age- 1(hx546) (C) and sGFP::ATZ;DAF-
16(m26) (D) animals were treated with wortmannin (100 µM) for 24 h and analyzed using the ArrayscanVTI. 
GFP(RNAi) treatment was included as a control to show that ATZ levels could be further reduced in each line. Note 
wortmannin reduced the sGFP::ATZ level in the wild-type N2 but not in AGE-1(hx546) or DAF-16(m26) mutant 
backgrounds. Panel e shows the effect of various drugs on sGFP::ATZ;DAF-16(m26) animals. Of the drugs known 
to decrease sGFP::ATZ levels in the N2 background, only wortmannin failed to reduce sGFP::ATZ in the DAF-
16(m26) background. Panel f shows data from ATZ::GFP animals that were treated with 5,12.5 or 50M of 
fluphenazine and wortmannin, either singly or in combination. The data was normalized to the untreated DMSO 
control within each experiment. All experiments were repeated at least 3 times with n>150 animals/treatment. Error 
bars represent SD (A-E) or SEM (F). Statistical significance was determined using the Student’s t-test. ***P < 
0.001, **P < 0.01, *P < 0.05 (From [65]) 
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3.4 METHODOLOGY FOR HIGH CONTENT SCREENING DATA ANALYSIS AND 
HIT DIVERSIFICATION  
As part of the A1AD project, the Perlmutter, Silverman and Pak labs have screened the 
Prestwick chemical library (PCL) to test the ability of these drugs to modulate ATZ aggregation 
using the transgenic C. elegans model that was developed as the model system [129;130]. The 
Prestwick library consists of 1280 drugs approved for human use and mostly off-patent provided 
in DMSO solution at 10 mM concentration hence ready for rapid screening deployment [96]. 
The effect on suppressing ATZ aggregation has been quantified using ‘B-scores’ where lower 
scores indicate aggregation suppression, and higher scores indicate increased aggregation. In 
accord with the terminology adopted in our earlier work [65] compounds that significantly 
suppress ATZ aggregation are called ‘inhibitors’ (B-score < - 2); those that increase ATZ 
aggregation are termed  ‘enhancers’ (B-score > 2). Both groups have significant effect, and are 
collectively called ‘actives’. The remaining are called ‘no-effect’ compounds.   
We analyzed the high content screening (HCS) data by a 4-step protocol: (i) chemical-
based active diversification; (ii) target-based active diversification, (iii) mapping of drugs to their 
targets and the pathways of these targets, and the identification of the targets and pathways of 
active compounds that are significantly enriched. Each of these four steps is described in detail in 
the following subsections, with the methodology employed for the mapping of drugs to 
targets/pathways and the enrichment analysis of these targets/pathways (steps (iii) and (iv)) 
described together because their analysis steps were inseparably connected. 
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3.4.1 Chemical-Based Active Diversification 
The inhibitor chemicals have the desired effect of suppressing ATZ aggregation; hence it is 
useful to discover other purchasable compounds that could potentially be better therapeutic 
agents than those found in the Prestwick screen.  
First, we decided to identify the chemical descriptors that distinguish the inhibitor 
compounds from those with no-effect and the enhancers – in other words compounds with B-
score < -2 vs the rest. We have performed this through training a logistic regression classifier that 
learns to classify a compound based on its chemical fingerprints as inhibitor or not. To extract 
fingerprints from the chemical structures we used OpenBabel’s python wrapper Pybel and 
specifically the MACCS
6
 fingerprints (of which there are 166) as calculated by Pybel [93;131]. 
The distribution of weights of this classifier, along with the chemical structures of the highest 
and lowest coefficients are shown in Figure 22. The highest coefficients represent the chemical 
features most useful for discriminating actives; while the lowest coefficients, conversely, identify 
chemical groups that are least discriminative. We used this classifier to classify all 12.8 million 
purchase-ready compounds in ZINC [132]. We identified the compounds classified as being 
potential inhibitors against ATD, then clustered them based on chemical composition, selected 
one representative from each cluster (the closest to the centroid of the cluster), and provided a 
list of 342 compounds to be tested for activity, and this list can be found in Appendix F. The 
workflow we adopted is visualized in Figure 23. 
                                                 
6 MACCS: Molecular ACCess System 
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Figure 22: Visual representation of the chemical fingerprint classifier for active identification 
The coefficients corresponding to chemical fingerprints that best classify the ATZ aggregation modulator chemicals 
have high absolute values. To extract fingerprints from the chemical structures we used OpenBabel’s python 
wrapper Pybel and specifically the MACCS fingerprints (of which there are 166) as calculated by Pybel [93;131]. 
The features with strong positive values (shown on the right hand side) select for chemicals with high activity in 
ATZ clearance. Conversely, the features with strongly negative values represent features that strongly select for 
molecules with little or inverse effect in the disease progression. Therefore the chemical has the features with high 
coefficient values (right hand side), and does not exhibit the chemical features that have low cofficient values (left 
hand side).   
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Figure 23: Visual description of the high content screening data analysis and hit diversification workflow.  
The right hand side panel shows the workflow of the computational process. Specifically, the tested drugs in the 
PCL (the distribution of the activity, as measured by the B-score, is provided on the top left) are used as input to 
identify the chemical features that distinguish the 52 actives from the remaining inactives, then these properties are 
used to search ZINC (the distribution of probability of activity is provided on the bottom left), as well as being used 
to search STITCH-target sharing compounds. The 157 results of the target based diversification are reported in 
Appendix F and the 342 results of the chemical based diversification are reported in Appendix G.  
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3.4.2 Target-Based Active Diversification 
Another approach to identify chemicals with the desirable inhibitory effects is to look for other 
drugs associated with the targets of the inhibitors.  To this end, we have identified the interaction 
partners (i.e. the proteins that are targeted) of the inhibitor compounds from the STITCH dataset 
v4 [119], then identified all the drugs that potentially interact with these targets (using STITCH), 
and then used the chemical feature based classifier we trained in the previous step to calculate 
the probability of being an inhibitor for each of these compounds. We extracted the compounds 
that were classified as actives by the classifier (based on their probability of being active 
estimated by the classifier) with molecular weight above 300 (to exclude non-drug-like 
molecules such as zinc, copper, or mercury in STITCH). There were 157 such compounds. We 
report them in Appendix G. 
3.4.3 Overlap between target-based and chemical-based active diversification 
We have reported 342 chemicals through the chemical based active diversification strategy 
(reported in Appendix F) and 157 chemicals selected through target based active diversification 
(reported in Appendix G). It is important to investigate the degree of overlap between these two 
different sets of chemicals. To evaluate if there are any compounds shared in both lists, we 
computed the Tanimoto similarity and identified that there were no compounds shared.  
We next asked if these two sets of chemicals are more similar than would be expected by 
chance. To this end, we compared the similarity between the two selected sets of compounds to 
the similarity between two sets of 1200 randomly selected (without replacement; i.e. these two 
sets are mutually exclusive) compounds from the ZINC purchase ready set library [132] . We 
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compared the resultant distributions using Kullback-Leibler (KL) divergence, which is a measure 
of the difference between two distributions as described by Baldi and Nasr {Baldi, 2010 585 
/id}, where the authors report that a typical molecule has a KL divergence of 0.003 whereas the 
atypical molecule has KL divergence of 1.075. The KL divergence between these two 
distributions (i.e. similarity of two sets of random compounds versus similarity of the 
compounds in two diversification sets) is 0.031, meaning that these two distributions are similar, 
which in turn means that the two different strategies have produced consistent compounds. The 
two histograms in Appendix H illustrate that these two sets of chemicals, the result of chemical 
based diversification (i.e. those in Appendix F) and the result of target based diversification (i.e. 
those in Appendix G) have as little similarity as to be expected in a two large randomly selected 
set of chemicals. This validates that our two diversification strategies are indeed necessary since 
they diversify and select for different compounds. 
3.4.4 Target/Pathway Identification Through Enrichment Scores  
To calculate enrichment scores, the Prestwick library of compounds were mapped to pathways in 
two ways: through STITCH [119] targets and through KEGG [133] targets. Prestwick 
compounds were mapped to the corresponding chemicals in the STITCH database [119], the 
proteins listed as their interaction partners in STITCH were identified, and these proteins were 
mapped to the corresponding proteins in KEGG [134] through ENSEMBL [135]. Finally, these 
targets and the pathways that these targets occur in were identified for each drug. 
Prestwick compounds were mapped to the corresponding drug entries in the KEGGdrug 
database [133]. The targets of these drugs, as well as the pathways of these targets were 
identified in KEGG and associated with each drug. 
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In both instances, the KEGG is used as the source of pathway information. However the 
target-to-drug mapping is more extensive in STITCH with 390,000 chemicals, 2.6M proteins and 
1 trillion interactions [119].  KEGG, on the other hand, has 10,103 drugs with no detailed 
statistics of the interactions.  Therefore, we will focus here on the enrichment scores derived 
from the STITCH, although these were also calculated for the KEGG. 
For each drug we define activity as either enhancing (B-score > 2) or suppressing (B-
score <-2) ATZ aggregate formation, which is a quantification of the disease phenotype. All 
drugs which influence a target/pathway of interest are expected to either increase or decrease 
aggregation, and conversely any drug that increases or decreases aggregation is influencing a 
pathway/target of interest. To quantitatively identify the targets/pathways of interest, we 
collected all drugs with suppressive or enhancory effect into a set of active drugs and calculated 
the enrichment score of a given target or pathway t as follows: 
     
                 
             
 
where A is the set of all active drugs, D is the set of all drugs, |.| denotes the number of elements 
in a set, and   is the indicator function that is 1 if drug d targets t (t is either target or pathway 
depending on the enrichment being calculated) and 0 otherwise. In our case |A|=104, and 
|D|=966.  
We identified the pathways/targets of interest by quantifying the candidate 
pathway/target set that best separates the actives (B-score < -2 or B-score > 2) from the inactives 
(-2 < B-Score < 2). In order to achieve this goal, we calculated the reduction in Shannon’s 
entropy after splitting the drugs according to their interaction with each candidate, and computed 
the enrichment score, picking the best target/pathway recursively. Lower entropy indicates less 
disorder (higher confidence) in the respective drug activity annotation. 
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In the Prestwick library (PL), the number of active compounds are less than the inactive 
compounds. This imbalance was corrected by weighting the actives with    
         
     
such that the total weighted sum of actives equals that of the inactives. The weighted data were 
used to learn a decision tree by minimizing the entropy using the method described by Quinlan 
[136]. In our case, this method selects the target that best separates the actives from the inactives 
by choosing the target that when split accordingly minimizes the information entropy (also called 
Shannon’s entropy) defined as:                          where the probabilities are 
frequency counts of the members of the two classes (actives/inactives) weighted according to the 
weighting scheme described above. Intuitively, the method selects those targets that  separate the 
drugs into two sets: actives and inactives. The results of this procedure are shown in Table 6 and 
Table 7 for the respective datasets KEGG and Stitch. The full names of the proteins listed in 
Table 6 are as follows: dopamine receptor D2 (DRD2), calcium channel, voltage-dependent, L 
type, alpha 1C subunit (CACNA1C), 5-hydroxytryptamine (serotonin) receptor 2C, G protein-
coupled (HTR2C), angiotensin I converting enzyme (ACE), calcium channel, voltage-dependent, 
N type, alpha 1B subunit (CACNA1B), adrenoceptor alpha 2B (ADRA2B), prostaglandin-
endoperoxide synthase 2 (PTGS2), glutamate receptor, ionotropic, kainate 5 (GRIK5), adenylate 
cyclase-coupled 5-hydroxytryptamine (serotonin) receptor 7 (HTR7), protein phosphatase 3, 
catalytic subunit, alpha isozyme (PPP3CA), prostaglandin-endoperoxide synthase 1 (PTGS1), 
calcium channel, voltage-dependent, T type, alpha 1H subunit (CACNA1H), adrenoceptor alpha 
1A (ADRA1A), solute carrier family 6 (neurotransmitter transporter), member 4 (SLC6A4), and 
5-hydroxytryptamine (serotonin) receptor 1A (HTR1A). The full names of the proteins listed in 
Table 7 are as follows: v-rel avian reticuloendotheliosis viral oncogene homolog A (RELA), 
adrenoceptor alpha 1A (ADRA1A), renin (REN), calcium channel, voltage-dependent, L type, 
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alpha 1S subunit (CACNA1S), cholinergic receptor, muscarinic 1 (CHRM1), ATP-binding 
cassette, sub-family B (MDR/TAP), member 1 (ABCB1), and adrenoceptor alpha 1D 
(ADRA1D). Since the results are based on different datasets, the drugs are annotated with 
different targets based on the dataset and thus the results vary between the two tables. 
Adrenoceptors and calcium channels are common in both tables. The results are described and 
discussed in detail in section 3.5.2.  
We  also performed this entire procedure for pathways instead of targets after mapping 
each target to its KEGG pathway. The results were not appropriately high quality because we do 
not have perfect information on the (i) drug-to-target mapping, (ii) target-to-pathway mapping 
and when these two get compounded in the drug-to-target-to-pathway mapping the end result 
was that the compounded errors made it impossible to form a convincingly accurate enrichment 
analysis. Therefore we did not analyze those results further. 
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Table 6: The tree structure of the targets of active drugs based on KEGG target information 
We trained an entropy-minimization based decision tree to separate active drugs from inactive drugs using the algorithm due to Quinlan [136]. The targets of the 
drugs identified to be active in the screen were analyzed using an information entropy minimization strategy to build the following tree. The calcium channels, 
which are overrepresented are highlighted in orange. At each node, the entropy of the class labels (i.e. ‘active’ or ‘inactive’) are shown.  
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Table 7: The tree structure of the targets of active drugs based on STITCH target information 
We trained an entropy-minimization based decision tree to separate active drugs from inactive drugs using the algorithm due to Quinlan [136]. The targets of the 
drugs identified to be active in the screen were analyzed using an information entropy minimization strategy to build the following tree. The calcium channels, 
which are overrepresented are highlighted in orange. At each node, the entropy of the class labels (i.e. ‘active’ or ‘inactive’) are shown. 
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3.5 DIVERSIFICATION OF PROTECTIVE AGENTS AND PROPOSED 
MECHANISM 
The computational analysis techniques that we have described in chapter 3.4 serve different 
goals, hence our results are divided among these different goals. Specifically, for compound 
diversification the STITCH-based results offer the best predictions for three reasons: Firstly, 
STITCH-based predictions offer repurposing possibilities since the predictions can be filtered to 
select for compounds that have been approved for use in humans. This has the advantage that it 
would reduce the time and cost of therapy development significantly when compared to the 
development of a novel chemical. Secondly, as the STITCH-based  compounds are also filtered 
using the chemical structure based active/inactive classifier, the STITCH-based  compounds 
have also been selected to possess chemical structures characteristic of desired activity; in 
addition to having at least one target in common with a drug already approved. Hence the 
STITCH-based  compound predictions perform diversification of hits in both the proteomic 
space as well as the chemical space. Finally this method screens from a space of 300,000 
chemicals as opposed to the 1,200 that were experimentally tested; therefore there is an 
advantage in using this computational method as it would not be feasible to brute force 
experimentally screen such a large chemical space. For these reasons, we have prioritized our 
STITCH-based target diversification method for discovering potential new actives.  
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3.5.1 Lead Diversification 
We performed three lead diversification predictions using the methodology described above, and 
then manually  screened the results reported in Appendix G to identify the top three potential 
candidates for ATZ aggregate inhibition to have a feasible number of experimentally testable 
predictions. Among the compounds in this list, we selected only the compounds that were 
already FDA approved for human use in order to enable repurposing and a quick translation of 
the discoveries we make. After sorting the compounds based on the number of targets (since the 
number of targets are all in the order of 10
1
 we took this to indicate mostly how well studied 
these compounds are) and proceeded down the list one by one, manually analyzing the 
compounds for multiple criteria.  
For each compound, if the compound was not an approved drug, we eliminated it and 
skipped to the next compound. Then, given the compound is approved, we looked at the targets 
that each compound shares with known actives, and looked for diversity. The idea here is that we 
do not want to have three compounds all very similar to each other. For example instead of 
having two compounds both  targeting ATP binding cassette containing proteins, it is preferable 
to have one of the two target the cholesterol pathway. This way of having multitude of targets 
provides a way for each tested compound to provide information about another set of targets 
instead of testing the validity of the same targets multiple times. As such, we can interrogate a 
larger segment of the chemical/proteomic interaction landscape with fewer experiments and thus 
maximize the utility gained from the experiments. Finally we filtered out compounds that were 
already tested and shown to be protective – such as docetaxel, which ranked high in our list but it 
has already been shown to be protective in our PCL screen experiments. We selected the three 
best predictions in order to maximize the cost/benefit from a feasible number of follow-up 
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experiments. These three predictions are interesting because they represent non-overlapping 
mechanisms of actions ranging from antineoplastic to antidepressive to blood cholesterol 
lowering drugs. Likewise their targets, and hence the targets that they share with the hits of the 
Prestwick screen are also entirely different allowing them to interrogate the various cellular 
processes that can be important for protection against ATD. If any of them fails in clinical testing 
whereas the others show neuroprotective activity, this is useful in enabling us to focus on the 
specific mechanism of action that is most relevant to ATD among the many different 
alternatives.  
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Figure 24: Possible repurposable candidates against ATD.  
We show the three repurposable predictions against ATD: antineoplastic sorafenib, antidepressive duloxetine and 
anti-hyperlipidemic ezetimibe. Sorafenib is approved for use as an antineoplastic in humans against kidney cancer, 
advanced thryoid carcinoma, and finally advanced primary liver cancer. Duloxetine is approved for use in humans 
against major depressive disorder and generalized anxiety disorder. Ezetimibe is approved for use in humans to 
lower blood cholesterol levels by decreasing cholesterol absorption in the small intestine. The chemical structure of 
the drug is shown on top. The targets that are shared with drugs successful in the screen are shown in the middle as a 
graph; where the prediction drug is shown in green, the targets are shown in yellow and finally other drugs that were 
successful in the screen that share a target are shown in red. Finally, the name of the gene products of each gene 
shown in the graph is presented in the tables at the bottom of each column.  
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3.5.1.1 Sorafenib 
The drug sorafenib has been approved for use as an antineoplastic in humans against primary 
kidney cancer, advanced primary liver cancer, and advanced thyroid carcinoma [137-141]. It has 
a well-characterized interaction profile in STITCH, with 62 targets listed in human. Since 
sorafenib is an antineoplastic drug, it shares targets mainly with other antineoplastics. We have 
discovered that six of these targets are shared with drugs that are of interest based on our 
experimental data. Furthermore, sorafenib has been classified as an active based on its chemical 
structure using our classifier that was trained on the chemical structure of the active drugs; 
therefore it matches all the characteristic chemical properties of the active chemicals. The 
interaction partners that sorafenib shares with other experimentally selected drugs are shown in 
Figure 24 along with other information.  
3.5.1.2 Duloxetine 
Duloxetine has been approved for use as an antidepressant in humans against major depressive 
disorder and generalized anxiety disorder [142-146]. Duloxetine is also well-characterized in 
STITCH, having 18 reported targets. There are 9 targets that are shared with the significantly 
neuroprotective drugs, which are shown in Figure 24 along with auxiliary information on 
compound structure and target names. Where sorafenib shared antineoplastic targets, duloxetine 
shares serotonin and sodium-dependent transporter targets with the ATD-protective drugs. Since 
the chemical structure based classifier has been applied to duloxetine as well, it clearly contains 
the chemical features that are important for the recognition of activity. The known activity, and 
therefore targets of duloxetine are different from those of sorafenib; therefore it represents a 
good alternative prediction for testing. 
 110   
3.5.1.3 Ezetimibe 
Ezetimibe is used to decrease blood cholesterol levels by decreasing absorption of cholesterol in 
the small intestines [147-149]. Ezetimibe has 16 targets reported in STITCH, two of them shared 
with simvastatin – which is also an anti-cholesterol drug, that ezetimibe is commonly co-
administered with. Simvastatin has been shown to be highly active in alleviating ATD as it has a 
experimentally reported B-score of -2.60. Since ezetimibe reportedly shares two of its 
mechanistic targets (shown in Figure 24) and ezetimibe has also passed the chemical structure 
based classifier that filters out the drugs with inactive-like chemical features; it is also a good 
candidate for further experimental validation.  
3.5.2 Mechanism Identification 
We have analyzed the targets of the drugs that showed protective activity against ATD, as well 
as the pathways that these targets occurred in, to identify the mechanism of action of the 
successful compounds. We have focused on the target analyses, and not the pathway analyses; 
the reason being that in pathways we are operating on two levels of uncertainty: there are drugs 
which have unannotated targets; likewise there are targets with unannotated involvement in 
pathways. Missing annotations from both of these compound when looking at drug-to-pathway 
results presents a significant problem; the correction of which is a database curation work. When 
considering target enrichment, however, this limitation no longer exists since we have only one 
mapping (drug-to-target) and while there might be targets missed, the confidence level of the 
targets we do know, is significantly higher.  Consequently we have found the most enriched 
pathway results to be inconsistent when evaluated with various different methods; whereas 
targets have given consistent results. Therefore we choose to focus on targets.  
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Furthermore, we wanted to focus on targets that showed a strong signal for being active 
in the mechanism. Therefore we wanted the effect to be reproducible. To ensure this, we looked 
for at least two inhibitor drugs that interact with each target in our enrichments. This ensures that 
the inhibitor effect of modulating the target is reproduced – by at least one other drug that 
interacts with this target.  
When we compared the results of target enrichment analysis using the score based 
approaches and the entropy based approaches, with both methods performed with both STITCH-
based  and KEGG-Drug based data, there was one target that always showed significance: 
calcium channel. 
3.5.2.1 Calcium channels 
The calcium channels appear high among the top ten most enriched targets when compared using 
the enrichment score defined in methods in both the STITCH-based  [119] and the KEGG-Drug 
based [133] approaches, as shown in Table 6 and Table 7. In addition, calcium channels also 
appear in the entropy minimization based decision trees that were learned on KEGG-Drug and 
STITCH data. This indicates four possibilities: (i) The direct interaction with calcium channels is 
responsible for protective effect, (ii) there is an indirect effect of interaction with calcium 
channels that leads to protection, (iii) there is a target similar to calcium channel, whose 
interactions are not captured in both of the two different databases that we used (the reason we 
used two different databases was to reduce this possibility) and that target is causing the 
response, (iv) there is no relationship between suppression of ATD and calcium channels; this is 
purely a random occurrence (the reason we used four method/database combinations was to 
reduce this possibility). 
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We used multiple databases to reduce the chances that there is an unknown interaction 
that dominates the activity that is missing from both databases. However, in analyses using both 
databases the calcium channels appeared high; hence this has a low likelihood. Likewise, the 
possibility that this is due to chance alone is unlikely when considering the fact that all four 
method/database combinations indicate that calcium channels are enriched among the targets of 
the drugs that showed ATD suppressive activity. Further determination of the possibility that 
calcium channel interaction leads to protection in ATD needs to be tested experimentally to be 
fully validated. 
3.5.2.2 Adrenoceptors 
Adrenoceptors appear enriched in the results shown in Table 6 and Table 7, in addition to 
calcium channels described in the previous subsection. Specifically, adrenoceptor alpha 2B 
(ADRA2B), adrenoceptor alpha 1A (ADRA1A), and adrenoceptor alpha 1D (ADRA1D) 
subtypes appear as important distinguishing targets in both tables. As with the calcium channels 
discussed in the previous subsection, these proteins have been selected due to the impact they 
have in differentiating the drugs that were active in modulating ATD disease phenotype and 
inactive drugs with no impact on the disease progression. Future experimental studies are 
required to confirm (or refute) the role of adrenoceptors in ATD or in other protein 
conformational disease contexts. 
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4.0  COMPUTATIONAL AND EXPERIMENTAL DETERMINATION OF 
NEUROPROTECTIVE THERAPEUTICS AGAINST HUNTINGTON’S DISEASE (HD) 
In the following chapter, I will report our results on determining the mechanism of action of a 
diverse set of compounds which were found to be neuroprotective in a model of Huntington’s 
disease using the LFM methodology we described in Chapter 2, specifically section 2.2.1 where 
we validated the use of LFM as descriptors. Then I will discuss our computational work for the 
identification of novel therapeutic candidates for use against Huntington’s disease. Finally, I am 
going to report the follow up experimental work to test those predictions which I have 
participated in. Therefore the chapter is divided into three sections, with the first describing the 
mechanism identification work, the second discussing the LFM based predictive work and the 
third describing the experimental work.  
4.1 MECHANISM OF ACTION OF DIVERSE NEUROPROTECTIVES 
In order to discover new therapeutic candidates against HD, we have mapped the list of drugs 
known to be neuroprotectives to their targets in STITCH, identified their overlapping targets, and 
listed other drugs known to interact with the selected targets while having diverse activity 
profiles otherwise. The process is intended to generate target-based diversification when a small 
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number of actives are available. Figure 30 presents a schematic description of the computational 
workflow designed for this process.  
First we compiled a list of 24 known broadly neuroprotective drugs, as follows: Most of 
these drugs were reported by Wang and coworkers [92] after a two-stage screen where they first 
screened for inhibition of cytochrome c release from isolated mitochondria, and then tested the 
hits in a secondary assay for neuronal cell death inhibition. The authors tested 1040 drugs from 
the National Institute of Neurological Disorders and Stroke (NINDS) library, and found 21 drugs 
that successfully prevented the release of cytochrome c from isolated mitochondria when 
challenged with calcium and protecting neuronal cells from death. Of these 21 compounds, 15 
were found to be effectively inhibiting neuronal cell death in follow-up assays, (with 6 having 
nanomolar IC50 values, termed Group I, and 9 having micromolar IC50 values, termed Group II) 
whereas 6 were found to be ineffective (Group III). Taking this information into account, we 
used the 15 that were effective in neuronal cell death inhibition as well as the cytochrome c 
release inhibition. We also compiled a list of all the drugs that were in clinical trials due to their 
neuroprotective effect to form Group IV. The structures, names and the groups of the entire set 
of compounds discussed here are shown in Figure 25. We collectively annotated the drugs in 
Groups I, II, and IV as the set of known neuroprotectives to inform our computational 
approaches.  
The compounds in this list are traditionally annotated with a highly diverse set of 
therapeutic indications with no unifying theme:methazolamide is used for treatment of glaucoma, 
minocycline is an antibiotic, while azathioprine is used for immunosuppression. Therefore we set 
out to determine the mechanism of action of these drugs using computational methods. 
Specifically, we looked at the interaction information available about these drugs in three 
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databases: known interactions in STITCH [45] and DrugBank [99], PMF predictions made as 
described in our previous work [97] on both of these databases, and SEA predictions [28] on 
ChemBL data [150]. We analyzed the information about these drugs using three different 
methods: direct set overlap of their targets, overlap between PMF predicted targets of these 
drugs, and 3D chemical similarity based search.  
4.1.1 Overlap of Known Targets 
To assess the mechanism of action of these drugs, we pooled together information on their 
known targets from two different databases: STITCH v3 [45] and DrugBank v3 [99]
7
. Detailed 
information about our results can be found in Error! Reference source not found.. Not every 
single neuroprotective could be found in both of these databases: we could map 14 of these 24 in 
DrugBank which is a smaller database with less than 10,000 chemicals; whereas STITCH is a 
bigger database with data on about 300,000 different chemicals therefore we could identify 22 of 
the 24 drugs. The drugs that could be identified in each database were subsequently mapped to 
50 known targets in DrugBank and 175 known targets in STITCH. The numbers of overlapping 
targets between all methods (see below the descriptions of the methods) across all databases are 
shown in Figure 27. 
We looked at the overlap between these different targets, with the results shown in Figure 
26. Specifically the only overlap among the known targets in DrugBank is between drugs 
melatonin and bepridil which share calmodulin, and minocyclin and doxyclyclin which share 
                                                 
7
 Please note that despite the fact that version 4 of both of these databases are currently available and the default for 
both of these resources, they have been released in 2014 whereas we conducted this study in 2013 therefore version 
3 was the latest version available at the time. 
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30S ribosomal proteins S4 and S9 as targets. There are no other overlapping targets in 
DrugBank. 
We identified the overlap between all 731 targets in six different ways, specifically the 
overlap between (i) PMF predicted targets in DrugBank, and 3D predicted targets in DrugBank, 
(ii) the DrugBank known targets and 3D predicted targets, (iii) STITCH and SEA, (iv) DrugBank 
and SEA, (v) DrugBank and STITCH, and finally (vi) DrugBank, STITCH and SEA. The results 
are shown in Figure 28. 
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Figure 25: Neuroprotective drugs used to inform computational method 
From an NINDS library of 1040 drugs, 21 were found to be inhibitors of cytochrome c release in isolated 
mitochondria which were then tested for their ability to inhibit neuronal cell death in a HD model cell line and 6 
were found to have IC50 values in the nanomolar range (Group I), 9 were found to have IC50 values in the 
micromolar range (Group II), whereas 6 were shown not to have a significant neuroprotective effect (Group III) in 
previous work [92]. We also compiled a list of 9 neuroprotective drugs currently in clinical trials (Group IV). We 
used groups I, II, and IV (24 total) as neuroprotectives to inform the computational method.  
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Table 8: Summary results of our analysis of target data for the known neuroprotectives 
The table below summarizes the findings from our computational assessment of the data available on the targets of the 24 known neuroprotectives. Of these 24 
compounds, 14 were identified in DrugBank [99], 22 were identified in STITCH [45], and 14 were amenable for query on the Similarity Ensemble Approach 
(SEA) server [28]. 
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4.1.2 Chemical Similarity Comparison 
We performed chemical similarity comparison and looked for the targets of the compounds that 
are highly similar to the known neuroprotectives. We used the Similarity Ensemble Approach 
(SEA) to predict 158 ChemBL targets based on chemical similarity, and we also used 3D 
similarity to identify 294 targets in DrugBank. Specifically, for our 3D similarity calculation we 
compared the structures of the 22 that we successfully mapped to STITCH compounds to all the 
chemical structures in DrugBank using the ROCS 3D small molecule structural similarity 
methods developed by OpenEye™ [151]. Briefly stated, this method represents a given chemical 
structure with Gaussians that are centered on each atom. There are two different types of 
Gaussians: ‘colorless’ for simple steric overlap and ‘colored’ Gaussians where each color 
represents a different physico-chemical property (positive charge, negative charge, 
hydrophobicity, etc). The overlap among these Gaussians allows us to numerically evaluate the 
similarity between two compounds in terms of their shape as well as their electrostatic 
properties.  
For the 22 drugs that could be mapped to the STITCH database, we identified their 
chemical structures from the data in STITCH, and used those structures to search for their 
analogues in DrugBank. We identified a total of 155 drugs that were similar to these 22 chemical 
structures. These drugs in turn mapped to 294 targets, 220 of which had KEGG pathways. These 
220 KEGG pathways were replicated among them, and therefore they matched to 149 unique 
pathways.  
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4.1.3 LFM Predictions 
We used LFM in predictive function in order to discover the unknown interactions of the drugs 
that we could map to DrugBank and STITCH. The results reported in Chapter 2 demonstrate that 
the latent factor models can function remarkably as predictors of drug-target interaction. In this 
biomedical project where we have a set of drugs with largely unexplained mechanisms of action 
for their reported neuroprotective activity, it is necessary to identify any potential targets of these 
drugs that might explain this novel activity. Therefore we trained latent factor models on both 
DrugBank and STITCH, and used them to predict the unknown interactions of the drugs of 
interest. 
Our results in STITCH show that there was one target, Lysine-specific demethylase 
(PHF2), which was predicted to be the interaction partner for seven drugs: bepridil, parthelonide, 
dioxycycline, mephenytoin, N-acetyl DL Tryptophan, ubiquinone and cysteamine. PHF2 is a 
lysine demethylase that functions only after activation by PKA, acts on both histones and non-
histone proteins, and is known to form a complex with and mediate the 
methylation/demethylation of ARID5B [152]. It is important to note that the interaction between 
these seven drugs and PHF2 is predicted using the LFM we built, and now reported to be known 
therefore it would be important to experimentally validate this interaction as a first step to further 
understanding. However it is important to note that this interaction might point to a key new 
neuroprotective mechanism when it is considered that in the literature it has been reported that 
PKA has a role in preventing the induction of apoptosis in astrocytes [153], where it has been 
shown that an agent that activates the PKA pathway (octadecaneuropeptide) leads to protection 
from apoptosis. Since PHF2 activity is only possible after PKA activation, and since PKA based 
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apoptotic protection in brain cells has been previously demonstrated in the literature, this target 
overlap result serves as an interesting precursor for further study.  
Based on STITCH data, HDAC was shared as a target by compounds melatonin and N-
acetyl DL Tryptophan. This was an important finding because HDAC inhibitors have been 
previously reported to ameliorate disease phenotype [154-156], transport deficit [157], and motor 
deficit [158] in Huntington’s disease models. These publications indicate that targeting HDAC 
ameliorates disease phenotype in HD and therefore point out the potential significance of this 
predictive finding.  
4.1.4 Pathway Mapping of Targets 
We have analyzed the targets that we identified for their roles in known pathways. Specifically, 
we mapped each of the drug targets to KEGG pathways and identified the pathways with the 
highest number of drugs acting on them. Calcium signaling pathway emerged as a significant 
pathway of interest from this study owing to the multitude of known and predicted targets of the 
known neuroprotectives in this pathway, in addition to the broad literature support for the role of 
calcium in HD pathophysiology. This section is dedicated to our findings on this pathway in 
detail. 
There are two known neuroprotectives, bepridil (drug #6) and melatonin (drug #12) that 
are known to target two proteins in the calcium signaling pathway: voltage-dependent calcium 
channel subunit α1 (CaV1) which is targeted by bepridil, and calmodulin (CALM) which is 
reportedly targeted by both bepridil and melatonin. The calcium channel subunit α1 has been 
reported to be singularly sufficient to conduct Ca
2+
 transfer across the membrane [159]. More 
generally bepridil is known to be a calcium channel blocker with the latest version of DrugBank 
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(v4.2) reporting interactions between bepridil and a large variety of calcium channel subunits, 
indicative of its broad calcium channel blocker activity. Traditionally calcium channel blockers 
are used for antihypertensive function in the clinic, therefore the role of bepridil in HD remains 
unclear at first, yet a deeper look reveals that this is actually a highly interesting discovery.  
The role of calcium channels in ataxia mechanistically caused by an expanded 
polyglutamine repeat have been established by previous studies: an expanded CAG repeat in 
human calcium channel subunit α1A has been reported to be the causal mutation for 
spinocerebellar ataxia type 6 (SCA6)  in humans [160]. There are multiple significant similarities 
between the two diseases. They are both late onset neurodegenerative disorders that manifest in 
uncontrolled muscle movements the characteristic chorea movement in Huntington’s disease is 
highly akin to uncontrolled movement in SCA6. Furthermore expanded polyglutamine repeats 
have been reported to be causal in multiple other late onset neurodegenerative diseases: 
spinocerebellar ataxia type 1 (SCA1) [161], spinocerebellar ataxia type 2 (SCA2) [162], 
spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) [163], spinobulbar muscular 
atrophy (SBMA) [164], dentatorubral-pollidoluysian atrophy/Haw-Rover syndrome 
(DRPLA/HRS) [165]. These results indicate that polyglutamine repeats are causal for multiple 
neurodegenerative diseases that have similar clinical presentations to HD and the further finding 
that one of those polyglutamine expansions has been localized to the calcium channel implicates 
the role of modulation of calcium. Hence the neuroprotective role of the calcium channel blocker 
bepridil to be due to its calcium channel interactions is reasonable when evaluated within the 
context of previous findings. 
Bepridil is reported to interact with calmodulin in a Ca
2+
-dependent manner [166], along 
with melatonin which is also reported to be a calmodulin inhibitor [167]. Furthermore, 
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melatonin’s activity on calmodulin is implicated in its rapid (<1 min) and transient (5-6h) effect 
of ROS generation in cells [168]. These findings implicate that the modulation of the calcium 
signaling pathway could be important for modulating Huntington’s disease.  
Furthermore, despite having only two drugs and targets implicated in the calcium 
signaling pathway, we have identified a large set of predicted interactions involving proteins in 
this pathway. This strong predicted role for calcium in the mechanism of Huntington’s disease is 
supported by previous findings reported in the literature.  
On the tissue level, researchers have discovered that in post-mortem brain specimens of 
patients who have died from Huntington’s disease there is a substantial loss of neurons 
containing the calcium-binding protein calbindin 28K [169]. These calbindin containing neurons, 
as well as the striatal component that they are located in are reported to be particularly reported 
in Huntington’s disease therefore the observed effect seems to be specific to Huntington’s 
disease instead of a general response to the neurodegenerative process.  
On the cellular level, researchers have identified that mutant huntingtin directly interacts 
with neuronal mitochondrial membranes and leads to mitochondrial membrane depolarization at 
lower calcium loads accompanied with lower membrane potential [170]. Furthermore, these 
mitochondrial calcium abnormalities have been observed months before the presentation of 
pathological or behavioral abnormalities. The researchers demonstrate that the mitochondria in 
lymphoblasts from HD patients have a significantly reduced Ca
2+
 retention capacity (on average 
64 nmol/mg protein in HD patients versus 146 nmol/mg protein in healthy control). Despite the 
fact that the exact long-term functional consequences of the mitochondrial Ca
2+
 defect are 
unknown, the fact remains that calcium related pathways are significantly defective in HD 
patients.  
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In summary, the multitude of predicted and known interactions with calcium signaling pathway 
shown in Figure 29 are grounded when considering the role of calcium widely reported in the 
literature on Huntington’s disease. 
 
Figure 26: The overlap between the known targets of the neuroprotective drugs in DrugBank 
The drugs are separated into groups and indexed as in Figure 25, with the known target information displayed in two 
ways: Panel a shows the number of targets identified for every single one of the 14 (out of 24) compounds that could 
be found in DrugBank. This panel shows which 14 of the 24 were mapped to DrugBank as well as the number of 
targets for each of them. Panel b shows the overlap between the targets of these drugs (and is therefore symmetric). 
This panel clearly shows that there is very little known target overlap in DrugBank, with only drugs 12 (melatonin) 
and 6 (bepridil) sharing one target (calmodulin), and drugs 13 (minocycline) and 11 (doxyclycline) sharing two 
targets (30S ribosomal proteins S4 and S9). There are no overlapping targets in DrugBank other than these. 
-
I II IV
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
I
1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
6 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
II
7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
11 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0
12 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
13 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0
14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
IV
16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
19 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
23 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
24 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
No. Targets
1 0
2 0
3 1
4 0
5 1
6 9
7 0
8 2
9 4
10 0
11 2
12 10
13 9
14 1
15 0
16 6
17 0
18 0
19 0
20 0
21 2
22 1
23 3
24 2
A B
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Figure 27: The summary visualization of the overlap between the 731 targets identified for neuroprotective drugs 
There are a total of 731 targets that were identified in the three databases that we considered using the five methods that we used to process the targets of these 
drugs. The diagonal terms on the matrix show the number of targets identified using that method, whereas the off-diagonal terms are the overlap of targets among 
the two specified method/databases (since overlap is symmetric, the matrix is also symmetric). The Venn diagrams show the overlap between the three main 
databases used, and internally the overlap between the target identification methods within STITCH and DrugBank visually.  
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Figure 28: The 731 targets of the neuroprotective drugs reported simultaneuously in multiple databases 
The targets of the neuroprotective compounds that overlap between the various databases are shown based on the overlapping resources. The targets that are 
reported in multiple data sources and/or by multiple methods are more likely to be correct targets and therefore they are more convincing in their potential to be 
of significance to neuroprotection.   
 127   
 
Figure 29: The calcium signaling pathway marked with the targets of neuroprotectives 
The figure displays the calcium signaling pathway as reported in KEGG, annotated with the targets of known neuroprotectives. As reported in the legend on the 
figure, the annotations in grey boxes first report the full name of the target being highlighted with the pointer. The indices of the targeting known neuroprotective 
drugs are then reported in red if there exist any (where the indices are as in Figure 25). Then the known neuroprotectives that are predicted to interact with the 
target by any of the prediction methods (SEA or PMF) are shown in yellow. Finally, the last line reports any known inhibitors that are structurally similar to the 
known neuroprotective (i.e. the ‘query drug’). Nitric oxide synthase is highlighted in red because of its relation to our experimental findings. 
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4.2 LFM-BASED ACTIVE DIVERSIFICATION 
We mapped the drugs in Groups I, II, and IV to form a set of known neuroprotective seed 
compound set. We then mapped these 24 known neuroprotective drugs to 349 targets in humans 
in STITCH v3.1 with a 90% cutoff (STITCH lists drug-target interactions with a 0% to 99.9% 
confidence score, and annotates those above 90% as being very high confidence interactions). Of 
these 349 targets, 32 were overlapping targets of two or more drugs. These targets were sorted 
based on the number of known neuroprotectives targeting them, with the target shared by the 
highest number of known neuroprotectives ranking first. For each target on this list, all the other 
drugs interacting with it (i.e. any drug not in the original set of 24 neuroprotective drugs but 
known to interact with a target of interest) were selected and sorted for maximal difference to the 
known neuroprotectives that were used to select that target. Specifically, we have trained a latent 
variable model on the drug-target interactions in STITCH using the method described in [97]. 
The drugs were sorted for maximal distance in the latent variable space, which represents 
maximal dissimilarity in their interaction profile to the neuroprotectives. The motivation here is 
that by selecting drugs that are targeting the most frequently shared targets of the known 
neuroprotectives that are otherwise as dissimilar as possible in their interaction profile, we will 
achieve two objectives (i) diversify the known neuroprotective drugs, (ii) potentially gain an 
insight into the mechanism of action. I am going to explain both of these points in more detail. 
Among all the drugs that are known to be neuroprotectives, it is highly unlikely that 
every single one operates on a different mechanism of action. Therefore, it is quite likely that the 
contrary is true – i.e. that there are a smaller number of mechanisms, shared by a subset of the 
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drugs in our initial seed set. Therefore looking at the list of most frequently shared targets gives 
us a ranked list of the targets which are most likely to be important for the mechanisms of action. 
Operating on this shortlist, which reduces the number of likely culprits in the mechanism of 
action from the set of all targets to 32, we have a higher likelihood of identifying compounds 
with high neuroprotective activity. Looking at the drugs of these 32 targets that are as dissimilar 
as possible to the known neuroprotectives is useful in helping us spend our limited experimental 
resources on as diverse a set of neuroprotective candidates as possible.  
Testing the drugs interacting with these targets but are as diverse as possible, 
simultaneously allows us to gain an insight into the mechanism of action. If there are a multitude 
of drugs that have been identified to work as neuroprotectives, all of which have been selected 
based on their interaction with a particular target, then that target is implicated for a key role in 
achieving neuroprotective activity. The identification of targets through testing of compounds for 
activity alone is useful because it enables the use of high levels of automation in handling 
compounds and running large compound library screens to provide useful information about 
target identification, which is traditionally not as amenable to high throughput methods. Deduce 
a strong hypothesis about the mechanism of action from running compounds alone, is ground-
breaking because what is arguably the least streamlined step of the drug discovery step (target 
identification) can be done as high-throughput amenable as the screening step because our 
method enables testing mechanism of action using compounds alone.  
Specifically, if compounds that are maximally dissimilar to the known neuroprotectives, 
but otherwise share the target of interest (shared by as many neuroprotectives as possible), also 
show the desired activity then this implicates the target. Conversely, if compounds that are 
maximally similar but do not share the target of interest do not show the desired activity, this 
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further implicates the target as being integral to the mechanism of action. Hence an informed 
hypothesis about the mechanism of action can be acquired by testing compounds alone, with the 
added benefit that compounds with the desired activity of interest can be identified in the 
process. 
When performing the analysis, each subsequent drug added to the list of predictions after 
the first one was chosen to be maximally distant from the previously selected predictions as well 
as the drugs that supported the hypothesis. This adaptive strategy prevents all the tests from 
focusing on a set of highly similar compounds, and ensures that the selected compounds all 
sample diverse parts of the chemical space. The results of this method are shown in Appendix I, 
where the target selected as the hypothesis is indicated, followed by the support drugs that led to 
the selection of that target. In the following rows, each row starts with the name of the chemical 
that is the top hypothesis, then the average similarity to all the PubChem CIDs that mapped to 
the support drug with the reported name on top of the column are reported. The rightmost 
column contains the average of the similarity scores to all of the support drugs. For every 
compound that comes after the first hypothesis compound, the similarity to all the prior 
compounds are also taken into account, in order to achieve adaptive selection of compounds that 
are not too similar to each other.  
We chose 18 drugs from among all the compounds selected for 6 targets, based on 
feasibility of acquisition and experimental testing. The drugs we selected and the targets that 
informed their selection are shown visually in Figure 31. To achieve the objective of forming an 
informed hypothesis would have required much more experimentation, testing at least 10 
compounds for every target of interest. Since we were constrained by experimental feasibility 
and therefore could not conduct experiments with a satisfactory number of compounds, our 
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objective was only to identify new neuroprotectives. We followed up on the selected compounds 
with a phenotypic cell based toxicity assay for validation of their neuroprotective activity.  
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Figure 30: Computational workflow for active diversification 
The computational workflow described above was used for diversification of compounds with neuroprotective 
activity, however it is broadly applicable for any desired activity type of interest. (1) The computational workflow 
starts with known active compounds, in this case we used 15 neuronal cell death inhibitors identified by Wang et al, 
2008 and 9 compounds currently in clinical trials. (2) The STITCH interaction dataset is used to train latent variable 
(LV) model that describes each drug and target’s interaction characteristics. (3) The known targets of the drugs of 
interest are looked up from STITCH. (4,5) The target(s) that interact with the highest number of drugs of interest 
selected as the top hypothesis. (6,7) The drugs known to interact with the targets of interest are extracted from 
STITCH, these constitute the repurposable candidates of interest. (8) The candidates of interest are sorted according 
to maximal LV distance (i.e. maximum dissimilarity) to the drugs of interest that interact with the selected target of 
interest. (9,10) The top candidate(s) tested for desired activity, in this case neuronal cell death inhibition. (11) The 
successful results feedback into the algorithm, (12) the successful results are stored.  
 133   
 
Figure 31: Compounds selected as neuroprotective candidates and the path to their selection.  
The drugs in the left column are the neuroprotective drugs that were used to inform the computational method. They 
are connected to the targets in the middle, shown in red, and multiple connections mean that the target is shared by 
multiple drugs as indicated. The drugs on the right hand side show the drugs that are known to influence the targets 
in the middle with very high confidence, that are otherwise dissimilar in their interaction profile to the drugs on the 
first column and that were feasibly acquired and used for experimental validation. Two of these predictions, 
thyroxine and sodium nitroprusside showed statistically significant protection; hence they are highlighted in green 
color. Thyroxine showed protection indistinguishable from the positive control drug, methazolamide at the same 
dose of 100 µM; whereas sodium nitroprusside showed statistically significantly better protection than 
methazolamide at 100 µM. 
134 
Table 9: The results from the LFM based neuroprotective diversification workflow 
The following table represents the LFM based neuroprotective results, specifically the results that led to the 
identification of Sodium Nitroprusside. The entire set of results are available in Appendix I. First the name of the 
target shared by the neuroprotectives is reported, i.e. the ‘hypothesis’ that this target is key for neuroprotective 
activity. In this case, that hypothesis is Caspase 3. Then the supporting neuroprotective drugs that led to the selection 
of this target are reported: Melatonin, and Minocycline in this case. Then the compounds that are selected based on 
the LFM-based workflow are listed along with the number of targets they have, their distances to the support drugs, 
and the average of those distances. It is important to keep in mind that the drugs after the first are selected based on 
their dissimilarity from not only the support drugs, but also all of the other previously selected compounds hence the 
average distance to support drugs does not indicate the order in which they were selected. 
Hypothesis 3: CASP3_HUMAN (Caspase-3 subunit p12, organism:9606) 
Support: Melatonin Minocycline 
Compounds to test hypothesis: 
Drug 
Target 
Count LV distance to support: Average: 
Sodium Nitroprusside (CID000045469) 14 5.237 5.148 5.193 
Imatinib (CID100005291) 48 5.290 5.061 5.175 
Staurosporine (CID000044259) 85 4.770 5.399 5.085 
Rxb (CID111632008) 1 4.743 4.842 4.793 
Tpck (CID000439647) 6 4.405 4.183 4.294 
Zoledronic Acid (CID100068740) 83 4.350 4.552 4.451 
P-Bromoanisole (CID000007730) 1 4.869 4.550 4.709 
Kainate (CID000010255) 69 4.318 4.652 4.485 
Nordihydroguaiaretic Acid (CID100004534) 21 4.703 4.503 4.603 
Inhibitor 65B (CID005327315) 1 4.725 4.043 4.384 
Ptf (CID100013016) 1 4.494 4.654 4.574 
Peroxynitrite (CID100104806) 21 4.461 4.515 4.488 
Gemcitabine (CID000060749) 28 3.829 4.191 4.010 
15-Deoxy-Delta12,14-Prostaglandin J2 (CID100001444) 20 4.433 4.331 4.382 
Thapsigargin (CID000446378) 84 3.754 4.319 4.036 
Chebi:400985 (CID009851134) 1 4.025 4.017 4.021 
Pyrrolidine Isatin Analogue 11F (CID111712912) 1 4.469 3.901 4.185 
Inhibitor 64B (CID005327307) 1 4.497 4.524 4.511 
Db08213 (CID100001389) 1 4.093 4.043 4.068 
3-Morpholinosydnonimine (CID100005219) 4 4.450 3.664 4.057 
Pzn (CID005289238) 1 3.724 3.933 3.828 
Ac-Devd-Cho (CID100004330) 5 3.880 4.150 4.015 
Salidroside (CID100159278) 2 4.093 3.316 3.704 
Chebi:461307 (CID111700402) 1 4.030 4.108 4.069 
Gsno (CID100003514) 5 3.782 4.016 3.899 
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4.3 EXPERIMENTAL VALIDATION 
We performed experimental testing of the 18 compounds selected from among the results of the 
computational method (Figure 31). We have identified sodium nitroprusside (SNP) to be 
significantly neuroprotective, statistically significantly outperforming the positive control 
compound methazolamide. These experiments were mainly conducted by Hossein Mousavi at 
the Friedlander Lab under the guidance of Robert Friedlander, with the results replicated in the 
University of Pittsburgh Drug Discovery Institute by Celeste Reese, Laura Vollmer, Seia Comsa 
and myself under the guidance of Lans Taylor, Andrew Stern and Mark Schurdak. We have then 
interrogated the effect of SNP on mitochondrial respiration, with these experiments conducted 
again by Hossein Mousavi in the Friedlander lab. The results are reported in detail below. 
4.3.1 Assessment of Neuronal Cell Death Inhibition for Computationally Selected 
Compounds 
We performed cell toxicity assay (LDH) using STHdh Q111/Q111 (Q111) striatal-derived cell 
lines, testing each drug at 7 different doses: doses increasing 10-fold from 1nM to 100µM, and 
an additional dose of 30µM, with a positive control of methazolamide at 100µM (see Appendix J 
for the entire set of results). The results were from an LDH screen where the readout is 
fluorescence from a reporter of LDH. LDH is a protein that occurs at a controlled level across all 
cells and it only leaks out after cell membrane impermeability is comprised, indicating cell death. 
The LDH viability assay is conducted by observing LDH separately first in the supernatant 
(indicating the released LDH from cells that have lost membrane integrity) and then in the cell 
lysate (indicating the LDH still contained in the cells). Q7 and Q111 model cell lines were grown 
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for 24 h in 96-well plates at 5000 cells/well followed by 24 h of treatment. Cells underwent 
stress conditions by being kept in non-permissive temperature (37C for the Q7 and Q111 cells) 
and serum free media for 18 hours. Cellular viability was measured Cytotoxicity Detection Kit 
(LDH) manufactured by Roche. 
In these experiments, we identified sodium nitroprusside as a significant neuroprotective. 
SNP at 50, 100 and 200 uM showed statistically significant neuroprotection against cell death (p-
values 0.02, 0.05, and 0.005 respectively) when compared to the vehicle control; with SNP at 
100µM showing statistically significantly better protection than the positive control 
methazolamide at 100µM (p-value 0.007). We next performed cell death assay using SNP in 
higher concentrations. SNP had the highest protection at 200 µM and was toxic in higher doses 
(Figure 33, panel a). To verify the results SNP in LDH assay we have performed propidium 
iodide (PI) uptake based cell death assessment. Similar results were obtained when the 
neuroprotection assay was reproduced on multiple dates and with both PI and LDH assays 
(Figure 32). These experimental findings support our in silico predictions that SNP would work 
as neuroprotective in HD.  
4.3.2 Sodium Nitroprusside Protection Does Not Impact Mitochondrial Respiration 
SNP degrades spontaneously and subsequently generates Fe
2+
, Cyanide and nitric oxide (NO). 
NO released from SNP and its role in cardiac and vascular cells has been widely explored over 
the past six decades owing to the long history of the use of SNP as an antihypertensive [171-
174]. However its potential as a neuroprotective has not been reported.  
NO has been known to be physiological modulator of mitochondria function and cyclic 
GMP pathway [175-177]. NO like carbon monoxide (CO) binds to the same site in mitochondria 
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as oxygen. It reversibly reduces the affinity of cytochrome C oxidase to oxygen, however this 
affect has been observed to be fast and more like a regulatory effect than a blocker effect, unlike 
CO. To understand whether SNP exerts its neuroprotection via releasing NO and attenuating 
mitochondrial function, we analyzed different states of mitochondrial respiration in addition of 
this compound. Glutamate/Malate and Succinate were used as substrates for mitochondrial 
complex-I and II respectively. SNP had no effect in either states of respiration (Figure 33, panels 
b & c). There was no change in mitochondrial membrane potential using SNP (Figure 33, panel 
d). These data suggest that SNP does not attenuate mitochondrial respiration via NO release in 
isolated mitochondria, and its neuroprotection effect in HD cells is unrelated to mitochondrial 
direct physiological alteration and it is more likely to be an accumulative effect rather than a 
direct and canonical effect like mitochondrial complexes blockers.   
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Figure 32: Neuroprotective effect of sodium nitroprusside is repeatedly stronger than methazolamide 
The neuroprotective effect of sodium nitroprusside observed to be statistically significantly better than the positive 
control drug, methazolamide (Appendix J), led us to subsequent experimentation with a different assay. The ordinate 
shows the percent cell death after insult on Q111 HD model cell lines, whereas the abscissa shows the concentration 
of the experimented drug. The significantly better neuroprotective effect of sodium nitroprusside reproduced over 
two different assays, LDH and PI performed on multiple dates.  
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Figure 33: Effect of SNP in Q111 cells and isolated mitochondria 
Experimental validation of our prediction based on data collected by our collaborator Hossein Mousavi in Robert 
Friedlander’s lab. (A) HD cells viability in stress condition (Serum deprivation and temperature shift to 37 C) in 
addition of SNP in different doses. (B) Effect of SNP in isolated brain mitochondria using G/M as substrate for 
complex-I. (C) Respiratory control ration (RCR) in isolated brain mitochondria with (gray) and without (black) 
SNP,. (D) Effect of SNP in isolated brain mitochondria membrane potential using TMRM. Traces are representative 
of 4 or more independent experiments. Mitochondria (Mito), sodium nitrprusside 100 µM (SNP), Glutamate/Malate 
(GM), Oligomycin (Oly), Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), tetramethyl rhodamine 
methyl ester (TMRM). 3/2 indicates state3/state2 respiration, 3/4 indicates state3/state4 respiration. (*, p<0.05, 
**,p<0.001, #, P=NS, ANOVA)  
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5.0  DISCUSSION 
We have discussed methods and results serving multiple different goals and biomedical projects. 
The LFM-based approach for predicting drug target interactions presented here proposes a 
solution to the important scientific problem of discovery of unknown interactions (Section 2.1). 
The methodologies we developed have improved upon the state-of-the-art (Section 2.2). 
BalestraWeb serves to make the solution we have developed usable by a large number of 
biomedical researchers all around the world (Section 2.3). Our work on ATD required 
computational techniques other than LFM, which we designed and then implemented to fit the 
needs of the particular project at hand with satisfactory results (Chapter 3.0 ). The data available 
on HD required the use of LFM, as well as a multitude of other methods that we developed and 
implemented with again satisfactory results, as we have managed to identify a drug, sodium 
nitroprusside, that worked better than the state-of-the-art neuroprotective (Chapter 4.0 ). Due to 
the extensive and broad implications of the work presented in this dissertation, the discussion is 
divided into sections structured according to the structure of the work presented. 
5.1 LFM APPROACHES FOR ANALYZING DRUG-TARGET INTERACTIONS 
Over the last couple of years, there have been a number of computational studies performed to 
identify targets of existing drugs and drug candidates other than those originally known/proposed 
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to be targeted.  A pioneering study is that of Roth, Shoichet and coworkers [26;28] based on 
compound chemical similarities. Dudley et al focused on inverse correlations between gene 
expression profiles in the presence of a drug and in a disease state [37]. Yamanishi and his 
colleagues represented drugs and targets in an integrated ‘pharmacological space’ [29;32]. 
Gonen used a KBMF method where chemical and genomic similarities were integrated [34]. We 
proposed a PMF-based AL methodology that can be advantageously used for large datasets.   
The applicability of the method to large datasets is worth further attention, given that we 
will increasingly have access to bigger data such as the STITCH database [45], which will be 
exploited for repurposable drug identification. The software developed here, made accessible in 
http://www.csb.pitt.edu/Faculty/bahar/files/, is readily scalable. For very large datasets, which 
typically have more known interactions, the PMF is able to construct a better model using the 
plethora of available data; whereas when the number of known interactions is limited, the use of 
chemical and genomic kernels allows KBMF to outperform PMF. The application of KBMF to 
large datasets may, however, become challenging, For example, STITCH contains on the order 
of 10
6
 proteins and 10
5
 compounds, implying that 10
12
 sequence and 10
10
 chemical similarity 
comparisons are needed to make predictions.  However, the PMF method is independent of 
chemical, structural or other similarity metrics, and its computation time scales linearly with the 
number of known interactions; and it proves to perform well on large datasets. The datasets 
reporting drug-target interactions are constantly improving in quality and quantity, and therefore 
expected to give even better results when analyzed by an efficient tool. The extension of the 
method to analyzing big data (with millions of nodes) is foreseeable in the near future. The 
GraphLab [108] or the GraphChi tool [178] can be used for optimized and parallelized model 
learning for further performance improvements. 
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The fact that the PMF is independent of 2D/3D shape comparison methods commonly 
employed in drug-target pair inferences implies that the derived LVs capture similarities based 
on the interaction patterns of drugs at the cellular level, even if their molecular structures are 
dissimilar (see Table 2, Figure 6, Figure 7 and Figure 8). As such, the method may be 
advantageously used for lead hopping, thus complementing those (e.g. SVM classification 
algorithms) used in conjunction with 2D or 3D pharmacophoric fingerprints as in the work of 
Saeh and coworkers [179]. Inasmuch as the currently proposed method does not require 
structural data for proteins but knowledge of drug-target interactions, it can be advantageously 
applied to membrane proteins (major drug targets) for which structural data still remain sparse.  
It can also be used to make predictions across major drug or target classification boundaries. One 
implication is that the de novo predictions are not restricted to major drug or target classification 
boundaries.  
A major utility of the developed tool is the ability to deliver testable hypotheses with 
regard to repurposable drugs, thus significantly reducing the search space for identifying potent 
applications of existing drugs (that proved to meet ADMET requirements). The number of 
experiments that can be efficiently conducted is usually limited, e.g. of the order of 10
2
 if not 10
1
 
for high-confidence assays as opposed to the complete space of ~1.5 million combinations for 
the dataset used in this study. The fact that the top-ranking predictions exhibit a hit ratio of 59% 
(for the top 1,000 predictions; or 88% for top 100 predictions) suggest that de novo predictions 
made by the presently introduced method of approach applied to increasingly large datasets are 
likely to provide useful guidance for experimentally testing, streamlining or prioritizing existing 
or investigational drugs or new compounds.  Another important by-product is the probabilistic 
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assessments on potential side effects, a topic that will become increasingly important with 
advances in personalized medicine.   
Owing to these important considerations, we have built BalestraWeb to make our work 
easily accessible to biomedical researchers. BalestraWeb provides users the ability to predict the 
most likely interaction partners of any drug or target beyond those known and compiled in 
DrugBank. The technology used to build the web server scales linearly with the number of drugs 
or targets and is therefore easily scalable to larger datasets as they become available. The 
modular architecture of the software allows us to update the web server to reflect changes as new 
data become available. Free, fast, and easy-to-use, BalestraWeb enables researchers to help 
eliminate improbable drug-target interactions and efficiently focus their limited resources on 
selected drugs.  
5.2 COMPUTATIONAL DISCOVERY OF THERAPEUTICS AGAINST ATD 
The major advantage of our study was the determination that this type of RNAi screen could be 
used to rapidly identify potential drug targets using computational approaches, even in the 
absence of extensive knowledge about target functions, other than their effects on SGFP::ATZ 
accumulation. We employed two independent, but complementary sources, STITCH and 
MetaCore, to identify chemical/drug and protein interactions [45;124]. Of the 85 human PN 
modifiers queried, a total of eight compounds (two directed against each of four targets) were 
selected as a proof-of principal for this strategy. Remarkably, one compound for each of the four 
targets showed a dose-dependent decrease sGFP::ATZ accumulation in C. elegans. Failure of the 
other four compounds to have the predicted effects in C. elegans were not investigated, but 
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might be due to differences in pharmacokinetics, pharmacodynamics or target-binding site 
homology between the C. elegans and mammalian systems. While the overall success rate of 
50% was encouraging, small numbers preclude the calculation of a meaningful positive 
predictive value. The results do, however, underscore the great potential for combining genome-
wide RNAi screens with computational drug-discovery methodologies. The demonstration that 
one of the compounds, fluspirilene, was also effective in reducing ATZ accumulation in a 
mammalian cell line lends additional support for further development of this rapid preclinical 
drug discovery/repurposable strategy. 
A second advantage of this drug-discovery strategy was the use of facile genetic 
techniques in C. elegans to determine whether the observed drug effect was due to activity 
within the predicted target pathway or to an off-target effect. Wortmannin was identified in the 
screen as a potential inhibitor of the type I PI3K kinase, AGE-1. AGE-1 functions downstream 
of the sole insulin-like receptor, DAF-2, and inhibition of this IIS pathway suppresses the 
proteotoxic effects of sGFP::ATZ in this C. elegans model, as well as other C. elegans models of 
misfolded protein accumulation [180]. However, wortmannin also inhibits the class III PI3K, 
VPS-34, which blocks autophagy in C. elegans and mammals as well [127]. Since autophagy 
was an important means of reducing sGFP:: ATZ accumulation [181], suppression of this 
pathway would be deleterious to these animals. Treatment of the animals with wortmannin 
decreased sGFP::ATZ accumulation, and this effect was neither enhanced in AGE-1 mutants nor 
effective in animals with a mutation in the downstream AGE-1 target gene, DAF-16. Taken 
together, we concluded that the effects of wortmannin at the concentrations used in these animals 
were via inhibition of AGE-1 and not VPS-34 or some off-target pathway. The large collection 
of C. elegans single gene mutants, combined with a simple quantitative readout system using 
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fluorescent fusion proteins, makes this system ideal for identifying potential drug targets or 
target pathways after phenotype-based drug screening. While this technology was not meant to 
replace target identification by the gold-standard of drug–ligand binding measurements in vitro, 
it does provide the rationale for embarking upon more detailed kinetic or structural studies with 
purified reagents or expensive development of a lead series by exploring structure–activity 
relationshipsin vitro. 
A third advantage of this drug-discovery strategy was the ability to test for the efficacy of 
combinational therapy. Due to their toxicity, drugs like wortmannin have been largely abandoned 
as therapeutics in humans. One means to lower toxicity is to use different delivery systems, such 
as microspheres, to directly deliver lower concentrations of a drug directly to the tissue of 
interest [182]. Another means to avoid toxicity is to utilize lower concentration of drug by 
combining it with other therapeutics directed at different targets or target pathways. By using the 
genetic methods outlined above, we showed that unlike wortmannin, none of the other three 
candidates exerted their effect via the IIS pathway. This observation was validated by using 
the C. elegans model to show that comparable reductions of sGFP::ATZ accumulation could be 
achieved at lower doses of wortmannin when it was combined with one of the other drugs. This 
effect underscores the ability of this experimental system to both identify and test the efficacy of 
complementary therapeutics. In conclusion, these studies showed that by utilizing the hits from a 
genome-wide RNAi screen, computational methods could be used to rapidly and strategically 
develop compounds to prime the preclinical drug-discovery pipeline for rare or neglected 
diseases lacking effective treatments. 
We have also presented two novel computational analysis methods that were designed 
specifically for the purpose of analyzing the Prestwick dataset screening results in order to 
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discover the mechanism of action of protective drugs as well as the diversification of the known 
protectives in Section 3.5. There were two goals: (i) to diversify leads, and identify other 
potential lead compounds; (ii) to identify potential mechanism of action regulators. We have 
identified sorafenib, duloxetine, and ezetimibe as the potential new hits based on the fact that 
they share chemical structure and targets with known suppressors. For the mechanism of action, 
we have identified that calcium channels are a strong candidate based on evaluation of the 
experimental data using two different databases, with two different evaluation methods. The 
hypothesis that calcium channels could be relevant to the ATZ aggregation inhibition, and the 
hypotheses that the three suggested drugs (see Figure 24) could be therapeutically useful needs to 
be tested experimentally to be validated. 
5.3 NEUROPROTECTIVE IDENTIFICATION FOR HD 
In this study, we have devised and applied a novel in silico method to perform target based hit 
diversification using previously published information and public databases. We then 
demonstrated that by testing 18 of the predictions we identified two new neuroprotective 
repurposable candidates in HD with one of them, SNP, outperforming the other compounds. The 
exact mechanism with which SNP exerts its neuroprotective effect is not known, however it has 
been first reported to be an effective antihypertensive in 1928, its potential has been clinically 
realized between 1951 and 1955, and it became commercially available as an approved 
antihypertensive for use in the United States in 1974 [171;172]. In addition to being a well 
established hypotensive agent, it has long been known to increase cGMP levels [183], inhibit 
cytosolic Ca
2+
 levels [184], and increase nitric oxide (NO) levels [173]. More recently, it has 
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been reported to be effective in prevention of apoptosis of macrophages after hydrogen peroxide 
insult by preventing activation of caspase-3 and caspase-9 with a 24 hour pretreatment before 
insult [185]. SNP has been widely reported to be an apoptosis inducer at relatively higher doses, 
but protective in lower doses: induces apoptosis in mouse C2C12 myoblast cells [186]; induces 
apoptosis in H9C2 cardiac muscle cells at doses of 2mM or higher [187]; in vascular smooth 
muscle cells, induces apoptosis at 1.5mM, while pretreatment with 30 µM or higher SNP was 
found to be protective against high dose SNP induced toxicity [188]; it was found to reduce 
staurosporine induced caspase activity and apoptosis in cardiomyocytes at doses of 100 µM 
[189]. These findings demonstrate that SNP impacts caspase activation through its multitude of 
effects on nitric oxide levels, cGMP levels, and mitochondrial activity. These are potentially 
driven by its chemical composition as SNP can create NO and cyanide through decomposition, 
with the latter disrupting mitochondrial activity. Literature also shows that it is important to keep 
SNP at low doses for safety, and thus our findings that SNP can be a neuroprotective in 
concentration ranges as low as 30 – 100 µM makes SNP a feasible therapeutic agent candidate 
for use in HD in vivo studies.  
The fact that 2 of the 18 tested predictions (thyroxine and SNP) were statistically 
significantly protective represents an 11% hit rate, which compares against the reported average 
hit rate of 1.8% hit rate in uninformed compound collection screens conducted by the NIH [122]. 
In a comprehensive study using the SEA method [27], 27.8% of all the experiments suggested by 
SEA and later executed were found to be correct interactions. However, we note that: (1) the 
computational method we developed here was mostly designed to implicate targets regulating 
neuroprotective activity, this was not a method designed purely to find more neuroprotectives but 
primarily to identify mechanism of action of neuroprotectives; (2) a significant portion of our 
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predictions have not been tested, in contrast to the fact that almost every strong prediction was 
experimentally tested in this study. Due to the low number of total compounds tested a 
reasonably strong assessment of the hit rate cannot be made without conducting significantly 
higher numbers of experiments. However this preliminary finding might be viewed an 
encouraging result demonstrating the potential of the computational analysis of publicly 
available data, combined with the previously available information, in general. There is a 
potential to form informed hypotheses in silico using the compendium of public data resources 
and this can help generate effective translational therapies by allowing the repositioning of 
known drugs against new indications with efficiency. Furthermore, considering that these 18 
drugs were not selected purely based on the method’s suggestions but instead heavily influenced 
by the feasibility of acquisition suggests that the method could potentially yield an even higher 
discovery rate.  
To summarize, in this study we have demonstrated the viability of target-based active 
diversification as a computational technique for finding therapeutic agent candidates for 
repurposable drugs against diseases with no known therapies; and that SNP or its safer 
derivatives could potentially be used in HD therapy as a neuroprotective agent. More generally, 
the computational techniques described here can be used for a diverse range of diseases. 
Specifically, the LFM based methodology described in Section 4.2 can be broadly applied to any 
disease of interest where some small set of initial hits are identified. Thus, the methodology 
described herein could be helpful in identifying the mechanism of action of any compounds of 
interest within any disease as the method is entirely independent of HD. Once the targets of 
interest are identified, the method could be used to select drugs that act on different targets thus 
create polypharmacological therapeutic strategies that target multiple different mechanisms to 
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potentially achieve synergistic effect. Furthermore, the patients could be characterized using 
genomic/transcriptomic profiling and for patients with a signifcant change in one or more of the 
targets implicated as being related to the mechanism, that information could be used to adjust the 
therapeutic strategy thereby achieveing patient stratification. Our study also invites attention to 
the importance of access to big data sources for rapid discoveries of repurposable drugs against 
myriad untreated diseases.  
5.4 CONCLUDING REMARKS 
On the broadest level, the work presented in this dissertation aims to demonstrate that 
computational analysis of experimental data can help build useful testable hypotheses. The 
importance of experimental work in generating new biomedical data is without question. 
However guiding the experimental work using both the results from previous experimental 
results and the large public datasets as appropriate can deliver improved returns. The private data 
that are acquired within the context of a specific project are important in generating models 
about the biomedical components of significance for that particular question. The public datasets, 
on the other hand, provide collections of big data that cannot be compiled by any single research 
group; therefore they present an important source to explore. The combination of those two 
datasets, and the development and implementation of computational methods designed 
specifically for the needs of the biomedical driving project at hand appear to consistently yield 
plausible hypotheses, both in ATD (as evidenced by the discovery of glibenclamide and four 
new repurposable drug candidates) and HD (as suggested by the discovery of sodium 
nitroprusside as a neuroprotective in HD). It is my hope that this work, as well as many other 
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valuable contributions to the field, will help enable the widespread use of computational 
techniques to guide biomedical assays and thus facilitate efficient use of the resources available. 
Finally, by combining and packaging the code I have written over the course of my PhD to 
handle drug-target interaction datasets in BalestraTK, I hope to facilitate any follow-up of the 
research activity described in my dissertation.  
 
5.5 FUTURE DIRECTIONS 
The work described in this dissertation ranges from machine learning (Chapter 2) to big data 
analysis (Chapters 3 and 4) to experimental validation of predictions (Chapter 4). Consequently 
the future directions are also quite diverse. For the work described in Chapter 2, it would be 
important to test the top predictions (>90% confidence) made by BalestraWeb (shown in Table 
3) experimentally to validate/refute. As these predictions are made by an average of 128 models 
which place true but unknown interactions among the top 20 predictions 50% of the time, they 
come with a good level of confidence. The researchers can always use BalestraWeb to find out 
the known and most probable interactions of specific drugs/targets that they are interested in. 
However to test BalestraWeb itself and to significantly increase its use by the community, it is 
imperative that the top predictions of BalestraWeb be systematically tested – not a subset 
selected for feasibility. 
For the ATD work, the future directions would be to test Ezetimibe, Sorafenib, and 
Duloxetine in an ATD model. There is substantial reason for thinking that these drugs can be 
active, based both on chemical models and target-based models as described in Section 3.5. If 
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proven to beactive, it would increase the likelihood of repurposing a known drug candidate 
against ATD, thus increasing the likelihood of developing an effective therapy to this disease 
that negatively affects 1 in 1600 to 2000 children. 
For the HD project, the LFM- based hypothesized compounds have not been thoroughly 
tested as originaly intended. The objective when designing the methodology was to give 100 
predictions to be tested. Hence, to continue that work in its original spirit I would recommend 
building a new LFM of STITCH v4 using the strategies I laid out in Section 2.6. In parallel, the 
set of known neuroprotective drugs shown in Figure 25 could be experimentally tested to find 
the subset of drugs that work reproducibly in an HD model (i.e. to identify a refined set of 
neuroprotectives). Then the algorithmic workflow shown in Figure 30 could be adopted with this 
improved LFM and data to build a new set of hypotheses, from which a second generation of 100 
compounds could be tested, by interrogating 10 compounds for each of the top 10 target 
hypotheses. New neuroprotectives, probably more powerful than sodium nitroprusside, will be 
discovered. Perhaps even more importantly, if there exists any target that has led to the discovery 
of multiple new neuroprotectives, this will implicate a specific mechanism of action. This is very 
important because it will provide us with a mechanistic understanding of neuroprotection with 
compound-based experimentation alone.  
In general, new machine learning based computational methods are always dependent on 
the input data being of high quality to function accurately. Therefore it is important to make sure 
that the public datasets are as comprehensive and well-curated as possible. To that end, 
integrating data available on multiple databases accurately is highly important. The construction 
of the STITCH database [45;119;190] was such an effort - in fact the name can be seen as 
referring to ‘stitching’ different data sources together. Likewise there is a recent initiative aiming 
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to bring different databases together drug-drug interactions [191]. It is with this goal that we 
have envisioned BalestraTK, where the aggregate data on drug-drug, drug-protein and protein-
protein interactions can all be potentially accessed over a single API and where a new integrator 
can be written for each new database, while conserving the foundation data access API. 
Moreover, BalestraTK provides significant time savings as it makes arbitrary data access a 
constant time, rapid operation in what are otherwise large datasets. This enables rapid access to 
data, and if its development is kept-up-to-date with the future versions (it is up-to-date with the 
most recent versions of the required databases currently available) utilizing the newest data 
sources with no code change to existing services.  
More broadly speaking, I would suggest the biomedical research community at large to 
make use of computational approaches coupled with the data available at their hand related to 
their specific project(s) to guide their experimentation. Oftentimes scientists with more 
biomedical background than computational will try to use computational tools as a ‘black box’ 
when in fact they are usually made accessible as an open source, and they should ideally be used 
in an integrated manner. For the computational scientists, my advice is that it is important to 
produce algorithmic approaches tailored to the data and questions at hand instead of trying to 
force the use of a specific approach that they have developed. My recommendation would be to 
think about the method that would make the most sense given the data and the specific problem 
under investigation and then devise the computational technique to best addresses that need. I 
think the full potential of computational methods in revolutionizing biomedical research is yet to 
be realized. 
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APPENDIX A 
THE CONTENTS OF THE ONLINE FILES FOR PMF 
The contents of active_passive_learning_code.zip are described in the table below: 
Filename Description of contents 
al.m Active learner code (Matlab) 
pl.m Passive learner code (Matlab) 
pmfchang.m PMF code (Matlab) 
rl.m Random learner code (Matlab) 
runme.m The user only needs to run this file in Matlab to execute the code and get the 
results. 
dtdata.mat The data file (Matlab) 
ReadMe.txt Instructions on running the code. 
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The contents of denovo.zip: 
Filename Description of contents 
README.txt Instructions on running the code 
runpreds.m Code for generating de novo predictions repeatedly (Matlab) 
pmfchang_d.m PMF code (Matlab) 
whole.m Code for calculating prediction results in matrix form (Matlab) 
denovo.m Code for outputting prediction results in txt file (Matlab) 
dtdata_5041.txt Dataset from DrugBank used for de novo predictions 
drug_inddict.txt Index directory for all drugs used for de novo predictions 
trgt_inddict.txt Index directory for all targets used for de novo predictions 
translate.py Code for translating the output of prediction results into interactions with 
real names (Python) 
predictionfolder Folder that stores all the prediction results when code is executed 
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APPENDIX B 
DRUG TARGET PAIRS FROM BALESTRAWEB WITH PREDICTED INTERACTION 
SCORE ABOVE 70% 
The columns represent from left to right: the DrugBank v4 ID of the drug, the name of the drug, 
the DrugBank v4 ID of the target, the name of the target, the BalestraWeb predicted interaction 
score. The interactions are sorted based on the predicted interaction score. In DrugBank v4, there 
are 1313 approved drugs, which have 1455 targets with 4860 known interactions between them. 
Among the 1,905,555 unknown interactions between these drugs and targets, the following 589 
are predicted by BalestraWeb’s LFM based engine to be top (i.e. above the 70% threshold). 
Drug ID Drug Name Target ID Target Name Score 
DB00116 Tetrahydrofolic acid BE0002176 Methylenetetrahydrofolate reductase 1 
DB00116 Tetrahydrofolic acid BE0000331 Serine hydroxymethyltransferase, cytosolic 1 
DB00145 Glycine BE0000331 Serine hydroxymethyltransferase, cytosolic 0.99971 
DB00116 Tetrahydrofolic acid BE0000292 Serine hydroxymethyltransferase, mitochondrial 0.99954 
DB00128 L-Aspartic Acid BE0000277 Calcium-binding mitochondrial carrier protein 
Aralar2 
0.9993 
DB00145 Glycine BE0000292 Serine hydroxymethyltransferase, mitochondrial 0.99912 
DB00370 Mirtazapine BE0000291 5-hydroxytryptamine receptor 1A 0.92736 
DB00543 Amoxapine BE0000572 Alpha-2B adrenergic receptor 0.92068 
DB00408 Loxapine BE0000393 5-hydroxytryptamine receptor 2B 0.91003 
DB04946 Iloperidone BE0000533 5-hydroxytryptamine receptor 2C 0.9008 
DB00696 Ergotamine BE0000342 Alpha-2C adrenergic receptor 0.90057 
DB04946 Iloperidone BE0000289 Alpha-2A adrenergic receptor 0.89727 
DB00477 Chlorpromazine BE0000560 Muscarinic acetylcholine receptor M2 0.89704 
DB00334 Olanzapine BE0000715 Alpha-1D adrenergic receptor 0.89653 
DB00363 Clozapine BE0000145 D(1B) dopamine receptor 0.89481 
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DB00246 Ziprasidone BE0000715 Alpha-1D adrenergic receptor 0.88781 
DB06148 Mianserin BE0000797 5-hydroxytryptamine receptor 1B 0.88758 
DB00543 Amoxapine BE0000342 Alpha-2C adrenergic receptor 0.88596 
DB06148 Mianserin BE0000659 5-hydroxytryptamine receptor 1D 0.88587 
DB01142 Doxepin BE0000650 5-hydroxytryptamine receptor 7 0.88378 
DB01238 Aripiprazole BE0000715 Alpha-1D adrenergic receptor 0.88376 
DB06148 Mianserin BE0000501 Alpha-1A adrenergic receptor 0.88306 
DB00988 Dopamine BE0000451 5-hydroxytryptamine receptor 2A 0.88301 
DB00726 Trimipramine BE0000342 Alpha-2C adrenergic receptor 0.88223 
DB00408 Loxapine BE0000715 Alpha-1D adrenergic receptor 0.88034 
DB06216 Asenapine BE0000145 D(1B) dopamine receptor 0.87895 
DB00363 Clozapine BE0000715 Alpha-1D adrenergic receptor 0.8786 
DB01142 Doxepin BE0000020 D(1A) dopamine receptor 0.8778 
DB00321 Amitriptyline BE0000572 Alpha-2B adrenergic receptor 0.87746 
DB00370 Mirtazapine BE0000572 Alpha-2B adrenergic receptor 0.87546 
DB06216 Asenapine BE0000575 Alpha-1B adrenergic receptor 0.87291 
DB01142 Doxepin BE0000581 D(3) dopamine receptor 0.87012 
DB00363 Clozapine BE0000393 5-hydroxytryptamine receptor 2B 0.87007 
DB00543 Amoxapine BE0000575 Alpha-1B adrenergic receptor 0.86803 
DB04946 Iloperidone BE0000572 Alpha-2B adrenergic receptor 0.86684 
DB01224 Quetiapine BE0000393 5-hydroxytryptamine receptor 2B 0.86663 
DB01238 Aripiprazole BE0000393 5-hydroxytryptamine receptor 2B 0.86338 
DB04946 Iloperidone BE0000575 Alpha-1B adrenergic receptor 0.86263 
DB00370 Mirtazapine BE0000575 Alpha-1B adrenergic receptor 0.86254 
DB00477 Chlorpromazine BE0000715 Alpha-1D adrenergic receptor 0.86204 
DB06148 Mianserin BE0000389 D(4) dopamine receptor 0.86199 
DB01142 Doxepin BE0000389 D(4) dopamine receptor 0.86155 
DB00726 Trimipramine BE0000715 Alpha-1D adrenergic receptor 0.86027 
DB00370 Mirtazapine BE0000020 D(1A) dopamine receptor 0.8602 
DB06148 Mianserin BE0000020 D(1A) dopamine receptor 0.85984 
DB00246 Ziprasidone BE0000393 5-hydroxytryptamine receptor 2B 0.8584 
DB00321 Amitriptyline BE0000342 Alpha-2C adrenergic receptor 0.85827 
DB00247 Methysergide BE0000659 5-hydroxytryptamine receptor 1D 0.85811 
DB00321 Amitriptyline BE0000311 5-hydroxytryptamine receptor 3A 0.85767 
DB01403 Methotrimeprazine BE0000291 5-hydroxytryptamine receptor 1A 0.85537 
DB01608 Propericiazine BE0000501 Alpha-1A adrenergic receptor 0.85532 
DB00543 Amoxapine BE0000659 5-hydroxytryptamine receptor 1D 0.85478 
DB00543 Amoxapine BE0004889 D(1B) dopamine receptor 0.85449 
DB00543 Amoxapine BE0000145 D(1B) dopamine receptor 0.854 
DB00696 Ergotamine BE0000581 D(3) dopamine receptor 0.85365 
DB00370 Mirtazapine BE0000389 D(4) dopamine receptor 0.8499 
DB00726 Trimipramine BE0000581 D(3) dopamine receptor 0.84813 
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DB06216 Asenapine BE0000659 5-hydroxytryptamine receptor 1D 0.84753 
DB00696 Ergotamine BE0000020 D(1A) dopamine receptor 0.84715 
DB00726 Trimipramine BE0000797 5-hydroxytryptamine receptor 1B 0.84638 
DB00321 Amitriptyline BE0000756 D(2) dopamine receptor 0.84574 
DB00734 Risperidone BE0000715 Alpha-1D adrenergic receptor 0.84545 
DB00540 Nortriptyline BE0000650 5-hydroxytryptamine receptor 7 0.84446 
DB00477 Chlorpromazine BE0000342 Alpha-2C adrenergic receptor 0.84381 
DB00988 Dopamine BE0000533 5-hydroxytryptamine receptor 2C 0.84278 
DB00734 Risperidone BE0000797 5-hydroxytryptamine receptor 1B 0.84266 
DB00477 Chlorpromazine BE0000247 Muscarinic acetylcholine receptor M5 0.84249 
DB00477 Chlorpromazine BE0000393 5-hydroxytryptamine receptor 2B 0.84201 
DB00477 Chlorpromazine BE0000405 Muscarinic acetylcholine receptor M4 0.84182 
DB00477 Chlorpromazine BE0000289 Alpha-2A adrenergic receptor 0.8412 
DB01392 Yohimbine BE0000020 D(1A) dopamine receptor 0.84103 
DB00370 Mirtazapine BE0000797 5-hydroxytryptamine receptor 1B 0.841 
DB00934 Maprotiline BE0000749 Sodium-dependent serotonin transporter 0.84065 
DB00734 Risperidone BE0000145 D(1B) dopamine receptor 0.84029 
DB08815 Lurasidone BE0000572 Alpha-2B adrenergic receptor 0.84022 
DB00726 Trimipramine BE0000020 D(1A) dopamine receptor 0.84005 
DB00508 Triflupromazine BE0000451 5-hydroxytryptamine receptor 2A 0.83931 
DB01151 Desipramine BE0000501 Alpha-1A adrenergic receptor 0.83865 
DB00193 Tramadol BE0000092 Muscarinic acetylcholine receptor M1 0.83824 
DB00726 Trimipramine BE0000650 5-hydroxytryptamine receptor 7 0.83717 
DB00458 Imipramine BE0000289 Alpha-2A adrenergic receptor 0.83601 
DB01403 Methotrimeprazine BE0000650 5-hydroxytryptamine receptor 7 0.83485 
DB00656 Trazodone BE0000756 D(2) dopamine receptor 0.83467 
DB00420 Promazine BE0000342 Alpha-2C adrenergic receptor 0.83463 
DB00508 Triflupromazine BE0000045 Muscarinic acetylcholine receptor M3 0.83372 
DB01267 Paliperidone BE0000715 Alpha-1D adrenergic receptor 0.83331 
DB00656 Trazodone BE0000572 Alpha-2B adrenergic receptor 0.83318 
DB00777 Propiomazine BE0000291 5-hydroxytryptamine receptor 1A 0.83313 
DB00734 Risperidone BE0000650 5-hydroxytryptamine receptor 7 0.83306 
DB06148 Mianserin BE0000575 Alpha-1B adrenergic receptor 0.83264 
DB00420 Promazine BE0000581 D(3) dopamine receptor 0.8319 
DB01392 Yohimbine BE0000389 D(4) dopamine receptor 0.83169 
DB00726 Trimipramine BE0000393 5-hydroxytryptamine receptor 2B 0.83139 
DB00714 Apomorphine BE0000650 5-hydroxytryptamine receptor 7 0.83129 
DB00696 Ergotamine BE0000393 5-hydroxytryptamine receptor 2B 0.83083 
DB01142 Doxepin BE0000797 5-hydroxytryptamine receptor 1B 0.82926 
DB00726 Trimipramine BE0000389 D(4) dopamine receptor 0.82833 
DB00420 Promazine BE0000291 5-hydroxytryptamine receptor 1A 0.82818 
DB00696 Ergotamine BE0000650 5-hydroxytryptamine receptor 7 0.82744 
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DB00477 Chlorpromazine BE0000572 Alpha-2B adrenergic receptor 0.82677 
DB01142 Doxepin BE0000659 5-hydroxytryptamine receptor 1D 0.82598 
DB01151 Desipramine BE0000650 5-hydroxytryptamine receptor 7 0.8257 
DB00679 Thioridazine BE0000715 Alpha-1D adrenergic receptor 0.8255 
DB00434 Cyproheptadine BE0000247 Muscarinic acetylcholine receptor M5 0.82539 
DB00458 Imipramine BE0000581 D(3) dopamine receptor 0.82529 
DB04946 Iloperidone BE0000145 D(1B) dopamine receptor 0.82485 
DB00247 Methysergide BE0000756 D(2) dopamine receptor 0.82417 
DB00777 Propiomazine BE0000342 Alpha-2C adrenergic receptor 0.82347 
DB05271 Rotigotine BE0000451 5-hydroxytryptamine receptor 2A 0.82311 
DB06216 Asenapine BE0000715 Alpha-1D adrenergic receptor 0.82294 
DB04946 Iloperidone BE0000797 5-hydroxytryptamine receptor 1B 0.82281 
DB00420 Promazine BE0000572 Alpha-2B adrenergic receptor 0.82277 
DB00540 Nortriptyline BE0000020 D(1A) dopamine receptor 0.82273 
DB01069 Promethazine BE0000575 Alpha-1B adrenergic receptor 0.82257 
DB04946 Iloperidone BE0000659 5-hydroxytryptamine receptor 1D 0.82228 
DB08815 Lurasidone BE0000501 Alpha-1A adrenergic receptor 0.82165 
DB01267 Paliperidone BE0000797 5-hydroxytryptamine receptor 1B 0.82133 
DB00370 Mirtazapine BE0000945 5-hydroxytryptamine receptor 6 0.82128 
DB00434 Cyproheptadine BE0000405 Muscarinic acetylcholine receptor M4 0.82019 
DB00420 Promazine BE0000289 Alpha-2A adrenergic receptor 0.81976 
DB04843 Mepenzolate BE0000560 Muscarinic acetylcholine receptor M2 0.81963 
DB01267 Paliperidone BE0000650 5-hydroxytryptamine receptor 7 0.81953 
DB06148 Mianserin BE0000311 5-hydroxytryptamine receptor 3A 0.81945 
DB00193 Tramadol BE0000560 Muscarinic acetylcholine receptor M2 0.81899 
DB00751 Epinastine BE0000342 Alpha-2C adrenergic receptor 0.8189 
DB00734 Risperidone BE0000393 5-hydroxytryptamine receptor 2B 0.81778 
DB00589 Lisuride BE0000650 5-hydroxytryptamine receptor 7 0.81776 
DB00458 Imipramine BE0000342 Alpha-2C adrenergic receptor 0.81758 
DB00370 Mirtazapine BE0000715 Alpha-1D adrenergic receptor 0.81683 
DB00777 Propiomazine BE0000572 Alpha-2B adrenergic receptor 0.81672 
DB00656 Trazodone BE0000575 Alpha-1B adrenergic receptor 0.81667 
DB08815 Lurasidone BE0000020 D(1A) dopamine receptor 0.81667 
DB01622 Thioproperazine BE0000715 Alpha-1D adrenergic receptor 0.81611 
DB00656 Trazodone BE0000342 Alpha-2C adrenergic receptor 0.81572 
DB04946 Iloperidone BE0000393 5-hydroxytryptamine receptor 2B 0.81479 
DB00543 Amoxapine BE0000045 Muscarinic acetylcholine receptor M3 0.81475 
DB00696 Ergotamine BE0000389 D(4) dopamine receptor 0.81449 
DB01392 Yohimbine BE0000650 5-hydroxytryptamine receptor 7 0.81424 
DB05271 Rotigotine BE0000342 Alpha-2C adrenergic receptor 0.81414 
DB00934 Maprotiline BE0000291 5-hydroxytryptamine receptor 1A 0.81351 
DB00726 Trimipramine BE0000945 5-hydroxytryptamine receptor 6 0.81342 
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DB00458 Imipramine BE0000020 D(1A) dopamine receptor 0.81299 
DB00777 Propiomazine BE0000581 D(3) dopamine receptor 0.81216 
DB00540 Nortriptyline BE0000289 Alpha-2A adrenergic receptor 0.81204 
DB00458 Imipramine BE0000389 D(4) dopamine receptor 0.81174 
DB00714 Apomorphine BE0000501 Alpha-1A adrenergic receptor 0.81007 
DB00413 Pramipexole BE0000650 5-hydroxytryptamine receptor 7 0.80998 
DB01267 Paliperidone BE0000145 D(1B) dopamine receptor 0.80994 
DB00543 Amoxapine BE0000560 Muscarinic acetylcholine receptor M2 0.80993 
DB00546 Adinazolam BE0000764 Gamma-aminobutyric acid receptor subunit alpha-6 0.80874 
DB01595 Nitrazepam BE0004797 Gamma-aminobutyric acid receptor subunit theta 0.80873 
DB00934 Maprotiline BE0000020 D(1A) dopamine receptor 0.80861 
DB01403 Methotrimeprazine BE0000659 5-hydroxytryptamine receptor 1D 0.8077 
DB01625 Isopropamide BE0000560 Muscarinic acetylcholine receptor M2 0.80749 
DB00543 Amoxapine BE0000715 Alpha-1D adrenergic receptor 0.80713 
DB00546 Adinazolam BE0000478 Gamma-aminobutyric acid receptor subunit alpha-4 0.80712 
DB00925 Phenoxybenzamine BE0000172 Beta-1 adrenergic receptor 0.80707 
DB01608 Propericiazine BE0000572 Alpha-2B adrenergic receptor 0.80667 
DB00248 Cabergoline BE0000945 5-hydroxytryptamine receptor 6 0.80663 
DB00408 Loxapine BE0000694 Beta-2 adrenergic receptor 0.8066 
DB00777 Propiomazine BE0000289 Alpha-2A adrenergic receptor 0.80646 
DB00805 Minaprine BE0000291 5-hydroxytryptamine receptor 1A 0.80642 
DB00268 Ropinirole BE0000650 5-hydroxytryptamine receptor 7 0.80634 
DB08815 Lurasidone BE0000533 5-hydroxytryptamine receptor 2C 0.80615 
DB00934 Maprotiline BE0000501 Alpha-1A adrenergic receptor 0.80549 
DB00751 Epinastine BE0000575 Alpha-1B adrenergic receptor 0.80536 
DB00458 Imipramine BE0000572 Alpha-2B adrenergic receptor 0.80526 
DB01267 Paliperidone BE0000393 5-hydroxytryptamine receptor 2B 0.80455 
DB01614 Acepromazine BE0000715 Alpha-1D adrenergic receptor 0.80403 
DB01594 Cinolazepam BE0000764 Gamma-aminobutyric acid receptor subunit alpha-6 0.80373 
DB00711 Diethylcarbamazine BE0000262 Prostaglandin G/H synthase 2 0.80317 
DB00370 Mirtazapine BE0000145 D(1B) dopamine receptor 0.80299 
DB00370 Mirtazapine BE0000146 Histamine H4 receptor 0.80296 
DB01142 Doxepin BE0004889 D(1B) dopamine receptor 0.8026 
DB00185 Cevimeline BE0000560 Muscarinic acetylcholine receptor M2 0.80259 
DB00458 Imipramine BE0000393 5-hydroxytryptamine receptor 2B 0.80254 
DB01403 Methotrimeprazine BE0000945 5-hydroxytryptamine receptor 6 0.80251 
DB00268 Ropinirole BE0000501 Alpha-1A adrenergic receptor 0.8023 
DB00797 Tolazoline BE0000575 Alpha-1B adrenergic receptor 0.80203 
DB01151 Desipramine BE0000945 5-hydroxytryptamine receptor 6 0.80197 
DB00751 Epinastine BE0000572 Alpha-2B adrenergic receptor 0.80183 
DB01142 Doxepin BE0000145 D(1B) dopamine receptor 0.80161 
DB00696 Ergotamine BE0000749 Sodium-dependent serotonin transporter 0.80143 
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DB05271 Rotigotine BE0000289 Alpha-2A adrenergic receptor 0.80069 
DB00751 Epinastine BE0000756 D(2) dopamine receptor 0.80031 
DB00413 Pramipexole BE0000501 Alpha-1A adrenergic receptor 0.79947 
DB00321 Amitriptyline BE0000393 5-hydroxytryptamine receptor 2B 0.79912 
DB00540 Nortriptyline BE0000389 D(4) dopamine receptor 0.79909 
DB00934 Maprotiline BE0000945 5-hydroxytryptamine receptor 6 0.79908 
DB01392 Yohimbine BE0000145 D(1B) dopamine receptor 0.79866 
DB00540 Nortriptyline BE0000572 Alpha-2B adrenergic receptor 0.79852 
DB00424 Hyoscyamine BE0000247 Muscarinic acetylcholine receptor M5 0.79805 
DB00988 Dopamine BE0000393 5-hydroxytryptamine receptor 2B 0.79799 
DB00420 Promazine BE0000145 D(1B) dopamine receptor 0.7979 
DB06148 Mianserin BE0000145 D(1B) dopamine receptor 0.79694 
DB00321 Amitriptyline BE0000389 D(4) dopamine receptor 0.79676 
DB06216 Asenapine BE0004889 D(1B) dopamine receptor 0.7962 
DB00411 Carbachol BE0000045 Muscarinic acetylcholine receptor M3 0.79617 
DB01151 Desipramine BE0000020 D(1A) dopamine receptor 0.79601 
DB00751 Epinastine BE0000533 5-hydroxytryptamine receptor 2C 0.79573 
DB00540 Nortriptyline BE0000342 Alpha-2C adrenergic receptor 0.79531 
DB06288 Amisulpride BE0000020 D(1A) dopamine receptor 0.79522 
DB00321 Amitriptyline BE0004889 D(1B) dopamine receptor 0.79473 
DB01142 Doxepin BE0000647 Sodium-dependent dopamine transporter 0.79444 
DB01069 Promethazine BE0000020 D(1A) dopamine receptor 0.79418 
DB00589 Lisuride BE0000575 Alpha-1B adrenergic receptor 0.794 
DB08815 Lurasidone BE0000581 D(3) dopamine receptor 0.79388 
DB01403 Methotrimeprazine BE0000393 5-hydroxytryptamine receptor 2B 0.79318 
DB00714 Apomorphine BE0000575 Alpha-1B adrenergic receptor 0.79318 
DB04946 Iloperidone BE0000715 Alpha-1D adrenergic receptor 0.79275 
DB05271 Rotigotine BE0000533 5-hydroxytryptamine receptor 2C 0.79218 
DB01594 Cinolazepam BE0000478 Gamma-aminobutyric acid receptor subunit alpha-4 0.79176 
DB00589 Lisuride BE0000501 Alpha-1A adrenergic receptor 0.79172 
DB00413 Pramipexole BE0000575 Alpha-1B adrenergic receptor 0.79159 
DB06148 Mianserin BE0000715 Alpha-1D adrenergic receptor 0.79142 
DB01242 Clomipramine BE0000756 D(2) dopamine receptor 0.79139 
DB00800 Fenoldopam BE0000756 D(2) dopamine receptor 0.79107 
DB00809 Tropicamide BE0000247 Muscarinic acetylcholine receptor M5 0.79076 
DB00751 Epinastine BE0000291 5-hydroxytryptamine receptor 1A 0.79068 
DB00320 Dihydroergotamine BE0000291 5-hydroxytryptamine receptor 1A 0.79001 
DB00246 Ziprasidone BE0004889 D(1B) dopamine receptor 0.78919 
DB00805 Minaprine BE0000560 Muscarinic acetylcholine receptor M2 0.78892 
DB00696 Ergotamine BE0000145 D(1B) dopamine receptor 0.78874 
DB00477 Chlorpromazine BE0000797 5-hydroxytryptamine receptor 1B 0.78841 
DB08815 Lurasidone BE0000575 Alpha-1B adrenergic receptor 0.78801 
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DB00457 Prazosin BE0000342 Alpha-2C adrenergic receptor 0.78759 
DB00268 Ropinirole BE0000575 Alpha-1B adrenergic receptor 0.78621 
DB00363 Clozapine BE0004889 D(1B) dopamine receptor 0.78532 
DB01224 Quetiapine BE0004889 D(1B) dopamine receptor 0.78497 
DB01151 Desipramine BE0000393 5-hydroxytryptamine receptor 2B 0.78423 
DB00543 Amoxapine BE0000247 Muscarinic acetylcholine receptor M5 0.78404 
DB00988 Dopamine BE0000797 5-hydroxytryptamine receptor 1B 0.7836 
DB01224 Quetiapine BE0000146 Histamine H4 receptor 0.78347 
DB01622 Thioproperazine BE0000289 Alpha-2A adrenergic receptor 0.78308 
DB00458 Imipramine BE0000797 5-hydroxytryptamine receptor 1B 0.78289 
DB01392 Yohimbine BE0000501 Alpha-1A adrenergic receptor 0.78281 
DB00216 Eletriptan BE0000451 5-hydroxytryptamine receptor 2A 0.78176 
DB06288 Amisulpride BE0000291 5-hydroxytryptamine receptor 1A 0.78167 
DB00321 Amitriptyline BE0000581 D(3) dopamine receptor 0.78152 
DB01403 Methotrimeprazine BE0000797 5-hydroxytryptamine receptor 1B 0.78141 
DB00387 Procyclidine BE0000247 Muscarinic acetylcholine receptor M5 0.78093 
DB00458 Imipramine BE0000146 Histamine H4 receptor 0.78067 
DB00777 Propiomazine BE0000650 5-hydroxytryptamine receptor 7 0.78066 
DB00988 Dopamine BE0000501 Alpha-1A adrenergic receptor 0.7802 
DB00233 Aminosalicylic Acid BE0000017 Prostaglandin G/H synthase 1 0.77966 
DB00777 Propiomazine BE0000145 D(1B) dopamine receptor 0.77944 
DB01151 Desipramine BE0000581 D(3) dopamine receptor 0.77847 
DB01238 Aripiprazole BE0004889 D(1B) dopamine receptor 0.77845 
DB00370 Mirtazapine BE0000659 5-hydroxytryptamine receptor 1D 0.77844 
DB00656 Trazodone BE0000486 Sodium-dependent noradrenaline transporter 0.77842 
DB01608 Propericiazine BE0000715 Alpha-1D adrenergic receptor 0.77837 
DB00988 Dopamine BE0000575 Alpha-1B adrenergic receptor 0.77808 
DB00247 Methysergide BE0000581 D(3) dopamine receptor 0.77755 
DB01200 Bromocriptine BE0000945 5-hydroxytryptamine receptor 6 0.77748 
DB00540 Nortriptyline BE0004889 D(1B) dopamine receptor 0.77746 
DB00805 Minaprine BE0000501 Alpha-1A adrenergic receptor 0.77737 
DB00934 Maprotiline BE0000581 D(3) dopamine receptor 0.77708 
DB00392 Ethopropazine BE0000045 Muscarinic acetylcholine receptor M3 0.77697 
DB00477 Chlorpromazine BE0000659 5-hydroxytryptamine receptor 1D 0.77673 
DB00247 Methysergide BE0000289 Alpha-2A adrenergic receptor 0.77656 
DB00420 Promazine BE0000650 5-hydroxytryptamine receptor 7 0.77648 
DB00805 Minaprine BE0000442 Histamine H1 receptor 0.77646 
DB00726 Trimipramine BE0000145 D(1B) dopamine receptor 0.77637 
DB00540 Nortriptyline BE0000311 5-hydroxytryptamine receptor 3A 0.77609 
DB01614 Acepromazine BE0000289 Alpha-2A adrenergic receptor 0.77581 
DB00246 Ziprasidone BE0000146 Histamine H4 receptor 0.77579 
DB00247 Methysergide BE0000020 D(1A) dopamine receptor 0.77509 
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DB00656 Trazodone BE0000020 D(1A) dopamine receptor 0.77502 
DB00800 Fenoldopam BE0000389 D(4) dopamine receptor 0.77465 
DB00320 Dihydroergotamine BE0000572 Alpha-2B adrenergic receptor 0.77459 
DB01142 Doxepin BE0000311 5-hydroxytryptamine receptor 3A 0.77452 
DB01151 Desipramine BE0000575 Alpha-1B adrenergic receptor 0.77444 
DB06216 Asenapine BE0000146 Histamine H4 receptor 0.77382 
DB00543 Amoxapine BE0000405 Muscarinic acetylcholine receptor M4 0.77374 
DB00804 Dicyclomine BE0000045 Muscarinic acetylcholine receptor M3 0.77368 
DB00988 Dopamine BE0000945 5-hydroxytryptamine receptor 6 0.77261 
DB00777 Propiomazine BE0000945 5-hydroxytryptamine receptor 6 0.77242 
DB00842 Oxazepam BE0000736 Translocator protein 0.77206 
DB01628 Etoricoxib BE0000017 Prostaglandin G/H synthase 1 0.77196 
DB00216 Eletriptan BE0000533 5-hydroxytryptamine receptor 2C 0.77182 
DB01069 Promethazine BE0000533 5-hydroxytryptamine receptor 2C 0.77181 
DB00540 Nortriptyline BE0000581 D(3) dopamine receptor 0.77139 
DB01622 Thioproperazine BE0000533 5-hydroxytryptamine receptor 2C 0.77102 
DB05271 Rotigotine BE0000797 5-hydroxytryptamine receptor 1B 0.77092 
DB00449 Dipivefrin BE0000172 Beta-1 adrenergic receptor 0.77078 
DB01148 Flavoxate BE0000045 Muscarinic acetylcholine receptor M3 0.77012 
DB01238 Aripiprazole BE0000146 Histamine H4 receptor 0.76975 
DB00420 Promazine BE0000945 5-hydroxytryptamine receptor 6 0.7692 
DB00810 Biperiden BE0000560 Muscarinic acetylcholine receptor M2 0.7687 
DB00508 Triflupromazine BE0000533 5-hydroxytryptamine receptor 2C 0.76869 
DB00540 Nortriptyline BE0000659 5-hydroxytryptamine receptor 1D 0.76857 
DB00247 Methysergide BE0000389 D(4) dopamine receptor 0.76852 
DB00679 Thioridazine BE0000289 Alpha-2A adrenergic receptor 0.76836 
DB01614 Acepromazine BE0000533 5-hydroxytryptamine receptor 2C 0.76826 
DB01608 Propericiazine BE0000342 Alpha-2C adrenergic receptor 0.76781 
DB00434 Cyproheptadine BE0000756 D(2) dopamine receptor 0.76776 
DB00988 Dopamine BE0000659 5-hydroxytryptamine receptor 1D 0.76733 
DB01069 Promethazine BE0000715 Alpha-1D adrenergic receptor 0.76684 
DB00805 Minaprine BE0000045 Muscarinic acetylcholine receptor M3 0.76665 
DB00988 Dopamine BE0000342 Alpha-2C adrenergic receptor 0.76588 
DB08815 Lurasidone BE0000797 5-hydroxytryptamine receptor 1B 0.76536 
DB01151 Desipramine BE0000389 D(4) dopamine receptor 0.76473 
DB00543 Amoxapine BE0000476 5-hydroxytryptamine receptor 1E 0.76443 
DB00458 Imipramine BE0000311 5-hydroxytryptamine receptor 3A 0.76438 
DB00458 Imipramine BE0000659 5-hydroxytryptamine receptor 1D 0.76417 
DB00656 Trazodone BE0000715 Alpha-1D adrenergic receptor 0.764 
DB01594 Cinolazepam BE0003597 Gamma-aminobutyric acid receptor subunit theta 0.76386 
DB00193 Tramadol BE0000311 5-hydroxytryptamine receptor 3A 0.76331 
DB00321 Amitriptyline BE0000020 D(1A) dopamine receptor 0.76327 
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DB01625 Isopropamide BE0000092 Muscarinic acetylcholine receptor M1 0.76323 
DB01235 L-DOPA BE0000451 5-hydroxytryptamine receptor 2A 0.76281 
DB08815 Lurasidone BE0000393 5-hydroxytryptamine receptor 2B 0.76272 
DB06288 Amisulpride BE0000533 5-hydroxytryptamine receptor 2C 0.76256 
DB00734 Risperidone BE0000945 5-hydroxytryptamine receptor 6 0.76252 
DB00656 Trazodone BE0000393 5-hydroxytryptamine receptor 2B 0.76237 
DB00280 Disopyramide BE0000405 Muscarinic acetylcholine receptor M4 0.76236 
DB00247 Methysergide BE0000342 Alpha-2C adrenergic receptor 0.76218 
DB00805 Minaprine BE0000486 Sodium-dependent noradrenaline transporter 0.76196 
DB00800 Fenoldopam BE0000451 5-hydroxytryptamine receptor 2A 0.76186 
DB00988 Dopamine BE0000442 Histamine H1 receptor 0.76181 
DB06216 Asenapine BE0000476 5-hydroxytryptamine receptor 1E 0.76179 
DB00800 Fenoldopam BE0000291 5-hydroxytryptamine receptor 1A 0.76161 
DB00797 Tolazoline BE0000715 Alpha-1D adrenergic receptor 0.76148 
DB01622 Thioproperazine BE0000342 Alpha-2C adrenergic receptor 0.76143 
DB05271 Rotigotine BE0000659 5-hydroxytryptamine receptor 1D 0.76019 
DB00248 Cabergoline BE0000476 5-hydroxytryptamine receptor 1E 0.75958 
DB01614 Acepromazine BE0000342 Alpha-2C adrenergic receptor 0.75916 
DB05271 Rotigotine BE0000393 5-hydroxytryptamine receptor 2B 0.75902 
DB00696 Ergotamine BE0000945 5-hydroxytryptamine receptor 6 0.75868 
DB00805 Minaprine BE0000581 D(3) dopamine receptor 0.75863 
DB01151 Desipramine BE0000647 Sodium-dependent dopamine transporter 0.75839 
DB00800 Fenoldopam BE0000533 5-hydroxytryptamine receptor 2C 0.75809 
DB01392 Yohimbine BE0000575 Alpha-1B adrenergic receptor 0.75723 
DB00320 Dihydroergotamine BE0000342 Alpha-2C adrenergic receptor 0.75719 
DB00656 Trazodone BE0000650 5-hydroxytryptamine receptor 7 0.75697 
DB00477 Chlorpromazine BE0000749 Sodium-dependent serotonin transporter 0.75667 
DB01221 Ketamine BE0000749 Sodium-dependent serotonin transporter 0.75662 
DB00540 Nortriptyline BE0000393 5-hydroxytryptamine receptor 2B 0.75638 
DB00321 Amitriptyline BE0000145 D(1B) dopamine receptor 0.75576 
DB00458 Imipramine BE0000145 D(1B) dopamine receptor 0.75569 
DB00540 Nortriptyline BE0000647 Sodium-dependent dopamine transporter 0.75557 
DB00696 Ergotamine BE0000442 Histamine H1 receptor 0.75549 
DB00934 Maprotiline BE0000389 D(4) dopamine receptor 0.75546 
DB01100 Pimozide BE0000020 D(1A) dopamine receptor 0.75398 
DB00777 Propiomazine BE0000393 5-hydroxytryptamine receptor 2B 0.75327 
DB00477 Chlorpromazine BE0000311 5-hydroxytryptamine receptor 3A 0.75324 
DB01142 Doxepin BE0000476 5-hydroxytryptamine receptor 1E 0.75315 
DB08815 Lurasidone BE0000389 D(4) dopamine receptor 0.75271 
DB00964 Apraclonidine BE0000342 Alpha-2C adrenergic receptor 0.75244 
DB08815 Lurasidone BE0000659 5-hydroxytryptamine receptor 1D 0.7515 
DB01151 Desipramine BE0004889 D(1B) dopamine receptor 0.75144 
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DB06148 Mianserin BE0000476 5-hydroxytryptamine receptor 1E 0.75138 
DB00540 Nortriptyline BE0000797 5-hydroxytryptamine receptor 1B 0.75133 
DB00193 Tramadol BE0000405 Muscarinic acetylcholine receptor M4 0.75102 
DB00751 Epinastine BE0000020 D(1A) dopamine receptor 0.75065 
DB01242 Clomipramine BE0000291 5-hydroxytryptamine receptor 1A 0.75035 
DB01614 Acepromazine BE0000572 Alpha-2B adrenergic receptor 0.75021 
DB08801 Dimetindene BE0000092 Muscarinic acetylcholine receptor M1 0.75019 
DB00751 Epinastine BE0000715 Alpha-1D adrenergic receptor 0.75014 
DB01235 L-DOPA BE0000291 5-hydroxytryptamine receptor 1A 0.74995 
DB06216 Asenapine BE0000311 5-hydroxytryptamine receptor 3A 0.74954 
DB00934 Maprotiline BE0000575 Alpha-1B adrenergic receptor 0.74951 
DB00248 Cabergoline BE0000442 Histamine H1 receptor 0.7495 
DB01618 Molindone BE0000020 D(1A) dopamine receptor 0.74912 
DB00715 Paroxetine BE0000756 D(2) dopamine receptor 0.7488 
DB00321 Amitriptyline BE0000647 Sodium-dependent dopamine transporter 0.74879 
DB00477 Chlorpromazine BE0000476 5-hydroxytryptamine receptor 1E 0.74862 
DB04946 Iloperidone BE0004889 D(1B) dopamine receptor 0.74854 
DB00540 Nortriptyline BE0000146 Histamine H4 receptor 0.74844 
DB00546 Adinazolam BE0003597 Gamma-aminobutyric acid receptor subunit theta 0.74813 
DB00988 Dopamine BE0000289 Alpha-2A adrenergic receptor 0.74774 
DB05271 Rotigotine BE0000575 Alpha-1B adrenergic receptor 0.74764 
DB00508 Triflupromazine BE0000581 D(3) dopamine receptor 0.7476 
DB01151 Desipramine BE0000289 Alpha-2A adrenergic receptor 0.74758 
DB00319 Piperacillin BE0004290 Penicillin-binding protein 1A 0.7475 
DB01151 Desipramine BE0000715 Alpha-1D adrenergic receptor 0.74748 
DB00216 Eletriptan BE0000289 Alpha-2A adrenergic receptor 0.74746 
DB00934 Maprotiline BE0000393 5-hydroxytryptamine receptor 2B 0.74702 
DB00656 Trazodone BE0000797 5-hydroxytryptamine receptor 1B 0.74685 
DB00215 Citalopram BE0000486 Sodium-dependent noradrenaline transporter 0.74685 
DB00477 Chlorpromazine BE0000486 Sodium-dependent noradrenaline transporter 0.74672 
DB00988 Dopamine BE0000572 Alpha-2B adrenergic receptor 0.74661 
DB00800 Fenoldopam BE0000581 D(3) dopamine receptor 0.74632 
DB00540 Nortriptyline BE0000145 D(1B) dopamine receptor 0.74632 
DB04855 Dronedarone BE0000694 Beta-2 adrenergic receptor 0.74625 
DB00247 Methysergide BE0000572 Alpha-2B adrenergic receptor 0.74623 
DB00482 Celecoxib BE0000017 Prostaglandin G/H synthase 1 0.74591 
DB08801 Dimetindene BE0000045 Muscarinic acetylcholine receptor M3 0.74591 
DB01622 Thioproperazine BE0000572 Alpha-2B adrenergic receptor 0.74585 
DB01608 Propericiazine BE0000756 D(2) dopamine receptor 0.74525 
DB00715 Paroxetine BE0000442 Histamine H1 receptor 0.74491 
DB00656 Trazodone BE0000581 D(3) dopamine receptor 0.74395 
DB00280 Disopyramide BE0000247 Muscarinic acetylcholine receptor M5 0.74387 
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DB00751 Epinastine BE0000581 D(3) dopamine receptor 0.74386 
DB00193 Tramadol BE0000756 D(2) dopamine receptor 0.74357 
DB01594 Cinolazepam BE0004797 Gamma-aminobutyric acid receptor subunit theta 0.74306 
DB00508 Triflupromazine BE0000291 5-hydroxytryptamine receptor 1A 0.74305 
DB00679 Thioridazine BE0000581 D(3) dopamine receptor 0.74292 
DB01151 Desipramine BE0000797 5-hydroxytryptamine receptor 1B 0.74233 
DB01267 Paliperidone BE0000945 5-hydroxytryptamine receptor 6 0.74225 
DB01151 Desipramine BE0000311 5-hydroxytryptamine receptor 3A 0.74218 
DB00679 Thioridazine BE0000342 Alpha-2C adrenergic receptor 0.74201 
DB00546 Adinazolam BE0004797 Gamma-aminobutyric acid receptor subunit theta 0.742 
DB00321 Amitriptyline BE0000476 5-hydroxytryptamine receptor 1E 0.74193 
DB00589 Lisuride BE0000715 Alpha-1D adrenergic receptor 0.74169 
DB01403 Methotrimeprazine BE0000311 5-hydroxytryptamine receptor 3A 0.74164 
DB01595 Nitrazepam BE0000736 Translocator protein 0.74161 
DB00805 Minaprine BE0000289 Alpha-2A adrenergic receptor 0.74096 
DB00715 Paroxetine BE0000533 5-hydroxytryptamine receptor 2C 0.74085 
DB00964 Apraclonidine BE0000575 Alpha-1B adrenergic receptor 0.74067 
DB00508 Triflupromazine BE0000247 Muscarinic acetylcholine receptor M5 0.73998 
DB01625 Isopropamide BE0000247 Muscarinic acetylcholine receptor M5 0.73959 
DB00679 Thioridazine BE0000533 5-hydroxytryptamine receptor 2C 0.73944 
DB08815 Lurasidone BE0000715 Alpha-1D adrenergic receptor 0.73915 
DB01403 Methotrimeprazine BE0004889 D(1B) dopamine receptor 0.73912 
DB00653 Magnesium Sulfate BE0002359 Voltage-dependent L-type calcium channel subunit 
alpha-1D 
0.73903 
DB00420 Promazine BE0000393 5-hydroxytryptamine receptor 2B 0.73859 
DB00679 Thioridazine BE0000572 Alpha-2B adrenergic receptor 0.73813 
DB08810 Cinitapride BE0000756 D(2) dopamine receptor 0.738 
DB01200 Bromocriptine BE0000442 Histamine H1 receptor 0.73784 
DB00622 Nicardipine BE0002355 Voltage-dependent L-type calcium channel subunit 
alpha-1S 
0.73774 
DB00934 Maprotiline BE0000647 Sodium-dependent dopamine transporter 0.73747 
DB00805 Minaprine BE0000389 D(4) dopamine receptor 0.7374 
DB00216 Eletriptan BE0000756 D(2) dopamine receptor 0.73732 
DB00193 Tramadol BE0000247 Muscarinic acetylcholine receptor M5 0.73697 
DB00714 Apomorphine BE0000715 Alpha-1D adrenergic receptor 0.73645 
DB00679 Thioridazine BE0000291 5-hydroxytryptamine receptor 1A 0.73641 
DB01018 Guanfacine BE0000342 Alpha-2C adrenergic receptor 0.73622 
DB00714 Apomorphine BE0000945 5-hydroxytryptamine receptor 6 0.73617 
DB01100 Pimozide BE0000451 5-hydroxytryptamine receptor 2A 0.73616 
DB01622 Thioproperazine BE0000389 D(4) dopamine receptor 0.73611 
DB01337 Pancuronium BE0000092 Muscarinic acetylcholine receptor M1 0.73609 
DB01226 Mivacurium BE0000092 Muscarinic acetylcholine receptor M1 0.73607 
DB01622 Thioproperazine BE0000581 D(3) dopamine receptor 0.73582 
DB00215 Citalopram BE0000560 Muscarinic acetylcholine receptor M2 0.73577 
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DB00726 Trimipramine BE0000146 Histamine H4 receptor 0.73567 
DB00777 Propiomazine BE0000797 5-hydroxytryptamine receptor 1B 0.7356 
DB00413 Pramipexole BE0000715 Alpha-1D adrenergic receptor 0.73552 
DB01049 Ergoloid mesylate BE0000451 5-hydroxytryptamine receptor 2A 0.7351 
DB01200 Bromocriptine BE0004889 D(1B) dopamine receptor 0.73507 
DB00193 Tramadol BE0000442 Histamine H1 receptor 0.73493 
DB01618 Molindone BE0000533 5-hydroxytryptamine receptor 2C 0.73467 
DB01338 Pipecuronium BE0000092 Muscarinic acetylcholine receptor M1 0.73387 
DB00777 Propiomazine BE0000659 5-hydroxytryptamine receptor 1D 0.73357 
DB01235 L-DOPA BE0000533 5-hydroxytryptamine receptor 2C 0.73336 
DB01618 Molindone BE0000560 Muscarinic acetylcholine receptor M2 0.73277 
DB01069 Promethazine BE0000289 Alpha-2A adrenergic receptor 0.73209 
DB00268 Ropinirole BE0000715 Alpha-1D adrenergic receptor 0.7319 
DB00247 Methysergide BE0000145 D(1B) dopamine receptor 0.73142 
DB00247 Methysergide BE0000945 5-hydroxytryptamine receptor 6 0.73126 
DB00248 Cabergoline BE0000311 5-hydroxytryptamine receptor 3A 0.73105 
DB00502 Haloperidol BE0000291 5-hydroxytryptamine receptor 1A 0.73094 
DB05271 Rotigotine BE0000650 5-hydroxytryptamine receptor 7 0.73086 
DB00408 Loxapine BE0004863 Alpha-1D adrenergic receptor 0.73066 
DB00508 Triflupromazine BE0000389 D(4) dopamine receptor 0.73056 
DB00420 Promazine BE0000659 5-hydroxytryptamine receptor 1D 0.73044 
DB01614 Acepromazine BE0000389 D(4) dopamine receptor 0.73043 
DB00508 Triflupromazine BE0000405 Muscarinic acetylcholine receptor M4 0.73033 
DB00589 Lisuride BE0000945 5-hydroxytryptamine receptor 6 0.73 
DB01233 Metoclopramide BE0000451 5-hydroxytryptamine receptor 2A 0.72978 
DB00502 Haloperidol BE0000533 5-hydroxytryptamine receptor 2C 0.72945 
DB00805 Minaprine BE0000650 5-hydroxytryptamine receptor 7 0.72942 
DB00934 Maprotiline BE0000289 Alpha-2A adrenergic receptor 0.72935 
DB01621 Pipotiazine BE0000533 5-hydroxytryptamine receptor 2C 0.7292 
DB00656 Trazodone BE0000389 D(4) dopamine receptor 0.72905 
DB00988 Dopamine BE0000311 5-hydroxytryptamine receptor 3A 0.72896 
DB00831 Trifluoperazine BE0000575 Alpha-1B adrenergic receptor 0.72874 
DB01151 Desipramine BE0000342 Alpha-2C adrenergic receptor 0.7279 
DB00268 Ropinirole BE0000945 5-hydroxytryptamine receptor 6 0.72778 
DB01242 Clomipramine BE0000442 Histamine H1 receptor 0.72753 
DB00656 Trazodone BE0000659 5-hydroxytryptamine receptor 1D 0.72709 
DB00726 Trimipramine BE0000092 Muscarinic acetylcholine receptor M1 0.72708 
DB00589 Lisuride BE0000442 Histamine H1 receptor 0.72613 
DB01233 Metoclopramide BE0000560 Muscarinic acetylcholine receptor M2 0.72598 
DB05271 Rotigotine BE0000501 Alpha-1A adrenergic receptor 0.7259 
DB01614 Acepromazine BE0000581 D(3) dopamine receptor 0.72528 
DB00350 Minoxidil BE0000262 Prostaglandin G/H synthase 2 0.72524 
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DB00800 Fenoldopam BE0000659 5-hydroxytryptamine receptor 1D 0.72508 
DB00546 Adinazolam BE0000736 Translocator protein 0.72471 
DB00934 Maprotiline BE0004889 D(1B) dopamine receptor 0.72399 
DB00413 Pramipexole BE0000945 5-hydroxytryptamine receptor 6 0.72394 
DB00216 Eletriptan BE0000581 D(3) dopamine receptor 0.72355 
DB00652 Pentazocine BE0000420 Delta-type opioid receptor 0.72335 
DB06288 Amisulpride BE0000389 D(4) dopamine receptor 0.72303 
DB01608 Propericiazine BE0000451 5-hydroxytryptamine receptor 2A 0.72288 
DB00320 Dihydroergotamine BE0000533 5-hydroxytryptamine receptor 2C 0.72264 
DB00679 Thioridazine BE0000389 D(4) dopamine receptor 0.72262 
DB00714 Apomorphine BE0000442 Histamine H1 receptor 0.72256 
DB00248 Cabergoline BE0000146 Histamine H4 receptor 0.72239 
DB00745 Modafinil BE0000501 Alpha-1A adrenergic receptor 0.72212 
DB00462 Methylscopolamine 
bromide 
BE0000405 Muscarinic acetylcholine receptor M4 0.7217 
DB00517 Anisotropine 
Methylbromide 
BE0000405 Muscarinic acetylcholine receptor M4 0.72097 
DB00831 Trifluoperazine BE0000020 D(1A) dopamine receptor 0.72089 
DB01618 Molindone BE0000045 Muscarinic acetylcholine receptor M3 0.72058 
DB00216 Eletriptan BE0000342 Alpha-2C adrenergic receptor 0.72041 
DB01062 Oxybutynin BE0000405 Muscarinic acetylcholine receptor M4 0.72036 
DB00434 Cyproheptadine BE0000291 5-hydroxytryptamine receptor 1A 0.72031 
DB00215 Citalopram BE0000045 Muscarinic acetylcholine receptor M3 0.72023 
DB00696 Ergotamine BE0000647 Sodium-dependent dopamine transporter 0.71961 
DB00187 Esmolol BE0000694 Beta-2 adrenergic receptor 0.71893 
DB00246 Ziprasidone BE0000112 Histamine H2 receptor 0.71878 
DB00629 Guanabenz BE0000342 Alpha-2C adrenergic receptor 0.71872 
DB01594 Cinolazepam BE0000736 Translocator protein 0.71781 
DB01175 Escitalopram BE0000575 Alpha-1B adrenergic receptor 0.71748 
DB00986 Glycopyrrolate BE0000405 Muscarinic acetylcholine receptor M4 0.71741 
DB01242 Clomipramine BE0000650 5-hydroxytryptamine receptor 7 0.71674 
DB00934 Maprotiline BE0000342 Alpha-2C adrenergic receptor 0.71661 
DB00934 Maprotiline BE0000311 5-hydroxytryptamine receptor 3A 0.71654 
DB00420 Promazine BE0000797 5-hydroxytryptamine receptor 1B 0.71633 
DB01621 Pipotiazine BE0000581 D(3) dopamine receptor 0.71614 
DB00247 Methysergide BE0000501 Alpha-1A adrenergic receptor 0.71581 
DB00193 Tramadol BE0000451 5-hydroxytryptamine receptor 2A 0.71578 
DB01409 Tiotropium BE0000405 Muscarinic acetylcholine receptor M4 0.71555 
DB06204 Tapentadol BE0000647 Sodium-dependent dopamine transporter 0.71528 
DB00458 Imipramine BE0004863 Alpha-1D adrenergic receptor 0.71526 
DB00216 Eletriptan BE0000572 Alpha-2B adrenergic receptor 0.7151 
DB00543 Amoxapine BE0000112 Histamine H2 receptor 0.71469 
DB01200 Bromocriptine BE0000476 5-hydroxytryptamine receptor 1E 0.7146 
DB01255 Lisdexamfetamine BE0000501 Alpha-1A adrenergic receptor 0.71453 
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DB00568 Cinnarizine BE0002354 Voltage-dependent L-type calcium channel subunit 
beta-2 
0.71439 
DB06711 Naphazoline BE0000572 Alpha-2B adrenergic receptor 0.71436 
DB01069 Promethazine BE0000581 D(3) dopamine receptor 0.71416 
DB00568 Cinnarizine BE0000451 5-hydroxytryptamine receptor 2A 0.71411 
DB00728 Rocuronium BE0000045 Muscarinic acetylcholine receptor M3 0.71402 
DB00953 Rizatriptan BE0000291 5-hydroxytryptamine receptor 1A 0.7139 
DB01104 Sertraline BE0000486 Sodium-dependent noradrenaline transporter 0.71389 
DB00216 Eletriptan BE0000020 D(1A) dopamine receptor 0.71378 
DB00383 Oxyphencyclimine BE0000405 Muscarinic acetylcholine receptor M4 0.7136 
DB00751 Epinastine BE0000393 5-hydroxytryptamine receptor 2B 0.7135 
DB01085 Pilocarpine BE0000405 Muscarinic acetylcholine receptor M4 0.71339 
DB00656 Trazodone BE0000945 5-hydroxytryptamine receptor 6 0.71308 
DB01156 Bupropion BE0000749 Sodium-dependent serotonin transporter 0.71307 
DB01100 Pimozide BE0000501 Alpha-1A adrenergic receptor 0.71283 
DB00477 Chlorpromazine BE0000647 Sodium-dependent dopamine transporter 0.71282 
DB01403 Methotrimeprazine BE0000476 5-hydroxytryptamine receptor 1E 0.71276 
DB01175 Escitalopram BE0000045 Muscarinic acetylcholine receptor M3 0.71242 
DB00734 Risperidone BE0004889 D(1B) dopamine receptor 0.71186 
DB01233 Metoclopramide BE0000045 Muscarinic acetylcholine receptor M3 0.71165 
DB01392 Yohimbine BE0000715 Alpha-1D adrenergic receptor 0.71158 
DB00751 Epinastine BE0000945 5-hydroxytryptamine receptor 6 0.7114 
DB01175 Escitalopram BE0000560 Muscarinic acetylcholine receptor M2 0.71138 
DB00502 Haloperidol BE0000389 D(4) dopamine receptor 0.71136 
DB00964 Apraclonidine BE0000715 Alpha-1D adrenergic receptor 0.71131 
DB00490 Buspirone BE0000451 5-hydroxytryptamine receptor 2A 0.71109 
DB01151 Desipramine BE0000572 Alpha-2B adrenergic receptor 0.71082 
DB00334 Olanzapine BE0004864 Alpha-2C adrenergic receptor 0.71082 
DB01135 Doxacurium chloride BE0000045 Muscarinic acetylcholine receptor M3 0.71054 
DB04946 Iloperidone BE0000146 Histamine H4 receptor 0.7105 
DB01151 Desipramine BE0000145 D(1B) dopamine receptor 0.71039 
DB00751 Epinastine BE0000389 D(4) dopamine receptor 0.71034 
DB06216 Asenapine BE0000560 Muscarinic acetylcholine receptor M2 0.70979 
DB00726 Trimipramine BE0000560 Muscarinic acetylcholine receptor M2 0.70941 
DB06709 Methacholine BE0000560 Muscarinic acetylcholine receptor M2 0.70915 
DB00216 Eletriptan BE0000389 D(4) dopamine receptor 0.70892 
DB08815 Lurasidone BE0000145 D(1B) dopamine receptor 0.70879 
DB00363 Clozapine BE0000112 Histamine H2 receptor 0.70815 
DB08815 Lurasidone BE0000945 5-hydroxytryptamine receptor 6 0.70797 
DB00202 Succinylcholine BE0000405 Muscarinic acetylcholine receptor M4 0.70734 
DB06288 Amisulpride BE0000393 5-hydroxytryptamine receptor 2B 0.70724 
DB04946 Iloperidone BE0000476 5-hydroxytryptamine receptor 1E 0.70714 
DB01119 Diazoxide BE0000535 Carbonic anhydrase 4 0.70698 
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DB01151 Desipramine BE0000146 Histamine H4 receptor 0.70584 
DB01069 Promethazine BE0000291 5-hydroxytryptamine receptor 1A 0.70581 
DB01392 Yohimbine BE0000945 5-hydroxytryptamine receptor 6 0.70539 
DB00332 Ipratropium bromide BE0000405 Muscarinic acetylcholine receptor M4 0.70527 
DB00370 Mirtazapine BE0000112 Histamine H2 receptor 0.70469 
DB00193 Tramadol BE0000647 Sodium-dependent dopamine transporter 0.7046 
DB00904 Ondansetron BE0000659 5-hydroxytryptamine receptor 1D 0.70453 
DB01587 Ketazolam BE0000523 Gamma-aminobutyric acid receptor subunit alpha-3 0.70431 
DB00450 Droperidol BE0000575 Alpha-1B adrenergic receptor 0.70421 
DB06216 Asenapine BE0000045 Muscarinic acetylcholine receptor M3 0.70377 
DB00714 Apomorphine BE0000476 5-hydroxytryptamine receptor 1E 0.70366 
DB00934 Maprotiline BE0000146 Histamine H4 receptor 0.70365 
DB01118 Amiodarone BE0000694 Beta-2 adrenergic receptor 0.70334 
DB00715 Paroxetine BE0000647 Sodium-dependent dopamine transporter 0.70323 
DB00215 Citalopram BE0000575 Alpha-1B adrenergic receptor 0.70311 
DB08910 Pomalidomide BE0000017 Prostaglandin G/H synthase 1 0.70299 
DB01364 Ephedrine BE0000749 Sodium-dependent serotonin transporter 0.70291 
DB01622 Thioproperazine BE0000650 5-hydroxytryptamine receptor 7 0.70277 
DB01614 Acepromazine BE0000650 5-hydroxytryptamine receptor 7 0.70273 
DB06216 Asenapine BE0000247 Muscarinic acetylcholine receptor M5 0.70233 
DB00805 Minaprine BE0000247 Muscarinic acetylcholine receptor M5 0.702 
DB00805 Minaprine BE0000342 Alpha-2C adrenergic receptor 0.70184 
DB00726 Trimipramine BE0000247 Muscarinic acetylcholine receptor M5 0.7014 
DB00320 Dihydroergotamine BE0000451 5-hydroxytryptamine receptor 2A 0.70088 
DB00805 Minaprine BE0000575 Alpha-1B adrenergic receptor 0.70087 
DB00934 Maprotiline BE0000715 Alpha-1D adrenergic receptor 0.70086 
DB00413 Pramipexole BE0000442 Histamine H1 receptor 0.70055 
DB00751 Epinastine BE0000659 5-hydroxytryptamine receptor 1D 0.70036 
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APPENDIX C 
THE DESCRIPTION OF THE CONTENTS OF BALESTRAWEB.ZIP 
The code and auxiliary files to run BalestraWeb are accessible online at 
http://balestra.csb.pitt.edu/static/balestraweb.zip and the contents of this file are explained below: 
Name Description of contents 
balestraweb.py The code that runs BalestraWeb (Python) 
cabinet Contains the data files that BalestraWeb uses in Python shelve format 
html Contains the HTML files that BalestraWeb serves to the users 
static Contains the static files (i.e. the figures in the tutorial, BalestraWeb icon, 
etc) that BalestraWeb serves to the users. 
helpers Contains the code to generate BalestraWeb data. To be used as follows: 
1) Run learn_multi_model.m (Matlab) 
2) Run getDrugBank.py (Python) 
Doing the above re-generates all the files in the ‘cabinet’ folder.  
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APPENDIX D 
LFM METHOD AND HYPERPARAMETER SEARCH RESULTS 
To decide on the optimal approach to build the LFM of STITCH v3 that I used in the HD project, 
I have conducted a search of the best performing method and hyperparameter combination on 
STITCH v3 data by partitioning the data 16 times into training, testing sets allocating 90% of the 
interactions for training, 10% for testing using GraphLab PowerGraph software. The RMSE over 
these 16 iterations are averaged in the ‘RMSE_mean’ column, and the standard deviation of 
these 16 iteration results are provided in the ‘RMSE_std’ column. The parameter text starts with 
the shorthand name of the method and then underscore (‘_’) character is used to delimit the 
parameters. The full list of results can be downloaded here:  
http://balestra.csb.pitt.edu/static/all_results.xlsx 
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APPENDIX E 
TABLE OF C. ELEGANS GENES THAT CAUSE REDUCED ATZ AGGREGATION 
PHENOTYPE UPON RNA INTERFERENCE KNOCKDOWN 
Batch 
ID 
Batch 
Date 
Inhibition target genes  
1 10-27 T01G9.3,F30A10.7 
3 11-10 R06C1.6,Y53C10A.10,T09E11.9,T15D6.8 
4 11-11 Y65B4B_10.d 
5 11-19 W10D9.5,C08G5.1 
6 11-20 C16C4.11 
7 11-21 W10G11.12 
8 12-11 T12F5.3,C50F2.5,R12E2.13 
9 12-12 F33D11.9 
11 12-20 R05G9.c,C18H9.6,C18H9.7,C18H9.8,T14B4.5,F18A1.4,T05H10.4 
12 12-21 W01C9.2,ZK1321.4 
17 4-14 C16C10.3 
19 4-17 ZK1098.6,C48B4.12a,T05G5.9,C05B5.5,C05B5.6,M04D8.3,M04D8.4,
M04D8.5,T20G5.6 
20 4-19 Y119D3_456.a 
21 4-20 C45G7.6 
22 4-21 F36H12.15 
23 4-22 K02B2.6,T13A10.8,C06G3.9,C34D4.1 
24 4-23 C49H3.2,C49H3.5,C49H3.6,C49H3.7 
27 6-11 R09E12.4,R09E12.5,R09E12.7,R13D11.3 
32 6-18 ZK262.9 
35 6-21 C05A9.1,C05C9.3,F13D2.2,F08B12.1 
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APPENDIX F 
LIST OF CHEMICALS PREDICTED TO REDUCE AGGREATION OF ATZ 
THROUGH THE ALPHA-1 ANTITRYPSIN HIGH CONTENT SCREENING RESULT 
ANALYSIS CHEMICAL HIT DIVERSIFICATION METHOD 
The columns contain the following information from the left to right:  
 ZINC_ID: ZINC compound identifier 
 MWT: Molecular weight 
 LogP: Partition coefficient 
 Desolv_apolar: Apolar desolvation energy (kcal/mol) 
 Desolv_polar: Polar desolvation energy (kcal/mol) 
 HBD: Number of hydrogen bond donors 
 HBA: Number of hydrogen bond acceptors 
 tPSA: Topological polar surface area (suspected to be in Å2, exact specification not found 
in ZINC documentation) 
 Charge: Net charge of the molecule 
 NRB: Number of rotatable bonds 
 Cluster size: Total number of chemicals in the same cluster as this chemical 
ZINC_ID MWT LogP Desolv_apolar Desolv_polar HBD HBA tPSA Charge NRB Cluster 
Size ZINC75662250 297.707 4.24 7.85 -7.72 1 1 12 0 1 797 
ZINC67287455 445.516 3.04 7.63 -11.21 2 9 106 0 10 643 
ZINC00641264 365.433 3.77 6.3 -13.72 3 6 79 0 4 588 
ZINC20283449 438.503 3.78 7.12 -11.36 2 7 74 0 7 585 
ZINC04482400 304.346 2.93 -0.56 -8.42 2 6 76 0 6 529 
ZINC72190830 251.251 2.1 6.57 -4.16 2 1 26 0 3 521 
ZINC04625454 228.23 1.84 5.86 -9.12 2 4 56 0 1 426 
ZINC43568601 222.218 2.31 4.27 -29.6 4 3 52 1 2 426 
ZINC83664119 218.255 1.64 4.98 -36.24 3 3 42 1 1 425 
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ZINC00073782 316.401 4.25 0.41 -7.33 2 5 67 0 5 409 
ZINC20906829 396.53 3.89 9.43 -43.05 1 4 20 1 4 403 
ZINC00716297 360.366 2.26 -2.69 -10.48 2 8 95 0 5 395 
ZINC76216131 354.381 3.71 9.04 -7.71 2 5 67 0 5 374 
ZINC38276461 194.273 2.8 5.97 -39.59 3 1 28 1 1 370 
ZINC34940780 250.362 3.47 7.47 -48.25 3 1 28 1 2 357 
ZINC00041497 292.291 1.33 1.64 -11.1 3 7 97 0 4 354 
ZINC19271873 200.664 2.85 5.98 -38.34 2 1 17 1 1 350 
ZINC65516145 344.333 1.52 5.5 -16.04 1 5 51 0 5 347 
ZINC75688609 297.251 3.65 4.71 -7.02 2 2 32 0 1 346 
ZINC43669139 345.374 2.77 5.1 -13.07 3 6 79 0 5 344 
ZINC23358157 393.641 3.51 8.96 -77.07 3 4 32 2 7 340 
ZINC01430262 338.72 4.14 2.65 -14.14 2 4 56 0 3 339 
ZINC00060635 344.411 3.96 7.36 -8.96 2 6 77 0 5 337 
ZINC75961665 239.289 1.87 5.23 -39.96 2 2 20 1 1 332 
ZINC01815570 552.515 5.82 5.51 -27.97 1 5 66 0 8 331 
ZINC22765711 352.406 2.41 4.57 -11.82 1 4 42 0 5 331 
ZINC01257249 215.251 2.23 6 -34.34 4 2 52 1 2 327 
ZINC02414084 514.544 4.98 3.35 -29.47 1 6 75 0 8 323 
ZINC67803975 370.44 1 7.69 -45.47 2 7 85 1 4 322 
ZINC75644572 253.297 0.78 -1.7 -37.14 5 4 69 1 1 322 
ZINC00143298 300.365 3.62 7.67 -9.25 2 4 97 0 1 316 
ZINC36222011 252.341 3.81 9.77 -24.04 3 3 45 1 1 314 
ZINC22799364 428.578 2.07 9.7 -42.44 1 6 46 1 5 311 
ZINC12346325 393.443 2.89 -2.56 -18.54 2 7 80 0 6 310 
ZINC20560246 431.536 4.46 10.94 -9.23 2 6 71 0 7 306 
ZINC67898612 320.416 2.94 7.84 -32.61 2 4 42 1 4 305 
ZINC57992309 348.364 2.77 7.28 -45.35 3 4 46 1 6 303 
ZINC75778695 280.351 2.69 5.89 -39.41 3 4 51 1 2 301 
ZINC05342165 387.475 3.69 7.03 -41.93 3 5 67 1 5 299 
ZINC13353751 359.404 5.58 10.29 -11.31 3 4 57 0 3 293 
ZINC75688714 257.255 2.37 4.3 -3.53 1 2 21 0 1 290 
ZINC00193919 338.363 3.73 7.42 -9.31 2 6 77 0 5 289 
ZINC19952371 228.319 3.88 6.77 -28.87 4 3 52 1 2 288 
ZINC04898579 380.596 6.51 0.36 -35.47 3 2 36 1 7 287 
ZINC76216342 304.346 3.11 5.37 -9.51 2 6 77 0 6 280 
ZINC20450997 339.45 3.42 6.08 -32.95 2 3 28 1 5 279 
ZINC01426657 374.461 2.99 7.98 -43.7 3 7 81 1 7 277 
ZINC20389152 281.37 2.82 8.28 -36.71 1 2 8 1 3 271 
ZINC20213933 335.36 1.13 1.83 -11.76 2 8 93 0 6 269 
ZINC29538725 380.366 3.67 5.77 -12.77 1 5 51 0 6 267 
ZINC95076866 361.391 3.42 11.83 -40.26 1 4 35 1 4 265 
ZINC82741878 254.398 0.55 2.02 -41.38 2 4 32 1 3 263 
ZINC12345825 365.408 3.43 -1.67 -15.66 2 5 61 0 5 262 
ZINC31169347 425.598 3.73 9.01 -10.56 2 5 54 0 7 260 
ZINC57478401 407.514 4.34 9.51 -8.69 2 6 71 0 9 259 
ZINC40442615 182.218 2.16 2.76 -39.08 3 2 37 1 1 257 
ZINC12593869 424.576 4.88 13.45 -93.72 2 4 27 2 9 251 
ZINC82914685 204.253 0.97 3.61 -48.12 3 4 55 1 1 251 
ZINC72290854 320.457 2.53 7.53 -42.98 3 5 55 1 8 250 
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ZINC72292602 314.769 2.62 3.01 -9.44 3 4 61 0 4 250 
ZINC07538358 378.35 3.06 9.1 -17.6 1 5 59 0 6 249 
ZINC75739987 277.698 1.75 3.34 -6.54 2 3 41 0 4 246 
ZINC24205259 320.36 2.77 7.44 -21.77 1 8 86 0 3 245 
ZINC44256447 400.454 3.29 5.4 -20.63 4 7 91 0 7 241 
ZINC83370295 243.277 1.81 3.36 -43.67 2 3 29 1 3 240 
ZINC75340352 312.329 2.64 2.9 -14.24 4 7 99 0 3 238 
ZINC48270992 411.526 3.06 8.29 -47.88 4 7 84 1 7 234 
ZINC00709748 462.496 5.16 1.1 -14.08 2 5 59 0 4 232 
ZINC12995259 436.577 5.03 10.08 -13.16 1 5 51 0 6 229 
ZINC19911229 372.375 3.89 7.7 -11.6 1 6 69 0 5 229 
ZINC07405191 362.376 2.55 2.22 -18.7 1 5 58 0 6 227 
ZINC52095677 255.308 3.94 5.28 -5.59 1 2 21 0 3 227 
ZINC04854740 349.39 2.42 -2.7 -16.18 2 6 70 0 4 226 
ZINC58006085 386.398 3.25 8.5 -23.95 1 5 59 0 7 224 
ZINC04692860 371.452 5 11.74 -17.49 1 4 55 0 4 222 
ZINC36222030 268.34 3.41 8.61 -26.23 3 4 54 1 2 222 
ZINC05035242 369.403 4.78 11.92 -13.66 1 5 55 0 4 220 
ZINC19725286 269.343 2.17 7.3 -47.39 4 2 43 1 2 220 
ZINC36117077 536.713 6.72 16.68 -13.1 0 5 50 0 10 219 
ZINC84638394 346.452 2.42 3.8 -7.73 3 5 71 0 5 218 
ZINC75936661 274.254 0.86 5.24 -42.72 4 5 82 1 2 217 
ZINC00715242 370.352 2.95 3.05 -9.03 3 5 78 0 4 216 
ZINC85808113 409.848 5.79 9.57 -11.67 3 5 66 0 4 216 
ZINC00236831 277.388 3.35 -0.7 -36.16 1 2 7 1 3 215 
ZINC58860282 377.847 3.94 7.93 -11.36 2 5 54 0 5 215 
ZINC76004451 243.232 2.78 6.86 -7.67 0 3 31 0 2 215 
ZINC05791507 276.361 2.28 6.33 -15.35 2 4 50 0 3 214 
ZINC38050594 233.299 0.87 4.48 -48.12 5 6 94 1 2 213 
ZINC43080933 346.451 2.1 6.9 -44.97 3 6 64 1 4 213 
ZINC71799351 322.311 2.7 2.93 -12.79 3 5 71 0 6 213 
ZINC75688542 271.282 2.75 5.05 -2.85 1 2 21 0 1 213 
ZINC05512248 317.291 4.34 7.28 -9.78 1 4 51 0 4 212 
ZINC06646225 386.791 2.64 6.5 -8.32 1 7 77 0 4 212 
ZINC89873258 299.33 1.54 1.7 -18.73 3 6 79 0 5 211 
ZINC20284055 401.531 3.13 8.59 -38.19 3 7 75 1 8 210 
ZINC95985360 310.369 2.46 2.98 -14.96 3 5 71 0 5 209 
ZINC23549858 203.309 1.96 6.23 -38.64 2 2 20 1 1 208 
ZINC42872162 218.284 0.32 4.01 -31.29 5 5 81 1 3 208 
ZINC65396788 336.548 1.88 8.84 -173.28 4 5 42 3 5 207 
ZINC16137956 263.405 3.51 7.38 -33.56 2 3 37 1 1 206 
ZINC01262488 406.526 5.19 9.63 -11.58 2 5 60 0 3 205 
ZINC52267717 390.479 4 8.09 -45.2 3 6 64 1 8 205 
ZINC67689658 492.576 3.74 7.26 -10.97 2 9 92 0 8 204 
ZINC75873243 245.277 2.27 5.29 -34.87 4 3 61 1 3 204 
ZINC76236380 348.402 3.99 8.66 -12.87 2 5 67 0 3 204 
ZINC38041437 211.353 0.46 4.19 -81.04 4 3 33 2 2 202 
ZINC23372937 277.388 1.23 3.35 -41.39 2 4 37 1 4 201 
ZINC04368757 296.434 4.42 -0.98 -33.96 3 2 36 1 2 199 
ZINC04473477 383.377 3.23 6.21 -12.51 2 5 101 0 2 199 
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ZINC02086895 370.476 4.64 -1.44 -36.78 3 4 59 1 4 197 
ZINC11569834 256.304 2.56 -1 -50.02 3 3 45 1 3 195 
ZINC67898809 401.49 2.98 7.39 -43.21 2 6 65 1 5 195 
ZINC12114675 393.45 1.66 1.9 -71.4 1 8 79 1 5 193 
ZINC72021342 443.465 5.21 11.54 -17.13 1 4 48 0 7 193 
ZINC74327156 281.212 3.85 7.35 -10.19 1 3 42 0 2 193 
ZINC85559648 358.394 2.1 2.82 -13.1 3 7 89 0 6 193 
ZINC38073354 260.332 4 8.14 -40.93 2 2 26 1 4 191 
ZINC56443193 416.517 3.58 8.56 -54.03 3 6 64 1 8 191 
ZINC82507215 291.459 3.06 6.95 -41.24 2 3 29 1 5 190 
ZINC82529272 174.227 1.39 3.43 -7.83 3 3 52 0 1 188 
ZINC15836890 484.518 5.45 11.9 -25.97 2 5 67 0 5 187 
ZINC19326510 380.482 5.28 15.18 -111.17 2 2 9 2 5 187 
ZINC32905567 269.3 2.95 7.65 -20.62 1 4 55 0 4 186 
ZINC52451500 409.453 3 9.93 -44.62 1 6 52 1 11 186 
ZINC05201736 403.438 2.82 -2.81 -21.61 2 7 79 0 3 185 
ZINC00182971 342.42 3.71 -1.78 -8.49 2 5 67 0 5 184 
ZINC19838722 255.451 2.08 7.34 -34.72 1 2 8 1 2 184 
ZINC67803167 371.464 3.69 9.37 -39.56 2 5 55 1 4 184 
ZINC00720129 432.545 4.5 -0.26 -13.11 2 5 59 0 4 182 
ZINC75693137 265.259 2.78 4.43 -6.88 1 3 34 0 3 182 
ZINC83352758 224.299 2.88 5.69 -37.92 2 2 26 1 1 182 
ZINC22766897 320.438 2.65 6.23 -44.72 3 5 55 1 6 180 
ZINC19332662 429.564 3.34 9.44 -53.35 1 7 61 1 6 179 
ZINC20573365 398.487 1.07 6.09 -55.52 4 8 101 1 6 179 
ZINC62667439 275.376 0.12 2.74 -25.76 3 5 53 1 4 178 
ZINC00641398 374.128 4.48 -0.49 -8.28 2 3 41 0 2 177 
ZINC79002839 290.363 1.72 8.69 -24.47 1 5 59 0 7 175 
ZINC00710766 399.537 4.11 11.38 -16.13 1 4 55 0 4 173 
ZINC08609006 476.552 4.09 9.78 -16.54 3 7 83 0 8 173 
ZINC33009209 444.535 4.95 8.69 -18.78 3 7 83 0 6 173 
ZINC24831739 353.777 4.94 7.94 -16.08 1 3 38 0 4 172 
ZINC24839382 480.473 4.08 9.7 -16.57 2 10 129 0 11 172 
ZINC60974503 428.646 3.67 12.09 -90.67 4 5 50 2 7 172 
ZINC00727574 413.517 5.07 1.64 -11.55 1 4 47 0 3 171 
ZINC00823629 407.514 4.65 0.05 -9.02 2 6 70 0 9 171 
ZINC06051337 328.462 4.1 -2.48 -12.48 2 3 41 0 3 170 
ZINC20773830 349.498 3.58 10.79 -44.06 1 3 17 1 3 170 
ZINC45946335 220.271 1.64 5.7 -34.24 3 3 42 1 5 170 
ZINC13636088 368.452 5.77 12.71 -12.65 2 2 24 0 2 169 
ZINC43042690 197.277 1.25 2.53 -41.77 3 2 31 1 3 168 
ZINC35451500 461.585 3.94 14.59 -108.16 4 6 68 2 8 167 
ZINC95426014 344.435 1.69 5.26 -40.06 4 6 79 1 6 167 
ZINC32629276 295.378 2.58 7.05 -42.41 3 4 57 1 3 164 
ZINC76217380 343.21 4.34 7.04 -7.98 2 5 67 0 5 164 
ZINC13038176 426.542 3.51 6.72 -9.83 2 7 74 0 7 163 
ZINC19550215 402.486 2.72 5.31 -49.33 3 5 63 1 7 163 
ZINC62665393 271.315 2.55 7.06 -35.16 2 3 35 1 4 162 
ZINC04479596 343.358 2.35 -1.52 -17.49 2 6 70 0 4 161 
ZINC19334644 332.512 2.13 4.43 -34.91 2 4 31 1 5 161 
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ZINC00374241 321.323 3.86 2.68 -11.53 1 4 47 0 5 160 
ZINC83379541 249.378 2.84 5.78 -40.16 2 3 29 1 4 159 
ZINC76121475 207.321 1.08 5.42 -94.78 4 3 47 2 1 158 
ZINC39199636 336.377 4.04 9.7 -41.71 2 2 25 1 4 157 
ZINC82753682 222.243 0.95 1.48 -12.86 5 4 72 0 3 157 
ZINC00072989 284.315 2.19 -1.09 -15.44 2 5 59 0 3 156 
ZINC05164248 401.571 4.83 -2.52 -40.18 3 5 62 1 5 156 
ZINC02646442 316.748 2.47 6.6 -10.41 1 6 69 0 5 155 
ZINC09482238 354.4 4.58 1.07 -12.57 2 3 41 0 1 154 
ZINC77094259 248.371 1.54 6.22 -46.11 3 2 37 1 3 154 
ZINC31094802 342.414 3.36 7.14 -10.85 2 4 50 0 5 153 
ZINC00038297 346.385 3.9 -1.52 -41.78 3 4 59 1 4 152 
ZINC20465714 350.439 0.91 1.92 -44.58 5 7 95 1 5 152 
ZINC72190711 225.597 0.95 1.12 -5.73 3 2 46 0 2 151 
ZINC13154929 294.398 4.23 7.07 -4.52 2 3 45 0 2 150 
ZINC06738904 361.424 5.26 11.6 -16.22 1 5 55 0 3 149 
ZINC19785836 235.351 2.29 7.17 -33.06 3 3 40 1 5 149 
ZINC31912905 315.505 3.99 10.83 -104.62 4 3 46 2 5 149 
ZINC52003244 240.347 2.41 2.52 -9.73 3 4 61 0 2 149 
ZINC77403636 247.362 2.39 5.32 -43.03 2 3 29 1 2 149 
ZINC07406143 370.38 3.66 1.83 -18.56 1 6 71 0 5 148 
ZINC12522205 324.38 4.31 7.89 -12.85 2 3 41 0 2 148 
ZINC19326582 396.481 4.91 13.97 -128.43 2 3 18 2 6 148 
ZINC27579123 399.521 4.52 8.53 -50.26 2 3 29 1 6 147 
ZINC44709555 378.444 2.71 8.47 -16.27 0 6 59 0 4 146 
ZINC06529588 260.268 3.11 0.28 -11.38 2 4 50 0 4 145 
ZINC12776552 375.371 3.01 8.14 -14.78 0 5 48 0 4 145 
ZINC82869007 176.219 1.63 3.35 -5.59 2 3 37 0 3 145 
ZINC75738600 269.291 2.75 5.23 -7.97 1 3 30 0 4 143 
ZINC76217090 318.373 3.29 6.16 -9.33 2 6 77 0 6 142 
ZINC19894425 321.352 1.02 3.57 -24.58 1 6 63 0 5 141 
ZINC36446804 390.48 4.69 8.82 -11.23 1 3 32 0 4 140 
ZINC70270920 283.318 3.74 6.56 -12.11 1 3 38 0 5 140 
ZINC72305915 409.958 3.98 6.46 -5.98 3 6 74 0 4 139 
ZINC02547536 209.122 0.82 1.11 -30.17 4 3 58 1 2 138 
ZINC43193442 403.572 3.35 8.34 -44.43 3 6 58 1 8 138 
ZINC00718165 406.938 5.31 -1.46 -10.48 2 3 41 0 2 136 
ZINC65497500 244.322 0.99 5.06 -34.34 3 5 58 1 2 136 
ZINC90744993 334.322 2.52 3.67 -14.74 3 5 71 0 4 136 
ZINC16946471 193.246 3.09 5.16 -4.21 2 1 26 0 1 133 
ZINC83690790 260.317 1.12 4.12 -41.37 3 5 60 1 3 132 
ZINC15708530 420.559 0.93 5.02 -53.62 4 8 95 1 5 130 
ZINC02316333 403.529 3.26 -3.65 -18.23 4 6 93 0 6 129 
ZINC32624081 466.362 4.53 6.7 -17.1 3 6 92 0 5 129 
ZINC12496088 397.812 6.07 10.62 -12 1 4 39 0 3 128 
ZINC16940266 204.293 2.03 3.24 -40.23 3 2 37 1 1 127 
ZINC01426909 488.584 5.1 12.66 -15.22 2 5 67 0 5 126 
ZINC13033715 505.574 2.73 11.4 -48.52 2 9 99 1 7 126 
ZINC19697575 445.585 2.34 7 -13.64 1 7 71 0 7 126 
ZINC82505211 220.336 2.53 6.67 -41.15 2 2 26 1 1 126 
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ZINC83727166 225.262 1.92 3.57 -37.64 3 2 29 1 1 126 
ZINC00106521 292.697 3.85 2.28 -13.26 1 4 51 0 4 125 
ZINC06603031 411.408 3.11 -1.88 -12.37 4 6 93 0 7 125 
ZINC70636341 315.316 2.66 4.22 -9.25 2 3 49 0 5 125 
ZINC72002875 440.539 4.02 11.9 -52.52 2 6 55 1 4 125 
ZINC09464150 448.947 5.28 1.08 -17.7 1 5 58 0 7 124 
ZINC83322304 225.381 2.09 4.56 -39.85 2 2 20 1 2 124 
ZINC03626489 399.34 2.99 3.31 -13.2 2 5 75 0 6 123 
ZINC04387912 402.419 3.01 -6.63 -17.05 4 5 81 0 4 123 
ZINC67801214 285.408 3.84 5.34 -44.01 2 5 52 1 5 123 
ZINC09113497 461.558 5.47 13.38 -19.63 1 6 78 0 6 122 
ZINC20283200 424.521 3.67 9.62 -59.42 4 7 93 1 11 121 
ZINC31932998 310.421 3.95 11.61 -44.06 1 4 31 1 6 121 
ZINC62713739 303.332 2.93 8.36 -32.27 2 3 35 1 4 121 
ZINC82368377 219.283 3.05 4.83 -36.19 4 2 43 1 1 121 
ZINC02528993 253.223 4.14 1.49 -3.13 2 2 35 0 3 120 
ZINC75869391 223.295 0.16 3.83 -90.15 6 3 68 2 2 119 
ZINC76254880 299.331 2.3 6.25 -45.22 2 5 81 -1 3 119 
ZINC71506668 195.217 0.16 1.13 -57.92 4 3 57 1 1 118 
ZINC00181081 336.395 5.42 10.32 -12.32 0 6 57 0 1 117 
ZINC23359737 438.926 2.98 7.91 -36.99 3 5 55 1 9 117 
ZINC26387440 354.815 2.73 5 -20 1 6 76 0 5 116 
ZINC82795137 285.386 2.69 6.27 -49.61 3 2 31 1 2 116 
ZINC01686012 196.273 3.12 -0.5 -40.05 2 1 16 1 2 115 
ZINC07940530 366.464 2.51 -3.13 -17.76 1 6 75 0 6 115 
ZINC15734349 409.49 3.07 7.5 -14.53 2 8 81 0 3 115 
ZINC40007529 256.305 2.7 7.18 -11.72 2 4 50 0 5 115 
ZINC08672544 460.528 3.92 2.69 -48.79 1 7 64 1 7 114 
ZINC13497967 480.605 5.72 12.84 -13.4 1 5 59 0 8 114 
ZINC82729967 214.292 2.35 5.78 -31.87 3 3 43 1 2 114 
ZINC77090631 296.312 4.16 7.83 -43.84 3 2 41 1 3 113 
ZINC11570917 267.396 3.75 0.27 -39.14 2 2 20 1 2 112 
ZINC12346198 351.381 2.96 -1.6 -16.57 2 5 61 0 3 112 
ZINC20719888 393.414 3.46 9.49 -46.52 3 7 89 1 5 110 
ZINC28434156 368.477 3.99 9.92 -18.5 1 5 59 0 5 110 
ZINC35774882 217.358 0.04 0.8 -45.86 3 3 40 1 2 110 
ZINC19841532 301.863 2.71 6.18 -41.71 1 3 17 1 3 109 
ZINC55226540 413.905 4.3 8.41 -8.53 3 6 79 0 8 109 
ZINC05071760 367.412 2.73 6.73 -13.83 3 6 83 0 3 108 
ZINC32795799 290.363 2.15 7.85 -22.21 1 5 59 0 6 108 
ZINC03840100 452.511 1.37 -9.9 -26.08 7 9 153 0 7 107 
ZINC44016120 355.369 3.28 6.24 -12.5 3 6 83 0 4 107 
ZINC00058753 289.335 2.1 -0.72 -8.68 2 6 70 0 4 106 
ZINC02520974 471.548 4.39 13.87 -16.9 2 4 70 0 3 104 
ZINC04966738 398.776 3.05 -0.36 -6.78 0 7 68 0 4 104 
ZINC00184514 242.238 1.11 2.92 -9.65 2 6 76 0 1 103 
ZINC15955536 462.556 4.71 13.04 -9.41 0 4 33 0 4 103 
ZINC75848180 178.175 -1.25 0.03 -32.13 4 6 88 1 2 103 
ZINC00228756 246.313 4.19 8.08 -6.37 2 2 24 0 1 102 
ZINC02050214 437.225 4.23 1.97 -40.92 3 6 81 1 7 102 
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ZINC04479606 369.421 2.64 5.86 -18.53 2 7 80 0 6 102 
ZINC00092578 223.272 1.36 0.62 -6.01 3 4 62 0 2 101 
ZINC33009242 432.499 5.05 9.46 -18.41 3 6 73 0 5 101 
ZINC50182129 195.31 0.6 4.11 -88.21 5 3 58 2 2 101 
ZINC01060004 404.47 4.01 11.26 -14.31 2 7 85 0 6 100 
ZINC20213814 385.489 3.53 6.94 -10.14 3 6 79 0 8 97 
ZINC24926041 394.374 1.85 7.31 -14.98 1 7 85 0 6 97 
ZINC00087289 340.437 3.29 8.94 -15.99 0 6 69 0 3 96 
ZINC04373552 339.395 2.65 -1.94 -15.49 2 6 70 0 4 96 
ZINC75688453 257.279 2.17 4.45 -36.32 3 2 29 1 1 96 
ZINC95347952 257.299 4.4 7.68 -2.01 1 1 12 0 4 96 
ZINC50843460 211.191 2.25 2.84 -31.47 3 3 49 1 2 95 
ZINC10337067 433.854 3.93 11.48 -44.05 2 7 82 1 2 94 
ZINC02361911 293.482 4.81 -1.73 -9.64 1 1 12 0 0 92 
ZINC19834162 367.348 4.22 8.34 -18.07 1 6 74 0 7 92 
ZINC35526454 355.369 3.67 7.42 -10.99 3 6 83 0 6 92 
ZINC76039205 286.281 3.68 7.63 -11.91 0 3 30 0 3 92 
ZINC01126331 368.742 4.23 2.42 -17.7 1 4 50 0 4 91 
ZINC12156665 335.399 2.5 1.36 -50.33 2 5 65 1 6 90 
ZINC13220287 383.527 3.62 9.83 -16.41 4 5 69 0 5 90 
ZINC40747107 225.4 2.87 4.81 -34.79 2 2 20 1 4 90 
ZINC75486190 248.35 2.71 5.1 -27.33 4 4 61 1 3 90 
ZINC08039586 388.469 2.69 -2.13 -51.21 3 7 81 1 4 89 
ZINC10336776 440.483 4.42 11 -38.15 2 8 88 1 4 89 
ZINC18700207 335.4 4.98 9.37 -9.25 1 2 29 0 4 89 
ZINC35561767 358.463 4.09 9.09 -10.34 1 5 51 0 2 89 
ZINC02066671 514.973 7.22 -0.29 -6.9 2 2 41 0 3 88 
ZINC15017282 358.488 4.03 10.22 -9.94 2 4 50 0 5 87 
ZINC95080731 185.23 1.55 3.06 -87.35 4 3 54 2 0 87 
ZINC20371077 304.396 2.71 6.36 -14.55 2 4 58 0 2 86 
ZINC72270271 285.294 1.22 1.28 -9.52 3 5 65 0 4 86 
ZINC05783964 301.346 1.33 -3.55 -11.45 2 6 70 0 2 85 
ZINC13471085 303.314 1.27 1.49 -16.46 3 6 96 0 3 84 
ZINC04908497 353.487 1.27 5.12 -45.85 3 7 75 1 4 83 
ZINC19725288 281.379 2.06 6.62 -46.76 4 3 53 1 3 82 
ZINC75660792 243.733 2.45 5.77 -29.68 2 2 16 1 2 82 
ZINC12085435 409.461 2.69 -3.49 -17.29 2 6 71 0 2 81 
ZINC08435175 685.698 7.68 6.1 -11.32 0 6 72 0 8 80 
ZINC00083131 347.321 4.3 -2.21 -10.94 3 6 79 0 5 77 
ZINC02758246 458.602 6.38 15.41 -19.05 1 5 59 0 7 77 
ZINC26513997 212.293 1.59 3.84 -5.84 2 2 29 0 1 77 
ZINC04857304 386.61 4.35 -2.36 -45.05 3 3 28 1 6 76 
ZINC07652999 405.878 5.17 1.19 -13.24 1 4 55 0 6 76 
ZINC08788961 482.621 3.35 -0.32 -14.49 2 7 101 0 6 76 
ZINC18197292 485.462 4.26 6.62 -24.36 3 7 96 0 5 76 
ZINC27496201 337.678 4.37 6.23 -5.84 2 3 41 0 5 75 
ZINC05248322 353.731 4.25 4.35 -7.99 0 4 39 0 4 73 
ZINC20432021 431.479 5.78 10.72 -6 0 3 22 0 5 73 
ZINC35287371 331.358 5.53 6.06 -52.83 3 4 55 1 5 73 
ZINC47778114 330.408 1.44 6.05 -43.53 3 6 68 1 5 72 
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ZINC48077023 402.49 3.63 8.47 -52.63 3 6 64 1 8 70 
ZINC58277988 416.449 4.11 8.4 -15.94 2 5 67 0 7 70 
ZINC06596199 313.36 4.42 0.27 -14.25 0 4 43 0 3 66 
ZINC11932808 352.48 1.25 -0.42 -49.05 1 6 54 1 4 63 
ZINC18061181 308.337 2.42 4.04 -9.58 3 5 82 0 1 63 
ZINC09390019 374.418 3.04 -2.41 -13.27 1 7 88 0 5 62 
ZINC36042418 469.466 5.52 14.2 -8.97 0 4 68 0 4 61 
ZINC71781936 260.243 2.56 6.36 -11.33 1 3 34 0 2 61 
ZINC43544551 320.389 2.43 8.09 -19.47 1 6 68 0 6 59 
ZINC02052707 363.335 4.01 3.06 -11.06 1 4 51 0 5 58 
ZINC40106525 416.543 3.66 8.24 -15.13 1 6 76 0 7 58 
ZINC08007395 326.418 2.31 -3.8 -14.15 1 6 75 0 5 53 
ZINC05684707 252.277 0.21 -1.72 -15.43 3 5 94 0 1 52 
ZINC48341845 344.401 4.14 6.51 -42.16 4 4 58 1 3 52 
ZINC83050266 227.328 1.02 3.88 -47.92 3 4 57 1 2 52 
ZINC13010330 308.37 3.17 7.27 -15.91 1 6 68 0 4 49 
ZINC12357259 265.313 1.73 -2.87 -10.02 4 6 97 0 5 48 
ZINC71781001 258.195 1.77 3.87 -11.16 1 3 47 0 2 48 
ZINC13407933 473.366 3.92 3.55 -7.7 3 7 105 0 9 45 
ZINC00519469 277.344 2.12 -3.23 -34.16 3 5 55 1 2 44 
ZINC23182402 468.667 5.3 11.43 -12.45 2 4 31 0 8 44 
ZINC95959351 310.438 3.06 7.9 -12.26 2 5 67 0 4 44 
ZINC06738456 290.338 3.05 0.02 -20.6 1 4 50 0 3 43 
ZINC04577875 303.053 3.54 2.47 -35.28 2 1 16 1 2 42 
ZINC09283216 449.464 1.79 -4.01 -20.32 1 10 115 0 6 35 
ZINC12668089 234.299 -0.1 5.14 -7.37 2 4 58 0 0 34 
ZINC39083420 188.163 -0.15 0.03 -45.44 1 7 105 -1 2 34 
ZINC01397478 434.829 4.44 0.14 -41.83 2 6 73 1 6 31 
ZINC96008252 231.248 1.5 2.62 -9.25 0 4 47 0 2 31 
ZINC88613616 246.287 0.36 -0.8 -28.71 4 7 97 1 4 23 
ZINC19808440 436.527 3.69 13.03 -11.69 1 5 59 0 8 20 
ZINC03240785 473.401 2.31 -8.21 -23.68 4 8 127 0 5 18 
ZINC12412671 417.509 4.99 1.25 -18.41 1 6 72 0 5 10 
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APPENDIX G 
LIST OF CHEMICALS DEDUCED FROM THE ALPHA-1 ANTITRYPSIN HIGH 
CONTENT SCREENING RESULT ANALYSIS TARGET-BASED HIT 
DIVERSIFICATION METHOD 
 
The first column (from the left) represents the PubChem compound identifier (CID) of each 
compound, the second column reports the molecular weight of the compound, the third column 
reports the name of the chemical, finally the fourth column reports the number of targets in 
STITCH v4. 
Chemical ID Molecular Weight Chemical Name No of Targets 
CID00216239 464.82495 sorafenib 62 
CID00005002 383.5071 quetiapine 58 
CID00005376 371.51456 AC1L1K7T 51 
CID00060837 677.1848 irinotecan 21 
CID00003143 807.87922 Docetaxel trihydrate 20 
CID00091577 466.69514 AC1L3MCS 20 
CID00060834 333.8755 duloxetine 18 
CID00150311 409.425246 ezetimibe 16 
CID09936728 527.61104 CHEMBL91636 14 
CID00002689 334.33889 CGS 12066B 14 
CID00001238 344.90144 octoclothepin 14 
CID00017011 507.43949 Depixol 13 
CID00004609 397.29176 oxaliplatin 13 
CID00002781 343.89024 NSC293370 13 
CID00068595 934.15842 maduramicin 12 
CID00005268 379.4522 spiroxatrine 12 
CID00001224 361.51974 AC1Q7BEJ 11 
CID00004691 329.365403 AC-680 10 
CID00060662 568.550603 mibefradil 10 
CID09849669 523.66364 SR-973 10 
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CID00027991 1069.21696 DDAVP 10 
CID05311065 1069.21696 desmopressin 9 
CID00003404 318.33465 (Z) Fluvoxamine 9 
CID00037459 361.51974 butaclamol 9 
CID11653679 374.879463 CHEBI:590001 8 
CID10318916 402.41948 CHEBI:250218 8 
CID09802436 424.425 CHEMBL56837 8 
CID10319235 407.50536 SureCN4172086 8 
CID03069135 314.397123 Brn 4530212 8 
CID10150649 391.46136 CHEBI:447271 8 
CID00447475 328.38712 1o5a 8 
CID00133038 316.369943 fluorocarazolol 8 
CID11037377 429.46628 CHEBI:286771 8 
CID00445843 362.83218 1o5e 8 
CID11486446 401.901503 
4-[(1R,5S)-3-(4-chlorophenyl)-3-
hydroxy-8-azabicyclo[3.2.1]oct-8-yl]-1-
(4-fluorophenyl)butan-1-one 
7 
CID03086153 340.46574 SureCN11076489 7 
CID00005203 306.22958 Q740 7 
CID00001746 303.14269 uPA inhibitor 6 
CID09957375 494.1111 SureCN6399366 6 
CID10025307 423.37558 SureCN6731065 6 
CID00181743 339.38504 Thalictruberine 6 
CID10237550 393.43418 CHEBI:447270 6 
CID00060830 472.41628 tiotropium 6 
CID11553459 416.3944 SureCN4479393 6 
CID00127044 427.27665 CHEMBL2112942 6 
CID09905731 334.4531 CHEBI:495666 6 
CID02728531 382.3273 RH02255 6 
CID11544156 313.432203 SureCN4850678 6 
CID10335148 303.40084 CHEMBL2112912 6 
CID11501540 368.49246 CHEBI:429856 6 
CID09924938 358.3026 CHEMBL82093 6 
CID11374008 438.45158 CHEMBL58577 6 
CID10156375 376.4268 Sultam Hydroxamate 15a 6 
CID00068770 363.49432 talinolol 6 
CID00071240 408.432373 tefludazine 6 
CID11257884 393.39266 CHEBI:400792 6 
CID00068186 383.459143 spiramide 6 
CID10174078 472.6648 SureCN5209016 6 
CID11526445 518.5793 CHEMBL606904 6 
CID00154058 398.92568 solifenacin 6 
CID00060864 373.87316 AC1L1U2R 6 
CID11508116 325.40152 CHEBI:434654 6 
CID11590800 464.95413 SureCN4933186 6 
CID00065257 375.77238 PMBs 6 
CID10047100 409.349 SureCN6723167 6 
CID03052780 361.8673 SureCN10982044 5 
CID00003075 415.52578 NSC759576 5 
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CID05497171 453.461323 z-VAD-fmk 5 
CID11202065 462.58386 CHEMBL2112985 5 
CID00644185 453.461323 z-Val-Ala-Asp-fmk 5 
CID00108220 385.23997 beta-CIT 5 
CID00128564 379.45066 SC44463 5 
CID00004323 379.45066 AC1L1HWN 5 
CID00027287 624.0064 zinc protoporphyrin 5 
CID00122190 413.29313 RTI-121 5 
CID00003377 406.510726 AC1L1TJF 5 
CID09842753 378.46414 CHEMBL606963 4 
CID11690966 451.404263 SureCN1035715 4 
CID10474144 367.456443 
1-(4-fluorophenyl)-4-[(1R,5R)-3-
hydroxy-3-phenyl-8-
azabicyclo[3.2.1]oct-8-yl]butan-1-one 
4 
CID09852146 626.627863 Z-IETD-FMK 4 
CID00005567 409.417133 trifluperidol 4 
CID00122197 431.283593 FP-CIT 4 
CID10074155 486.67146 SureCN9006340 4 
CID09820163 358.43628 SureCN7554088 4 
CID00128054 315.4729 N 0734 4 
CID11441732 427.41098 L023686 4 
CID10788465 424.526006 CHEBI:299920 4 
CID00002384 366.37722 AC1L1DK5 4 
CID10409701 417.257013 MCL-301 4 
CID11603959 411.49406 CHEBI:435901 4 
CID11559589 362.48788 CHEBI:409256 4 
CID11532153 434.529023 CHEBI:593352 4 
CID05289508 661.8603 DB03005 4 
CID11620908 547.95661 3:00 PM 4 
CID00208917 375.438683 Elopiprazole 4 
CID09888555 423.57096 SureCN5507438 4 
CID09797476 328.23356 SureCN3423153 4 
CID11690910 448.52105 SureCN1034132 4 
CID09796407 302.12359 Org 12962 4 
CID11505592 644.659626 CHEBI:440657 4 
CID10598649 428.60894 CHEBI:205753 4 
CID11699469 537.69176 CHEBI:449977 4 
CID11676381 432.490003 CHEBI:593224 4 
CID11554489 464.95413 SureCN5180132 4 
CID00128918 417.89433 SR 57746A 4 
CID00005516 405.95962 AC1L1KIN 4 
CID00066004 302.41454 alniditan 4 
CID02737388 311.2494 1-(2-diphenyl)piperazine 4 
CID10131344 325.40152 CHEBI:434692 4 
CID10447533 300.36243 SureCN5996022 4 
CID09910222 424.425 CHEMBL61193 4 
CID11134191 453.587066 CHEBI:327101 4 
CID03929516 343.410226 difluorobenztropine 4 
CID11539598 446.516583 CHEBI:593418 4 
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CID11233292 346.77513 SureCN3562639 4 
CID05289507 661.8603 DB02226 4 
CID09839392 302.41278 SureCN7967298 4 
CID09821217 380.40403 CP-122721 4 
CID10024324 406.54044 CHEBI:187762 4 
CID10163178 485.938403 SureCN231072 4 
CID10024183 404.46826 SureCN6930132 4 
CID10472143 335.4427 PDSP2_001209 4 
CID10836499 432.572823 CHEMBL67024 4 
CID10184653 485.938403 afatinib 4 
CID11058664 410.31563 CHEBI:128185 4 
CID10054373 603.79136 SureCN5650667 4 
CID11006894 673.704146 CHEBI:287332 4 
CID00002386 334.37842 
bis(5-amidino-2-
benzimidazolyl)methane 
4 
CID11668034 380.478343 CHEBI:433105 4 
CID11695960 348.43816 CHEBI:430708 4 
CID09600423 525.60154 t - 87 3 
CID09998835 364.27678 
methyl (3S)-3-[4-[(Z)-2-
bromovinyl]phenyl]-8-methyl-8-
azabicyclo[3.2.1]octane-4-carboxylate 
3 
CID00131993 371.21339 N-Nor-cit 3 
CID09952054 385.23997 CTK8G8335 3 
CID09800811 395.296358 CHEMBL1214004 3 
CID11278435 313.794843 CHEMBL1812750 3 
CID10545894 351.457043 
1-(4-fluorophenyl)-4-[(1R,5S)-3-
phenyl-8-azabicyclo[3.2.1]oct-8-
yl]butan-1-one 
3 
CID11441438 416.53372 Sultam Hydroxamate 23c 3 
CID00148193 489.39578 NSC702818 3 
CID09947229 364.6945 CHEMBL87031 3 
CID10112621 416.53372 
(3S)-2-[4-(4-tert-butylphenyl)benzyl]-
1,1-diketo-thiazinane-3-
carbohydroxamic acid 
3 
CID09846169 442.296828 
Methyl (2S,3S)-8-[(E)-4-fluorobut-2-
enyl]-3-(4-iodophenyl)-8-
azabicyclo[3.2.1]octane-2-carboxylate 
3 
CID00159324 489.39578 tipifarnib 3 
CID11500578 311.37494 
methyl (1R,3S,4S,5S)-3-[4-(2-
furyl)phenyl]-8-
azabicyclo[3.2.1]octane-4-carboxylate 
3 
CID10410301 428.270248 
2-fluoranylethyl 3-[4-[(Z)-2-
iodanylethenyl]phenyl]-8-
azabicyclo[3.2.1]octane-4-carboxylate 
3 
CID05281881 434.51761 flupenthixol 3 
CID10765852 447.73819 
methyl (1S,3S,4S,5R)-8-(3-
chloropropyl)-3-(4-iodophenyl)-8-
azabicyclo[3.2.1]octane-4-carboxylate 
3 
CID11233397 350.2502 
methyl (1R,3R,4R,5S)-3-[4-[(Z)-2-
bromovinyl]phenyl]-8-
azabicyclo[3.2.1]octane-4-carboxylate 
3 
CID11371257 341.46712 CHEBI:400816 3 
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CID00115430 323.9006 AC1Q3F7T 3 
CID09800928 397.25067 
methyl 3-[4-[(Z)-2-iodovinyl]phenyl]-8-
azabicyclo[3.2.1]octane-4-carboxylate 
3 
CID10574379 425.30383 CHEMBL1945246 3 
CID09884800 350.845358 CHEMBL1214003 3 
CID11282852 472.40493 
3-(8,8-dimethyl-8-
azoniabicyclo[3.2.1]oct-3-yl)-2,2-
diphenyl-propanenitrile 
3 
CID10404382 330.425077 
methyl 8-[(E)-4-fluorobut-2-enyl]-3-(p-
tolyl)-8-azabicyclo[3.2.1]octane-4-
carboxylate 
3 
CID10363398 397.25067 CHEBI:114309 3 
CID03366356 525.60154 AC1MOB6C 3 
 
 
 186   
APPENDIX H 
COMPARISON OF RESULTS FROM CHEMICAL AND TARGET BASED 
DIVERSIFICATION OF PRESTWICK LIBRARY SCREEN HITS 
The similarity between the chemical based diversification results shown in Appendix F and 
target based diversification results shown in Appendix G:  
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The similarity between two groups of 1278 chemicals randomly selected from the ZINC 
purchase-ready compounds library (which has 12.8 million chemicals):  
 
 
 
The similarity distributions are highly similar with a Kullback-Leibler divergence of 0.031 which 
means that the sets of chemical based and target based diversification results are as similar as 
would be expected by chance alone. This means that our diversification strategies do actually 
diversify different sets of chemicals as originally intended. 
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APPENDIX I 
RESULTS FROM COMPUTATIONAL DIVERSIFICATION ANALYSIS OF DRUGS 
WITH KNOWN NEUROPROTECTIVE ACTIVITY 
The following table shows the results of the computational analysis used for neuroprotective 
diversification and mechanism of action identification. The drugs that were selected for 
experimental follow-up are shown in yellow, and the drugs that successfully worked as 
neuroprotectives in these experiments (sodium nitroprusside and thyroxine) by showing 
statistically significant neuroprotection are shown in green. 
Adaptive Compound Selection by Maximal Distance to Support and Previously Selected Compounds 
Hypothesis 1: PRL_HUMAN (Prolactin, organism:9606) 
  
Support: 
 
Cysteamine 
Melatoni
n 
Ritanseri
n Progesterone 
Compounds to test hypothesis: 
    
Drug 
Target 
Count LV distance to support: 
Averag
e: 
Fk 33-824 (CID000047470) 3 5.705 5.107 6.317 5.925 5.763 
Estradiol Benzoate (CID100003262) 6 6.058 5.406 5.360 6.112 5.734 
Thyroxine (CID100000853) 95 5.147 4.891 5.680 4.816 5.134 
Azinphos-Methyl (CID000002268) 4 5.066 4.512 6.028 5.470 5.269 
Clomipramine (CID100002801) 22 5.069 4.628 5.570 4.844 5.028 
Metergoline (CID100004090) 26 5.447 4.619 5.729 5.385 5.295 
M-Chlorophenylpiperazine (CID100001355) 18 5.236 4.875 5.623 5.256 5.247 
Nalmefene (CID100004422) 7 5.061 4.459 5.820 4.838 5.044 
Spiperone (CID100005265) 40 5.035 4.565 5.104 4.698 4.850 
Domperidone (CID100003151) 9 5.163 4.462 5.686 4.978 5.072 
Chlorpromazine (CID000002726) 48 4.863 4.475 5.335 4.418 4.773 
Aripiprazole (CID000060795) 27 4.906 4.260 4.515 4.648 4.582 
Ergot (CID100003250) 2 5.060 4.527 4.533 5.071 4.798 
Nomifensine (CID100004528) 9 5.010 4.618 5.245 4.962 4.959 
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8-Br-Camp (CID000032014) 21 4.698 3.721 5.281 4.708 4.602 
Ici 182,780 (CID100104741) 18 4.912 4.175 5.293 4.858 4.810 
Quinpirole (CID100001257) 22 4.947 4.583 5.393 4.737 4.915 
Metyrapone (CID100004174) 15 5.100 4.255 5.687 4.974 5.004 
Perphenazine (CID000004748) 19 4.756 3.714 5.066 4.720 4.564 
Ketanserin (CID000003822) 30 4.610 4.299 4.691 4.403 4.501 
8-Br-Camp (CID100001912) 14 4.995 3.906 5.109 4.872 4.721 
Bromocriptine (CID000031100) 47 4.555 3.926 5.025 4.891 4.599 
Clomiphene Citrate (CID100002800) 8 4.744 4.289 4.773 4.818 4.656 
Ritanserin (CID100005074) 24 4.854 4.023 4.925 4.644 4.612 
Ergovaline (CID000104843) 1 4.770 4.135 5.162 4.288 4.589 
       Hypothesis 2: CALM_HUMAN (Calmodulin, organism:9606) 
  
Support: 
 
Bepridil 
Melatoni
n Mephenytoin 
 Compounds to test hypothesis: 
    
Drug 
Target 
Count LV distance to support: 
Averag
e: 
 Aprindine (CID100002218) 1 5.438 5.129 5.438 5.335   
4-Chloroaniline (CID000007812) 1 4.826 4.530 4.826 4.727   
Compound 48/80 (CID000104735) 7 4.789 4.673 4.789 4.750 
 Promethazine (CID000004927) 5 4.911 4.623 4.911 4.815   
Trifluoperazine (CID100005566) 32 4.433 4.420 4.433 4.429 
 Cgs 9343B (CID100065909) 2 4.571 4.229 4.571 4.457 
 Nifedipine (CID100004485) 35 4.916 4.465 4.916 4.765 
 Phenothiazine (CID100007108) 3 4.734 4.227 4.734 4.565 
 Ww7 (CID000005681) 6 4.395 4.466 4.395 4.419 
 Verapamil (CID000002520) 40 4.240 3.963 4.240 4.148 
 Trifluoperazine (CID000005566) 33 4.150 3.918 4.150 4.073 
 Diltiazem (CID100003075) 10 4.435 4.139 4.435 4.336 
 Nicardipine (CID100004473) 8 4.677 4.223 4.677 4.526 
 Genistein (CID005280961) 97 4.155 4.033 4.155 4.114 
 B8509-035 (CID024847739) 1 4.185 3.825 4.185 4.065 
 Ww7 (CID100005681) 5 4.339 3.911 4.339 4.197 
 Dibucaine (CID100003025) 3 4.540 4.210 4.540 4.430 
 Pimozide (CID100016362) 26 4.233 3.804 4.233 4.090 
 Loperamide (CID100003954) 82 4.257 3.977 4.257 4.163 
 Compound 48/80 (CID100104735) 7 4.029 4.073 4.029 4.043 
 Bepridil (CID100002351) 5 3.987 3.795 3.987 3.923 
 Fluphenazine (CID100003372) 9 3.989 3.709 3.989 3.895 
 Kar-2 (CID100157684) 2 3.849 3.876 3.849 3.858 
 Phenothiazine (CID000007108) 3 4.141 3.517 4.141 3.933 
 Verapamil (CID100002520) 40 4.112 3.774 4.112 4.000 
 
       Hypothesis 3: CASP3_HUMAN (Caspase-3 subunit p12, organism:9606) 
 Support: 
 
Melatonin Minocycline 
  Compounds to test hypothesis: 
    
Drug 
Target 
Count LV distance to support: Average: 
  Sodium Nitroprusside (CID000045469) 14 5.237 5.148 5.193     
Imatinib (CID100005291) 48 5.290 5.061 5.175 
  Staurosporine (CID000044259) 85 4.770 5.399 5.085     
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Rxb (CID111632008) 1 4.743 4.842 4.793 
  Tpck (CID000439647) 6 4.405 4.183 4.294 
  Zoledronic Acid (CID100068740) 83 4.350 4.552 4.451 
  P-Bromoanisole (CID000007730) 1 4.869 4.550 4.709 
  Kainate (CID000010255) 69 4.318 4.652 4.485 
  Nordihydroguaiaretic Acid (CID100004534) 21 4.703 4.503 4.603 
  Inhibitor 65B (CID005327315) 1 4.725 4.043 4.384 
  Ptf (CID100013016) 1 4.494 4.654 4.574 
  Peroxynitrite (CID100104806) 21 4.461 4.515 4.488 
  Gemcitabine (CID000060749) 28 3.829 4.191 4.010 
  15-Deoxy-Delta12,14-Prostaglandin J2 
(CID100001444) 20 4.433 4.331 4.382 
  Thapsigargin (CID000446378) 84 3.754 4.319 4.036 
  Chebi:400985 (CID009851134) 1 4.025 4.017 4.021 
  Pyrrolidine Isatin Analogue 11F (CID111712912) 1 4.469 3.901 4.185 
  Inhibitor 64B (CID005327307) 1 4.497 4.524 4.511 
  Db08213 (CID100001389) 1 4.093 4.043 4.068 
  3-Morpholinosydnonimine (CID100005219) 4 4.450 3.664 4.057 
  Pzn (CID005289238) 1 3.724 3.933 3.828 
  Ac-Devd-Cho (CID100004330) 5 3.880 4.150 4.015 
  Salidroside (CID100159278) 2 4.093 3.316 3.704 
  Chebi:461307 (CID111700402) 1 4.030 4.108 4.069 
  Gsno (CID100003514) 5 3.782 4.016 3.899 
  
       Hypothesis 3: PA21B_HUMAN (Phospholipase A2, organism:9606) 
 
Support: 
 
Cysteamine 
Calcimyci
n 
   Compounds to test hypothesis: 
    
Drug 
Target 
Count LV distance to support: Average: 
  Fpl 55712 (CID000105007) 3 5.731 5.973 5.852     
1-Acyl-Sn-Glycero-3-Phosphocholines 
(CID124798684) 68 5.454 5.299 5.377 
  A23187 (CID100001959) 33 5.600 5.478 5.539 
  Manoalide (CID006437368) 4 5.199 4.847 5.023     
Calphostin C (CID100002533) 9 5.052 5.613 5.332     
Compound 48/80 (CID000104735) 7 5.003 5.471 5.237 
  Ochnaflavone (CID105492110) 3 5.458 5.308 5.383 
  Aristolochic Acid (CID000002236) 3 4.586 5.574 5.080 
  Nordihydroguaiaretic Acid (CID100004534) 21 5.173 5.228 5.200 
  Ochnaflavone (CID005492110) 3 4.995 4.746 4.871 
  Verapamil (CID000002520) 40 4.359 4.685 4.522 
  Phosphatidic Acid (CID100447791) 18 4.605 4.992 4.798 
  Chloroquine (CID000002719) 8 4.605 4.999 4.802 
  P-Bromophenacyl Bromide (CID000007454) 3 4.469 4.895 4.682 
  Platelet-Activating Factor (CID100461545) 10 4.535 4.433 4.484 
  Heparin (CID000008784) 77 4.709 4.845 4.777 
  Compound 48/80 (CID100104735) 7 4.817 4.759 4.788 
  Diacylglycerol (CID006026790) 2 4.578 4.790 4.684 
  Verapamil (CID100002520) 40 4.371 5.014 4.693 
  P-Bromophenacyl Bromide (CID100007454) 3 4.498 4.451 4.474 
  5,8,11,14-Eicosatetraynoic Acid (CID100001780) 3 4.158 4.039 4.098 
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Phosphatidylglycerol (CID045109789) 4 4.559 4.717 4.638 
  Aristolochic Acid (CID100002236) 3 4.172 4.750 4.461 
  Calphostin C (CID000002533) 14 4.328 4.643 4.486 
  Phenidone (CID000007090) 3 4.446 4.610 4.528 
  
       Hypothesis 4: CAH2_HUMAN (Carbonic anhydrase 2, organism:9606) 
 Support: 
 
Methazolamide 
   Compounds to test hypothesis: 
    
Drug 
Target 
Count 
LV distance to 
support: Average: 
   Chebi:178579 (CID044296104) 1 6.250 6.250 
   J71 (CID046916276) 1 5.633 5.633 
   Chembl35532 (CID010915515) 2 5.829 5.829 
   Imatinib (CID100005291) 48 5.308 5.308     
 Chebi:333101 (CID010843175) 2 5.825 5.825 
   Chebi:333241 (CID105067385) 1 5.408 5.408 
   N-(3-Chloro-7-Indolyl)-1,4-Benzenedisulfonamide 
(CID000216468) 12 5.473 5.473 
   Chebi:720036 (CID046197893) 2 5.477 5.477 
   2H-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide 1,1-
Dioxide 18 (CID019434092) 1 5.085 5.085 
   3,5-Dichlorosulfanilamide (CID100089607) 2 4.813 4.813 
   Chebi:415002 (CID144397294) 2 5.386 5.386 
   Chebi:332796 (CID010832697) 1 5.736 5.736 
   2H-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide 1,1-
Dioxide 4 (CID019434096) 1 4.909 4.909 
   Chebi:385160 (CID010625038) 3 5.487 5.487 
   Th0 (CID112563346) 1 5.433 5.433 
   Chebi:149899 (CID104094683) 1 4.885 4.885 
   Chebi:301123 (CID110519868) 3 5.683 5.683 
   Zinc00097317 (CID000708535) 3 4.496 4.496 
   Chembl97425 (CID011269105) 1 5.117 5.117 
   Chebi:223584 (CID010430595) 4 4.934 4.934 
   Chebi:427355 (CID111696964) 4 5.100 5.100 
   Nsc402851 (CID000345312) 4 4.703 4.703 
   Subsporin C (CID100151723) 5 5.182 5.182 
   Chebi:332454 (CID010833817) 2 5.484 5.484 
   Hydroxamate 21 (CID006916013) 3 5.401 5.401 
   
       Hypothesis 4: CAH7_HUMAN (Carbonic anhydrase 7, organism:9606) 
 Support: 
 
Methazolamide 
   Compounds to test hypothesis: 
    
Drug 
Target 
Count 
LV distance to 
support: Average: 
   Indanesulfonamide Derivative 11C (CID011640067) 4 4.961 4.961 
   Indanesulfonamide Derivative 12C (CID011718391) 6 4.649 4.649 
   6-Hydrogen-2-Benzothiazolesulfonamide 
(CID100067944) 3 4.404 4.404 
   Mafenide Acetate (CID000003998) 5 4.562 4.562     
 Metolazone (CID000004170) 3 4.160 4.160 
   Methazolamide (CID100001798) 87 4.481 4.481 
   Benzolamide (CID000018794) 14 4.551 4.551 
   4-Carboxybenzenesulfonamide (CID000008739) 6 4.116 4.116 
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Topiramate (CID100005514) 18 4.306 4.306     
 Chlorthalidone (CID000002732) 6 4.402 4.402 
   2-Ethylamido-5-Sulfonamidoindane (CID011543564) 4 4.700 4.700 
   Indanesulfonamide Derivative 6 (CID011414131) 4 4.347 4.347 
   2-Aminoindane-5-Sulfonic Acid (CID044395769) 3 4.009 4.009 
   Chebi:595853 (CID042609905) 5 4.250 4.250 
   Chlorthalidone (CID100002732) 6 4.409 4.409 
   Bumetanide (CID000002471) 13 4.139 4.139 
   3Cc (CID111537386) 3 4.430 4.430 
   5-Amino-1,3,4-Thiadiazole-2-Sulfonamide 
(CID100084724) 7 4.210 4.210 
   Molport-002-472-850 (CID005172475) 7 4.344 4.344 
   667-Coumate (CID105287541) 6 3.904 3.904 
   Chebi:494255 (CID117748220) 2 4.288 4.288 
   2-Nonylamido-5-Sulfonamidoindane (CID011660633) 4 4.090 4.090 
   Dorzolamide (CID100003154) 83 3.800 3.800 
   Dichlorphenamide (CID100003038) 39 4.227 4.227 
   2-Ethylamido-5-Sulfonamidoindane (CID111543564) 4 3.654 3.654 
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APPENDIX J  
EXPERIMENTAL TESTING OF NEUROPROTECTIVE ACTIVITY OF DRUGS WITH 
PREDICTED NEUROPROTECTIVE ACTIVITY 
The following table shows the results of experimental validation of the compounds with 
predicted neuroprotective activity. The experiments were performed by Dr. Hossein Mousavi in 
the Friedlander lab.  The results are from an LDH screen therefore higher values indicate more 
cell death and vice versa for lower values. The arbitrary units of fluorescence are normalized to 
control cells at 33C (i.e. normal culture) conditions. 
 
 
CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 1.00 0.75   0.97 1.00 0.79 0.98 0.91 1.09 3.19 
37 C 2.12 1.74   2.28 2.21 1.95 1.98 2.06 2.56 3.50 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
3.50 
4.00 
Promethazine 
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CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 1.00 0.75   1.02 0.96 0.98 0.97 0.99 0.83 1.00 
37 C 2.12 1.74   2.00 2.13 2.15 2.10 1.97 1.76 1.43 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
Sodium Nitroprusside 
CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 1.00 0.78   0.84 0.79 1.03 0.78 0.85 1.29 2.35 
37 C 2.20 1.65   1.98 2.06 2.07 2.09 2.03 2.35 1.86 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
Clomipramine 
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CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 1.00 0.78   0.94 0.92 1.00 1.06 0.93 0.91 0.88 
37 C 2.20 1.65   2.06 1.97 2.08 2.11 2.02 2.17 2.29 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
Chloroaniline 
CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 1.00 0.78   0.98 0.92 0.97 0.91 1.19 2.65 2.53 
37 C 2.20 1.65   2.06 2.21 2.14 2.15 2.37 1.89 1.84 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
Promethazine 
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CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 0.97 0.87   0.81 0.92 0.96 0.88 0.82 0.86 1.01 
37 C 1.94 1.68   2.22 1.78 1.78 1.91 1.89 1.65 1.71 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
Azinophos-Methyl 
CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 0.97 0.87   0.90 0.90 0.85 0.90 0.89 0.91 0.97 
37 C 1.94 1.68   2.01 1.92 1.95 1.82 1.98 2.19 2.68 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
Estradiol Benzoate 
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CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 1.00 0.94   0.94 0.93 1.05 1.02 1.09 0.96 0.96 
37 C 2.32 1.79   2.37 2.46 2.49 2.13 2.56 2.38 1.89 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
3.50 
Thyroxine 
CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 1.00 0.94   0.99 1.02 0.91 1.01 1.04 1.01 0.94 
37 C 2.32 1.79   2.04 2.28 2.06 2.03 2.29 2.28 2.31 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
Mafenide Acetate 
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CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 1.06 1.08   1.05 1.00 0.98 0.88 0.88 1.05 3.44 
37 C 2.06 1.78   2.00 2.18 2.43 1.94 2.36 3.52 8.84 
0.00 
1.00 
2.00 
3.00 
4.00 
5.00 
6.00 
7.00 
8.00 
9.00 
10.00 
Aprindine 
CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 1.06 1.08   0.89 0.86 0.93 0.94 0.84 0.93 5.08 
37 C 2.06 1.78   2.21 2.32 2.12 2.23 2.54 3.76 6.98 
0.00 
1.00 
2.00 
3.00 
4.00 
5.00 
6.00 
7.00 
8.00 
9.00 
Imatinib 
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CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 0.97 0.76   0.86 0.81 0.86 0.81 0.81 0.80 0.89 
37 C 2.13 1.74   2.00 1.94 1.93 1.84 1.89 1.97 1.85 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
Topiramate 
CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 0.97 0.76   0.84 0.87 0.96 0.80 0.90 0.81 0.00 
37 C 2.13 1.74   1.99 1.86 2.02 2.10 2.26 2.85 0.00 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
3.50 
Ketanserin 
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CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 0.97 0.76   0.84 0.82 0.85 0.90 0.83 1.01 0.90 
37 C 2.13 1.74   1.89 1.84 2.33 2.04 2.24 2.02 2.29 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
FK33-824 
CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 1.00 0.87   0.87 1.07 0.99 0.94 0.94 1.03 1.04 
37 C 2.32 1.74   2.19 2.62 2.35 2.37 2.24 2.42 2.06 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
Fpl 55712  
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CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 1.00 0.87   0.88 1.03 0.92 0.93 0.99 1.37 2.90 
37 C 2.32 1.74   2.23 2.32 2.22 2.58 7.37 9.82 10.59 
0.00 
2.00 
4.00 
6.00 
8.00 
10.00 
12.00 
Manoalide 
CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 1.00 0.87   0.92 0.86 0.86 1.56 9.45 9.24 9.08 
37 C 2.32 1.74   2.38 2.57 2.81 10.25 8.89 7.84 7.17 
0.00 
2.00 
4.00 
6.00 
8.00 
10.00 
12.00 
Calphostin C 
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CTRL 
Metha
zolami
de 
1 nM 10 nM 
100 
nM 
1 uM 10 uM 30 uM 
100 
uM 
33 C 1.00 0.87   0.88 0.92 1.07 2.19 2.97 2.82 6.49 
37 C 2.32 1.74   2.31 2.60 3.92 8.36 9.52 9.11 9.76 
0.00 
2.00 
4.00 
6.00 
8.00 
10.00 
12.00 
Staurosporine  
203 
BIBLIOGRAPHY 
[1] K. I. Kaitin and J. DiMasi, "Pharmaceutical innovation in the 21st century: new drug
approvals in the first decade, 2000-2009," Clinical pharmacology and therapeutics, vol.
89, no. 2, pp. 183-188, Mar.2011.
[2] S. M. Paul, D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R.
Lindborg, and A. L. Schacht, "How to improve R&D productivity: the pharmaceutical
industry's grand challenge," Nat Rev Drug Discovery, vol. 9, no. 3, pp. 203-214,
Mar.2010.
[3] J. W. Scannell, A. Blanckley, H. Boldon, and B. Warrington, "Diagnosing the decline
in pharmaceutical R&D efficiency," Nat Rev Drug Discovery, vol. 11, no. 3, pp. 191-
200, Mar.2012.
[4] D. F. Horrobin, "Innovation in the pharmaceutical industry," J. R. Soc. Med., vol. 93,
pp. 341-345, 2000.
[5] A. Mullard, "2011 FDA drug approvals," Nat Rev Drug Discovery, vol. 11, no.
February, pp. 91-94, 2012.
[6] L. M. Jarvis, "Biotechs Beat Pharma In First-Half Earnings," Chem. Eng. News, vol.
92, no. 32, pp. 16-17, Aug.2014.
[7] E. David, T. Tramontin, and R. Zemmel, "Pharmaceutical R&D: the road to positive
returns," Nat Rev Drug Discovery, vol. 8, no. 8, pp. 609-610, Aug.2009.
[8] A. L. Hopkins, J. S. Mason, and J. P. Overington, "Can we rationally design
promiscuous drugs?," Curr. Opin. Struct. Biol., vol. 16, no. 1, pp. 127-136, Feb.2006.
[9] A. L. Hopkins, "Network pharmacology," Nat. Biotechnol., vol. 25, no. 10, pp. 1110-
1111, 2007.
204 
[10] A. L. Hopkins, "Network pharmacology: the next paradigm in drug discovery," Nat.
Chem. Biol., vol. 4, no. 11, pp. 682-690, 2008.
[11] P. Csermely, V. Agoston, and S. Pongor, "The efficiency of multi-target drugs: the
network approach might help drug design," Trends Pharmacol. Sci., vol. 26, no. 4, pp.
178-182, Apr.2005.
[12] O. Keskin, a. Gursoy, B. Ma, and R. Nussinov, "Towards drugs targeting multiple
proteins in a systems biology approach," Current topics in medicinal chemistry, vol. 7,
no. 10, pp. 943-951, Jan.2007.
[13] T. Korcsmaros, M. S. Szalay, C. Bode, I. A. Kovacs, and P. Csermely, "How to design
multi-target drugs : Target search options in cellular networks," Discovery, pp. 1-10,
2007.
[14] G. R. Zimmermann, J. Leh+ír, and C. T. Keith, "Multi-target therapeutics: when the
whole is greater than the sum of the parts," Drug Discovery Today, vol. 12, no. 1-2, pp.
34-42, Jan.2007.
[15] S. K. Mencher and L. G. Wang, "Promiscuous drugs compared to selective drugs
(promiscuity can be a virtue)," BMC clinical pharmacology, vol. 5, no. 1, p. 3,
Jan.2005.
[16] P. Csermely, T. Korcsmaros, H. J. M. Kiss, G. London, and R. Nussinov, "Structure
and dynamics of molecular networks: A novel paradigm of drug discovery: A
comprehensive review," Pharmacol. Ther., no. 0 2013.
[17] M. E. Hillenmeyer, E. Fung, J. Wildenhain, S. E. Pierce, S. Hoon, W. Lee, M. Proctor,
R. P. St Onge, M. Tyers, D. Koller, R. B. Altman, R. W. Davis, C. Nislow, and G.
Giaever, "The chemical genomic portrait of yeast: uncovering a phenotype for all
genes," Science, vol. 320, no. 5874, pp. 362-365, Apr.2008.
[18] A. L. Barabasi and Z. N. Oltvai, "Network biology: understanding the cell's functional
organization," Nature Reviews Genetics, vol. 5, no. 2, pp. 101-113, Mar.2004.
[19] D. Cook, D. Brown, R. Alexander, R. March, P. Morgan, G. Satterthwaite, and M. N.
Pangalos, "Lessons learned from the fate of AstraZeneca's drug pipeline: a five-
dimensional framework," Nat Rev Drug Discovery, vol. 13, no. 6, pp. 419-431, 2014.
[20] J. Arrowsmith, "A decade of change," Nat Rev Drug Discovery, vol. 11, no. 1, pp. 17-
18, 2012.
[21] S. H. Yook, Z. N. Oltvai, and A. L. Barabasi, "Functional and topological
characterization of protein interaction networks," PROTEOMICS, vol. 4, pp. 928-942,
Apr.2004.
[22] P. K. Sorger, S. R. B. Allerheiligen, D. R. Abernethy, R. B. Altman, K. L. R. Brouwer,
A. Califano, Z. David, D. Argenio, R. Iyengar, W. J. Jusko, R. Lalonde, D. A.
 205   
Lauffenburger, B. Shoichet, J. L. Stevens, S. Subramaniam, P. V. D. Graaf, and R. 
Ward, "Quantitative and Systems Pharmacology in the Post-genomic Era: New 
Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms," NIH 
White Paper, pp. 1-47, 2011. 
 [23]  B. P. Zambrowicz and A. T. Sands, "Modeling drug action in the mouse with 
knockouts and RNA interference," Drug Discovery Today, vol. 3, no. 5, pp. 198-207, 
Oct.2004. 
 [24]  S. I. Berger and R. Iyengar, "Network analyses in systems pharmacology," 
Bioinformatics, vol. 25, no. 19, pp. 2466-2472, Oct.2009. 
 [25]  J. M. Berg, M. E. Rogers, and P. M. Lyster, "Systems biology and pharmacology," 
Clin. Pharmacol. Ther., vol. 88, no. 1, pp. 17-19, July2010. 
 [26]  M. J. Keiser, B. L. Roth, B. N. Armbruster, P. Ernsberger, J. J. Irwin, and B. K. 
Shoichet, "Relating protein pharmacology by ligand chemistry," Nat. Biotechnol., vol. 
25, no. 2, pp. 197-206, 2007. 
 [27]  E. Lounkine, M. J. Keiser, S. Whitebread, D. Mikhailov, J. Hamon, J. L. Jenkins, P. 
Lavan, E. Weber, A. K. Doak, S. Cote, B. K. Shoichet, and L. Urban, "Large-scale 
prediction and testing of drug activity on side-effect targets," Nature, vol. 486, no. 
7403, pp. 361-367, June2012. 
 [28]  M. J. Keiser, V. Setola, J. J. Irwin, C. Laggner, A. I. Abbas, S. J. Hufeisen, N. H. 
Jensen, M. B. Kuijer, R. C. Matos, T. B. Tran, R. Whaley, R. Glennon, J. +. Hert, K. L. 
H. Thomas, D. D. Edwards, B. K. Shoichet, and B. L. Roth, "Predicting new molecular 
targets for known drugs," Nature, vol. 462, no. 7270, pp. 175-181, Nov.2009. 
 [29]  Y. Yamanishi, M. Araki, A. Gutteridge, W. Honda, and M. Kanehisa, "Prediction of 
drugtarget interaction networks from the integration of chemical and genomic spaces," 
Bioinformatics, vol. 24, p. i232-i240, 2008. 
 [30]  T. van Laarhoven, S. B. Nabuurs, and E. Marchiori, "Gaussian interaction profile 
kernels for predicting drug-target interaction," Bioinformatics (Oxford, England), vol. 
27, no. 21, pp. 3036-3043, Nov.2011. 
 [31]  K. Bleakley and Y. Yamanishi, "Supervised prediction of drug-target interactions using 
bipartite local models," Bioinformatics, vol. 25, no. 18, pp. 2397-2403, Sept.2009. 
 [32]  Y. Yamanishi, M. Kotera, M. Kanehisa, and S. Goto, "Drug-target interaction 
prediction from chemical, genomic and pharmacological data in an integrated 
framework," Bioinformatics, vol. 26, no. 12, p. i246-i254, June2010. 
 [33]  L. Perlman, A. Gottlieb, N. Atias, E. Ruppin, and R. Sharan, "Combining drug and 
gene similarity measures for drug-target elucidation," J Comput Biol, vol. 18, no. 2, pp. 
133-145, Feb.2011. 
 206   
 [34]  M. Gonen, "Predicting drug-target interactions from chemical and genomic kernels 
using Bayesian matrix factorization," Bioinformatics, vol. 28, no. 18, pp. 2304-2310, 
June2012. 
 [35]  S. L. Swann, S. P. Brown, S. W. Muchmore, H. Patel, P. Merta, J. Locklear, and P. J. 
Hajduk, "A unified, probabilistic framework for structure- and ligand-based virtual 
screening," J. Med. Chem., vol. 54, no. 5, pp. 1223-1232, Mar.2011. 
 [36]  J. Lamb, E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J. 
P. Brunet, A. Subramanian, K. N. Ross, M. Reich, H. Hieronymus, G. Wei, S. 
Armstrong, S. J. Haggarty, P. Clemons, R. Wei, S. Carr, E. S. Lander, and T. R. Golub, 
"The Connectivity Map: using gene-expression signatures to connect small molecules, 
genes, and disease," Science, vol. 313, no. 5795, pp. 1929-1935, Sept.2006. 
 [37]  J. T. Dudley, M. Sirota, M. Shenoy, R. K. Pai, S. Roedder, A. P. Chiang, A. A. Morgan, 
M. M. Sarwal, P. J. Pasricha, and A. J. Butte, "Computational Repositioning of the 
Anticonvulsant Topiramate for Inflammatory Bowel Disease," Sci. Transl. Med., vol. 3, 
no. 96, pp. 1-6, 2011. 
 [38]  M. Sirota, J. T. Dudley, J. Kim, A. P. Chiang, A. A. Morgan, A. Sweet-Cordero, J. 
Sage, and A. J. Butte, "Discovery and Preclinical Validation of Drug Indications Using 
Compendia of Public Gene Expression Data," Sci. Transl. Med., vol. 3, no. 96, p. 
96ra77, 2011. 
 [39]  A. P. Chiang and A. J. Butte, "Systematic Evaluation of DrugDisease Relationships to 
Identify Leads for Novel Drug Uses," Clin. Pharmacol. Ther., vol. 86, no. 5, pp. 507-
510, 2009. 
 [40]  T. Cheng, Q. Li, Y. Wang, and S. H. Bryant, "Identifying Compound-Target 
Associations by Combining Bioactivity Profile Similarity Search and Public Databases 
Mining," J. Chem. Inf. Model., vol. 51, no. 9, pp. 2440-2448, 2011. 
 [41]  A. Gottlieb, G. Y. Stein, E. Ruppin, and R. Sharan, "PREDICT: a method for inferring 
novel drug indications with application to personalized medicine," Mol. Syst. Biol., vol. 
7, pp. 1-9, 2011. 
 [42]  S. L. Kinnings, N. Liu, N. Buchmeier, P. J. Tonge, L. Xie, and P. E. Bourne, "Drug 
Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan 
to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis," PLoS Comput Biol, 
vol. 5, no. 7, p. e1000423, 2009. 
 [43]  Y. Y. Li, J. An, and S. J. M. Jones, "A computational approach to finding novel targets 
for existing drugs," PLoS Comput Biol, vol. 7, no. 9, p. e1002139, 2011. 
 [44]  L. Xie and P. E. Bourne, "Detecting evolutionary relationships across existing fold 
space, using sequence order-independent profile-profile alignments," Proc. Natl. Acad. 
Sci. U. S. A., vol. 105, no. 14, pp. 5441-5446, Apr.2008. 
 207   
 [45]  M. Kuhn, D. Szklarczyk, A. Franceschini, C. von Mering, L. J. Jensen, and P. Bork, 
"STITCH 3: zooming in on protein-chemical interactions," Nucleic. Acids. Res., vol. 
40, no. Database issue, p. D876-D880, Jan.2012. 
 [46]  A. Schuffenhauer, J. Zimmermann, R. Stoop, J. J. van der Vyver, S. Lecchini, and E. 
Jacoby, "An Ontology for Pharmaceutical Ligands and Its Application for in Silico 
Screening and Library Design," J. Chem. Inf. Comput. Sci., vol. 42, no. 4, pp. 947-955, 
July2002. 
 [47]  D. Butina, "Unsupervised data base clustering based on daylight's fingerprint and 
Tanimoto similarity: A fast and automated way to cluster small and large data sets," J. 
Chem. Inf. Comput. Sci., vol. 39, no. 4, pp. 747-750, 1999. 
 [48]  S. F. Altschul, W. Gish, W. Miller, E. W. Myers, and D. J. Lipman, "Basic local 
alignment search tool," J. Mol. Biol., vol. 215, no. 3, pp. 403-410, Oct.1990. 
 [49]  M. Ashburner, C. A. Ball, J. A. Blake, D. Botstein, H. Butler, J. Michael Cherry, A. P. 
Davis, K. Dolinski, S. S. Dwight, J. T. Eppig, M. A. Harris, D. P. Hill, L. Issel-Tarver, 
A. Kasarskis, S. Lewis, J. C. Matese, J. E. Richardson, M. Ringwald, G. M. Rubin, and 
G. Sherlock, "Gene Ontology: tool for the unification of biology," Nat. Genet., vol. 25, 
no. 1, pp. 25-29, 2000. 
 [50]  M. McGann, "FRED and HYBRID docking performance on standardized datasets," J. 
Comput. Aided Mol. Des., vol. 26, no. 8, pp. 897-906, 2012. 
 [51]  R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. 
P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw, P. Francis, and P. S. 
Shenkin, "Glide: a new approach for rapid, accurate docking and scoring. 1. Method 
and assessment of docking accuracy," J. Med. Chem., vol. 47, no. 7, pp. 1739-1749, 
2004. 
 [52]  S. Riniker and G. A. Landrum, "Open-source platform to benchmark fingerprints for 
ligand-based virtual screening," Journal of Cheminformatics, vol. 5, no. 1, p. 26, 2013. 
 [53]  R. Salakhutdinov and A. Mnih, "Bayesian probabilistic matrix factorization using 
Markov chain Monte Carlo," in Proceedings of the 25th international conference on 
Machine learning Helsinki, Finland: ACM, 2008, pp. 880-887. 
 [54]  W. Du and O. Elemento, "Cancer systems biology: embracing complexity to develop 
better anticancer therapeutic strategies," Oncogene, 2014. 
 [55]  J. P. Bai and D. R. Abernethy, "Systems pharmacology to predict drug toxicity: 
integration across levels of biological organization*," Annu. Rev. Pharmacol. Toxicol., 
vol. 53, pp. 451-473, 2013. 
 [56]  T. Barrett and R. Edgar, "Gene expression omnibus: microarray data storage, 
submission, retrieval, and analysis," Methods Enzymol., vol. 411, no. 2005, pp. 352-
369, Jan.2006. 
 208   
 [57]  D. S. Wishart, C. Knox, A. C. Guo, D. Cheng, S. Shrivastava, D. Tzur, B. Gautam, and 
M. Hassanali, "DrugBank: a knowledgebase for drugs, drug actions and drug targets," 
Nucleic. Acids. Res., vol. 36, no. Database issue, p. D901-D906, Jan.2008. 
 [58]  M. Kanehisa and S. Goto, "KEGG: kyoto encyclopedia of genes and genomes," 
Nucleic. Acids. Res., vol. 28, no. 1, pp. 27-30, 2000. 
 [59]  S. Gunther, M. Kuhn, M. Dunkel, M. Campillos, C. Senger, E. Petsalaki, J. Ahmed, E. 
G. Urdiales, A. Gewiess, L. J. Jensen, R. Schneider, R. Skoblo, R. B. Russell, P. E. 
Bourne, P. Bork, and R. Preissner, "SuperTarget and Matador: resources for exploring 
drug-target relationships," Nucleic. Acids. Res., vol. 36, no. Database issue, p. D919-
D922, 2008. 
 [60]  A. Hamosh, A. F. Scott, J. Amberger, C. Bocchini, D. Valle, and V. A. McKusick, 
"Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and 
genetic disorders," Nucleic. Acids. Res., vol. 30, no. 1, pp. 52-55, 2002. 
 [61]  O. Bodenreider, "The Unified Medical Language System (UMLS): integrating 
biomedical terminology," Nucleic. Acids. Res., vol. 32, no. Database issue, p. D267-
D270, 2004. 
 [62]  R. Abagyan, M. Totrov, and D. Kuznetsov, "ICMa new method for protein modeling 
and design: applications to docking and structure prediction from the distorted native 
conformation," J. Comput. Chem., vol. 15, no. 5, pp. 488-506, 1994. 
 [63]  M. Rastegar-Mojarad, Z. Ye, J. M. Kolesar, S. J. Hebbring, and S. M. Lin, 
"Opportunities for drug repositioning from phenome-wide association studies," Nat. 
Biotechnol., vol. 33, no. 4, pp. 342-345, 2015. 
 [64]  F. J. de Serres, "Worldwide racial and ethnic distribution of alpha1-antitrypsin 
deficiency: summary of an analysis of published genetic epidemiologic surveys," Chest, 
vol. 122, no. 5, pp. 1818-1829, 2002. 
 [65]  L. P. O'Reilly, O. S. Long, M. C. Cobanoglu, J. A. Benson, C. J. Luke, M. T. Miedel, P. 
Hale, D. H. Perlmutter, I. Bahar, G. A. Silverman, and S. C. Pak, "A genome-wide 
RNAi screen identifies potential drug targets in a C. elegans model of alpha1-
antitrypsin deficiency," Hum. Mol. Genet., 2014. 
 [66]  S. Eriksson and C. Larsson, "Purification and partial characterization of PAS-positive 
inclusion bodies from the liver in alpha1-antitrypsin deficiency," N. Engl. J. Med., vol. 
292, no. 4, pp. 176-180, 1975. 
 [67]  J. O. Jeppsson, C. Larsson, and S. Eriksson, "Characterization of alpha1-antitrypsin in 
the inclusion bodies from the liver in alpha1-antitrypsin deficiency," N. Engl. J. Med., 
vol. 293, no. 12, pp. 576-579, 1975. 
 [68]  R. W. Carrell and D. A. Lomas, "Alpha1-antitrypsin deficiencya model for 
conformational diseases," N. Engl. J. Med., vol. 346, no. 1, pp. 45-53, 2002. 
 209   
 [69]  G. A. Silverman, J. C. Whisstock, S. P. Bottomley, J. A. Huntington, D. Kaiserman, C. 
J. Luke, S. C. Pak, J. M. Reichhart, and P. I. Bird, "Serpins flex their muscle I. Putting 
the clamps on proteolysis in diverse biological systems," J. Biol. Chem., vol. 285, no. 
32, pp. 24299-24305, 2010. 
 [70]  R. Huber and R. W. Carrell, "Implications of the three-dimensional structure of alpha 
1-antitrypsin for structure and function of serpins," vol. 28, no. 23, pp. 8951-8966, 
1989. 
 [71]  N. C. Perera, O. Schilling, H. Kittel, W. Back, E. Kremmer, and D. E. Jenne, "NSP4, an 
elastase-related protease in human neutrophils with arginine specificity," vol. 109, no. 
16, pp. 6229-6234, 2012. 
 [72]  H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. 
Shindyalov, and P. E. Bourne, "The Protein Data Bank," Nucleic. Acids. Res., vol. 28, 
no. 1, pp. 235-242, 2000. 
 [73]  S. Ye, A. L. Cech, R. Belmares, R. C. Bergstrom, Y. Tong, D. R. Corey, M. R. Kanost, 
and E. J. Goldsmith, "The structure of a Michaelis serpinprotease complex," Nat. 
Struct. Biol., vol. 8, no. 11, pp. 979-983, 2001. 
 [74]  J. A. Huntington, R. J. Read, and R. W. Carrell, "Structure of a serpin-protease 
complex shows inhibition by deformation," Nature, vol. 407, no. 6806, pp. 923-926, 
Oct.2000. 
 [75]  D. H. Perlmutter and G. A. Silverman, "Hepatic fibrosis and carcinogenesis in alpha1-
antitrypsin deficiency: a prototype for chronic tissue damage in gain-of-function 
disorders," Cold Spring Habor Perspectives in Biology, vol. 3, no. 3 2011. 
 [76]  M. Yamasaki, T. J. Sendall, M. C. Pearce, J. C. Whisstock, and J. A. Huntington, 
"Molecular basis of alpha1-antitrypsin deficiency revealed by the structure of a 
domain-swapped trimer," EMBO reports, vol. 12, no. 10, pp. 1011-1017, 2011. 
 [77]  D. H. Perlmutter, "Pathogenesis of chronic liver injury and hepatocellular carcinoma in 
alpha-1-antitrypsin deficiency," Pediatr. Res., vol. 60, no. 2, pp. 233-238, 2006. 
 [78]  D. H. Perlmutter, "Alpha-1-antitrypsin deficiency: importance of proteasomal and 
autophagic degradative pathways in disposal of liver disease-associated protein 
aggregates," Annu. Rev. Med., vol. 62, pp. 333-345, Jan.2011. 
 [79]  S. Eriksson, J. Carlson, and R. Velez, "Risk of cirrhosis and primary liver cancer in 
alpha 1-antitrypsin deficiency," vol. 314, no. 12, pp. 736-739, 1986. 
 [80]  R. G. Crystal, "Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic 
basis and strategies for therapy," vol. 85, no. 5, pp. 1343-1352, 1990. 
 [81]  A. Janoff, "Elastases and emphysema. Current assessment of the protease-antiprotease 
hypothesis," vol. 132, no. 2, pp. 417-433, 1985. 
 210   
 [82]  E. Janus, N. Phillips, and R. Carrell, "Smoking, lung function, and alpha1-antitrypsin 
deficiency," Lancet, vol. 325, no. 8421, pp. 152-154, 1985. 
 [83]  D. Rudnick and D. H. Perlmutter, "Alpha-1-antitrypsin deficiency: a new paradigm for 
hepatocellular carcinoma in genetic liver disease," Hepatology, vol. 42, no. 3, pp. 514-
521, Sept.2005. 
 [84]  D. A. Rudnick, Y. Liao, J.-K. An, L. J. Muglia, D. H. Perlmutter, and J. H. Teckman, 
"Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin 
deficiency," Hepatology, vol. 39, no. 4, pp. 1048-1055, 2004. 
 [85]  T. Sveger, "Liver disease in alpha1-antitrypsin deficiency detected by screening of 
200,000 infants," N. Engl. J. Med., vol. 294, no. 24, pp. 1316-1321, 1976. 
 [86]  M. E. MacDonald, C. M. Ambrose, M. P. Duyao, R. H. Myers, C. Lin, L. Srinidhi, G. 
Barnes, S. A. Taylor, M. James, and N. Groot, "A novel gene containing a trinucleotide 
repeat that is expanded and unstable on Huntington's disease chromosomes," Cell, vol. 
72, no. 6, pp. 971-983, 1993. 
 [87]  C. A. Ross and S. J. Tabrizi, "Huntington's disease: from molecular pathogenesis to 
clinical treatment," Lancet neurology, vol. 10, no. 1, pp. 83-98, Jan.2011. 
 [88]  R. M. Friedlander, "Apoptosis and caspases in neurodegenerative diseases," N. Engl. J. 
Med., vol. 348, no. 14, pp. 1365-1375, 2003. 
 [89]  P. H. Reddy, M. Williams, V. Charles, L. Garrett, L. Pike-Buchanan, W. O. Whetsell, 
G. Miller, and D. A. Tagle, "Behavioural abnormalities and selective neuronal loss in 
HD transgenic mice expressing mutated full-length HD cDNA," Nat. Genet., vol. 20, 
no. 2, pp. 198-202, 1998. 
 [90]  L. Mangiarini, K. Sathasivam, M. Seller, B. Cozens, A. Harper, C. Hetherington, M. 
Lawton, Y. Trottier, H. Lehrach, S. W. Davies, and G. P. Bates, "Exon 1 of the HD 
gene with an expanded CAG repeat is sufficient to cause a progressive neurological 
phenotype in transgenic mice," Cell, vol. 87, no. 3, pp. 493-506, 1996. 
 [91]  J. Heemskerk, A. J. Tobin, and L. J. Bain, "Teaching old drugs new tricks," Trends 
Neurosci., vol. 25, no. 10, pp. 494-496, 2002. 
 [92]  X. Wang, S. Zhu, Z. Pei, M. Drozda, I. G. Stavrovskaya, S. J. Del Signore, K. Cormier, 
E. M. Shimony, H. Wang, R. J. Ferrante, B. S. Kristal, and R. M. Friedlander, 
"Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease," 
J. Neurosci., vol. 28, no. 38, pp. 9473-9485, Sept.2008. 
 [93]  N. O'Boyle, C. Morley, and G. Hutchison, "Pybel: a Python wrapper for the OpenBabel 
cheminformatics toolkit," Chemistry Central Journal, vol. 2, no. 1, p. 5, 2008. 
 [94]  T. W. Harris, I. Antoshechkin, T. Bieri, D. Blasiar, J. Chan, W. J. Chen, N. De La Cruz, 
P. Davis, M. Duesbury, R. Fang, J. Fernandes, M. Han, R. Kishore, R. Lee, H. M. 
 211   
M++ller, C. Nakamura, P. Ozersky, A. Petcherski, A. Rangarajan, A. Rogers, G. 
Schindelman, E. M. Schwarz, M. A. Tuli, K. Van Auken, D. Wang, X. Wang, G. 
Williams, K. Yook, R. Durbin, L. D. Stein, J. Spieth, and P. W. Sternberg, "WormBase: 
a comprehensive resource for nematode research," Nucleic. Acids. Res., vol. 38, no. 
Database issue, p. D463-D467, Jan.2010. 
 [95]  D. D. Shaye and I. Greenwald, "OrthoList: a compendium of C. elegans genes with 
human orthologs," PloS one, vol. 6, no. 5, p. e20085, Jan.2011. 
 [96]  C. R. Chong and D. J. Sullivan, "New uses for old drugs," Nature, vol. 448, no. 7154, 
pp. 645-646, 2007. 
 [97]  M. C. Cobanoglu, C. Liu, F. Hu, Z. N. Oltvai, and I. Bahar, "Predicting Drug-Target 
Interactions Using Probabilistic Matrix Factorization," J. Chem. Inf. Model., vol. 53, 
no. 12, pp. 3399-3409, Dec.2013. 
 [98]  M. C. Cobanoglu, Z. N. Oltvai, D. L. Taylor, and I. Bahar, "BalestraWeb: efficient 
online evaluation of drug-target interactions," Bioinformatics, p. btu599, 2014. 
 [99]  C. Knox, V. Law, T. Jewison, P. Liu, S. Ly, A. Frolkis, A. Pon, K. Banco, C. Mak, V. 
Neveu, Y. Djoumbou, R. Eisner, A. C. Guo, and D. S. Wishart, "DrugBank 3.0: a 
comprehensive resource for 'omics' research on drugs," Nucleic. Acids. Res., vol. 39, 
no. Database issue, p. D1035-D1041, Jan.2011. 
 [100]  M. A. Yildirim, K. I. Goh, M. E. Cusick, A. L. Barabasi, and M. Vidal, "Drugtarget 
network," Nat. Biotechnol., vol. 25, no. 10, pp. 1119-1126, 2007. 
 [101]  R. Salakhutdinov and A. Mnih, "Probabilistic matrix factorization," Adv Neural Inf 
Process Syst, 2008. 
 [102]  M. K. Warmuth, J. Liao, G. R+ñtsch, M. Mathieson, S. Putta, and C. Lemmen, "Active 
learning with support vector machines in the drug discovery process," J. Chem. Inf. 
Comput. Sci., vol. 43, no. 2, pp. 667-673, 2003. 
 [103]  M. E. Smoot, K. Ono, J. Ruscheinski, P. L. Wang, and T. Ideker, "Cytoscape 2.8: new 
features for data integration and network visualization," Bioinformatics, vol. 27, no. 3, 
pp. 431-432, Feb.2011. 
 [104]  H. Akaike, "A New Look at the Statistical Model Identification," IEEE. T. Automat. 
Contr., vol. 19, no. 6, pp. 716-723, 1974. 
 [105]  E. R. Yera, A. E. Cleves, and A. N. Jain, "Chemical Structural Novelty: On-Targets and 
Off-Targets," J. Med. Chem., vol. 54, no. 19, pp. 6771-6785, 2011. 
 [106]  P. C. D. Hawkins, A. G. Skillman, G. L. Warren, B. A. Ellingson, and M. T. Stahl, 
"Conformer generation with OMEGA: algorithm and validation using high quality 
structures from the Protein Databank and Cambridge Structural Database," J. Chem. 
Inf. Model., vol. 50, no. 4, pp. 572-584, Apr.2010. 
 212   
 [107]  V. Law, C. Knox, Y. Djoumbou, T. Jewison, A. C. Guo, Y. Liu, A. Maciejewski, D. 
Arndt, M. Wilson, V. Neveu, A. Tang, G. Gabriel, C. Ly, S. Adamjee, Z. T. Dame, B. 
Han, Y. Zhou, and D. S. Wishart, "DrugBank 4.0: shedding new light on drug 
metabolism," Nucleic. Acids. Res., vol. 42, no. Database issue, p. D1091-D1097, 
Jan.2014. 
 [108]  Y. Low, J. Gonzalez, A. Kyrola, D. Bickson, C. Guestrin, and J. M. Hellerstein, 
"Graphlab: A new framework for parallel machine learning," 2010. 
 [109]  D. Nolan and D. T. Lang, "Scalable Vector Graphics," in XML and Web Technologies 
for Data Sciences with R Springer, 2014, pp. 537-580. 
 [110]  D. Lane, "Scalable vector graphics," AMC, vol. 10, p. 12, 2007. 
 [111]  A. Quint, "Scalable vector graphics," IEEE Multimedia, vol. 10, no. 3, pp. 99-102, 
2003. 
 [112]  J. Ferraiolo, F. Jun, and D. Jackson, Scalable vector graphics (SVG) 1.0 specification 
iuniverse, 2000. 
 [113]  M. C. Cobanoglu, Z. N. Oltvai, D. L. Taylor, and I. Bahar, "BalestraWeb: efficient 
online evaluation of drug-target interactions," Bioinformatics, vol. 31, pp. 131-133, 
2015. 
 [114]  Y. Zhou, D. Wilkinson, R. Schreiber, and R. Pan, "Large-scale parallel collaborative 
filtering for the netflix prize," 2008. 
 [115]  H. F. Yu, C. J. Hsieh, S. Si, and I. Dhillon, "Scalable Coordinate Descent Approaches 
to Parallel Matrix Factorization for Recommender Systems," IEEE, 2012, pp. 765-774. 
 [116]  H. F. Yu, C. J. Hsieh, S. Si, and I. S. Dhillon, "Parallel matrix factorization for 
recommender systems," Knowledge and Information Systems, vol. 41, no. 3, pp. 793-
819, 2014. 
 [117]  G. Takacs, I. Pilaszy, B. Nemeth, and D. Tikk, "Scalable collaborative filtering 
approaches for large recommender systems," The Journal of Machine Learning 
Research, vol. 10, pp. 623-656, 2009. 
 [118]  Y. Koren, R. Bell, and C. Volinsky, "Matrix Factorization Techniques for 
Recommender Systems," IEEE Computer, vol. 42, no. 8, pp. 30-37, 2009. 
 [119]  M. Kuhn, D. Szklarczyk, S. Pletscher-Frankild, T. H. Blicher, C. von Mering, L. J. 
Jensen, and P. Bork, "STITCH 4: integration of protein-chemical interactions with user 
data," Nucleic. Acids. Res., vol. 42, no. Database issue, p. D401-D407, Jan.2014. 
 [120]  O. S. Long, "Genetic Modifiers that Affect the Accumulation of the Mutant Protein 
Alpha-1 Antitrypsin-Z." 2011. 
 213   
 [121]  S. F. Altschul, T. L. Madden, a. a. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D. J. 
Lipman, "Gapped BLAST and PSI-BLAST: a new generation of protein database 
search programs," Nucleic. Acids. Res., vol. 25, no. 17, pp. 3389-3402, Sept.1997. 
 [122]  R. Huang, N. Southall, Y. Wang, A. Yasgar, P. Shinn, A. Jadhav, D. T. Nguyen, and C. 
P. Austin, "The NCGC pharmaceutical collection: a comprehensive resource of 
clinically approved drugs enabling repurposing and chemical genomics," Sci. Transl. 
Med., vol. 3, no. 80, p. 80ps16, 2011. 
 [123]  P. Flicek, M. R. Amode, D. Barrell, K. Beal, S. Brent, D. Carvalho-Silva, P. Clapham, 
G. Coates, S. Fairley, and S. Fitzgerald, "Ensembl 2012," Nucleic. Acids. Res., p. 
gkr991, 2011. 
 [124]  Y. Nikolsky, S. Ekins, T. Nikolskaya, and A. Bugrim, "A novel method for generation 
of signature networks as biomarkers from complex high throughput data," Toxicol. 
Lett., vol. 158, no. 1, pp. 20-29, July2005. 
 [125]  S. J. Gosai, J. H. Kwak, C. J. Luke, O. S. Long, D. E. King, K. J. Kovatch, P. A. 
Johnston, T. Y. Shun, J. S. Lazo, and D. H. Perlmutter, "Automated high-content live 
animal drug screening using C. elegans expressing the aggregation prone serpin alpha1-
antitrypsin Z," PloS one, vol. 5, no. 11, p. e15460, 2010. 
 [126]  Z. A. Knight, "Small molecule inhibitors of the PI3-kinase family," in Phosphoinositide 
3-kinase in Health and Disease Springer, 2011, pp. 263-278. 
 [127]  V. Samokhvalov, B. A. Scott, and C. M. Crowder, "Autophagy protects against hypoxic 
injury in C. elegans," Autophagy, vol. 4, no. 8, pp. 1034-1041, 2008. 
 [128]  K. D. Kimura, H. A. Tissenbaum, Y. Liu, and G. Ruvkun, "daf-2, an insulin receptor-
like gene that regulates longevity and diapause in Caenorhabditis elegans," Science, 
vol. 277, no. 5328, pp. 942-946, 1997. 
 [129]  L. P. O'Reilly, J. A. Benson, E. E. Cummings, D. H. Perlmutter, G. A. Silverman, and 
S. C. Pak, "Worming our way to novel drug discovery with the Caenorhabditis elegans 
proteostasis network, stress response and insulin-signaling pathways," Expert Opinion 
on Drug Discovery, vol. 9, no. 9, pp. 1021-1032, 2014. 
 [130]  O. S. Long, J. A. Benson, J. H. Kwak, C. J. Luke, S. J. Gosai, L. P. O'Reilly, Y. Wang, 
J. Li, A. C. Vetica, and M. T. Miedel, "A C. elegans model of human alpha1-antitrypsin 
deficiency links components of the RNAi pathway to misfolded protein turnover," 
Hum. Mol. Genet., p. ddu235, 2014. 
 [131]  N. M. OLBoyle, M. Banck, C. A. James, C. Morley, T. Vandermeersch, and G. R. 
Hutchison, "Open Babel: An open chemical toolbox," Journal of Cheminformatics, vol. 
3, pp. 33-47, 2011. 
 214   
 [132]  J. J. Irwin, T. Sterling, M. M. Mysinger, E. S. Bolstad, and R. G. Coleman, "ZINC: A 
free tool to discover chemistry for biology," J. Chem. Inf. Model., vol. 52, pp. 1757-
1768, 2012. 
 [133]  M. Kanehisa, S. Goto, Y. Sato, M. Kawashima, M. Furumichi, and M. Tanabe, "Data, 
information, knowledge and principle: back to metabolism in KEGG," Nucleic. Acids. 
Res., vol. 42, no. D1, p. D199-D205, 2014. 
 [134]  M. Kanehisa, S. Goto, Y. Sato, M. Kawashima, M. Furumichi, and M. Tanabe, "Data, 
information, knowledge and principle: back to metabolism in KEGG," Nucleic. Acids. 
Res., vol. 42, no. Database issue, p. D199-D205, Jan.2014. 
 [135]  F. Cunningham, M. R. Amode, D. Barrell, K. Beal, K. Billis, S. Brent, D. Carvalho-
Silva, P. Clapham, G. Coates, S. Fitzgerald, L. Gil, C. G. a. Gir+¦n, L. Gordon, T. 
Hourlier, S. E. Hunt, S. H. Janacek, N. Johnson, T. Juettemann, A. K. K+ñh+ñri, S. 
Keenan, F. J. Martin, T. Maurel, W. McLaren, D. N. Murphy, R. Nag, B. Overduin, A. 
Parker, M. Patricio, E. Perry, M. Pignatelli, H. S. Riat, D. Sheppard, K. Taylor, A. 
Thormann, A. Vullo, S. P. Wilder, A. Zadissa, B. L. Aken, E. Birney, J. Harrow, R. 
Kinsella, M. Muffato, M. Ruffier, S. M. J. Searle, G. Spudich, S. J. Trevanion, A. 
Yates, D. R. Zerbino, and P. Flicek, "Ensembl 2015," Nucleic. Acids. Res., pp. 1-8, 
Oct.2014. 
 [136]  J. R. Quinlan, "Induction of decision trees," Machine Learning, vol. 1, no. 1, pp. 81-
106, 1986. 
 [137]  E. T. Lam, M. D. Ringel, R. T. Kloos, T. W. Prior, M. V. Knopp, J. Liang, S. Sammet, 
N. C. Hall, P. E. Wakely, and V. V. Vasko, "Phase II clinical trial of sorafenib in 
metastatic medullary thyroid cancer," J. Clin. Oncol., vol. 28, no. 14, pp. 2323-2330, 
2010. 
 [138]  R. T. Kloos, M. D. Ringel, M. V. Knopp, N. C. Hall, M. King, R. Stevens, J. Liang, P. 
E. Wakely, V. V. Vasko, and M. Saji, "Phase II trial of sorafenib in metastatic thyroid 
cancer," J. Clin. Oncol., vol. 27, no. 10, pp. 1675-1684, 2009. 
 [139]  J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J. F. d. r. Blanc, A. C. de 
Oliveira, A. Santoro, J. L. Raoul, and A. Forner, "Sorafenib in advanced hepatocellular 
carcinoma," N. Engl. J. Med., vol. 359, no. 4, pp. 378-390, 2008. 
 [140]  V. Gupta-Abramson, A. B. Troxel, A. Nellore, K. Puttaswamy, M. Redlinger, K. 
Ransone, S. J. Mandel, K. T. Flaherty, L. A. Loevner, and P. J. O'Dwyer, "Phase II trial 
of sorafenib in advanced thyroid cancer," J. Clin. Oncol., vol. 26, no. 29, pp. 4714-
4719, 2008. 
 [141]  B. Escudier, T. Eisen, W. M. Stadler, C. Szczylik, S. p. Oudard, M. Siebels, S. Negrier, 
C. Chevreau, E. Solska, and A. A. Desai, "Sorafenib in advanced clear-cell renal-cell 
carcinoma," N. Engl. J. Med., vol. 356, no. 2, pp. 125-134, 2007. 
 215   
 [142]  M. Rynn, J. Russell, J. Erickson, M. J. Detke, S. Ball, J. Dinkel, K. Rickels, and J. 
Raskin, "Efficacy and safety of duloxetine in the treatment of generalized anxiety 
disorder: a flexible-dose, progressive-titration, placebo-controlled trial," Depress. 
Anxiety, vol. 25, no. 3, pp. 182-189, 2008. 
 [143]  J. Hartford, S. Kornstein, M. Liebowitz, T. Pigott, J. Russell, M. Detke, D. Walker, S. 
Ball, E. Dunayevich, and J. Dinkel, "Duloxetine as an SNRI treatment for generalized 
anxiety disorder: results from a placebo and active-controlled trial," Int. Clin. 
Psychopharmacol., vol. 22, no. 3, pp. 167-174, 2007. 
 [144]  D. L. Dunner, D. J. Goldstein, C. Mallinckrodt, Y. Lu, and M. J. Detke, "Duloxetine in 
treatment of anxiety symptoms associated with depression," Depress. Anxiety, vol. 18, 
no. 2, pp. 53-61, 2003. 
 [145]  D. J. Goldstein, C. Mallinckrodt, Y. Lu, and M. A. Demitrack, "Duloxetine in the 
treatment of major depressive disorder: a double-blind clinical trial," J. Clin. 
Psychiatry, vol. 63, no. 3, pp. 225-231, 2002. 
 [146]  M. J. Detke, Y. Lu, D. J. Goldstein, J. R. Hayes, and M. A. Demitrack, "Duloxetine, 60 
mg once daily, for major depressive disorder: a randomized double-blind placebo-
controlled trial," J. Clin. Psychiatry, vol. 63, no. 4, pp. 308-315, 2002. 
 [147]  B. Kerzner, J. Corbelli, S. Sharp, L. J. Lipka, L. Melani, A. LeBeaut, R. Suresh, P. 
Mukhopadhyay, E. P. Veltri, and "Ezetimibe Study Group"., "Efficacy and safety of 
ezetimibe coadministered with lovastatin in primary hypercholesterolemia," Am. J. 
Cardiol., vol. 91, no. 4, pp. 418-424, 2003. 
 [148]  C. A. Dujovne, M. P. Ettinger, J. F. McNeer, L. J. Lipka, A. P. LeBeaut, R. Suresh, B. 
Yang, E. P. Veltri, and "Ezetimibe Study Group", "Efficacy and safety of a potent new 
selective cholesterol absorption inhibitor, ezetimibe, in patients with primary 
hypercholesterolemia," Am. J. Cardiol., vol. 90, no. 10, pp. 1092-1097, 2002. 
 [149]  C. Gagne, H. E. Bays, S. R. Weiss, P. Mata, K. Quinto, M. Melino, M. Cho, T. A. 
Musliner, B. Gumbiner, and "Ezetimibe Study Group"., "Efficacy and safety of 
ezetimibe added to ongoing statin therapy for treatment of patients with primary 
hypercholesterolemia," Am. J. Cardiol., vol. 90, no. 10, pp. 1084-1091, 2002. 
 [150]  A. Gaulton, L. J. Bellis, A. P. Bento, J. Chambers, M. Davies, A. Hersey, Y. Light, S. 
McGlinchey, D. Michalovich, and B. Al-Lazikani, "ChEMBL: a large-scale bioactivity 
database for drug discovery," Nucleic. Acids. Res., vol. 40, no. D1, p. D1100-D1107, 
2012. 
 [151]  P. C. D. Hawkins, a. G. Skillman, and A. Nicholls, "Comparison of shape-matching and 
docking as virtual screening tools," J. Med. Chem., vol. 50, no. 1, pp. 74-82, Jan.2007. 
 [152]  R. Apweiler, C. O'onovan, M. Magrane, Y. am-Faruque, R. Antunes, B. Bely, M. 
Bingley, L. Bower, B. Bursteinas, and G. Chavali, "Reorganizing the protein space at 
 216   
the Universal Protein Resource (UniProt)," Nucleic. Acids. Res., vol. 40, no. Database 
issue, p. D71-D75, 2012. 
 [153]  Y. Hamdi, H. Kaddour, D. Vaudry, S. Bahdoudi, S. Douiri, J. +. Leprince, H. Castel, H. 
Vaudry, M. C. Tonon, and M. Amri, "The octadecaneuropeptide ODN protects 
astrocytes against hydrogen peroxide-induced apoptosis via a PKA/MAPK-dependent 
mechanism," PloS one, vol. 7, no. 8, p. e42498, 2012. 
 [154]  E. A. Thomas, G. Coppola, P. A. Desplats, B. Tang, E. Soragni, R. Burnett, F. Gao, K. 
M. Fitzgerald, J. F. Borok, and D. Herman, "The HDAC inhibitor 4b ameliorates the 
disease phenotype and transcriptional abnormalities in Huntington's disease transgenic 
mice," Proceedings of the National Academy of Sciences, vol. 105, no. 40, pp. 15564-
15569, 2008. 
 [155]  J. Pallos, L. Bodai, T. Lukacsovich, J. M. Purcell, J. S. Steffan, L. M. Thompson, and J. 
L. Marsh, "Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a 
Drosophila model of HuntingtonÇÖs disease," Hum. Mol. Genet., vol. 17, no. 23, pp. 
3767-3775, 2008. 
 [156]  R. J. Ferrante, J. K. Kubilus, J. Lee, H. Ryu, A. Beesen, B. Zucker, K. Smith, N. W. 
Kowall, R. R. Ratan, and R. Luthi-Carter, "Histone deacetylase inhibition by sodium 
butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's 
disease mice," The Journal of neuroscience, vol. 23, no. 28, pp. 9418-9427, 2003. 
 [157]  J. P. Dompierre, J. D. Godin, B. n. d. C. Charrin, F. P. Cordelieres, S. J. King, S. 
Humbert, and F. d. r. Saudou, "Histone deacetylase 6 inhibition compensates for the 
transport deficit in Huntington's disease by increasing tubulin acetylation," The Journal 
of neuroscience, vol. 27, no. 13, pp. 3571-3583, 2007. 
 [158]  E. Hockly, V. M. Richon, B. Woodman, D. L. Smith, X. Zhou, E. Rosa, K. Sathasivam, 
S. Ghazi-Noori, A. Mahal, and P. A. Lowden, "Suberoylanilide hydroxamic acid, a 
histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of 
Huntington's disease," Proceedings of the National Academy of Sciences, vol. 100, no. 
4, pp. 2041-2046, 2003. 
 [159]  S. W. Jones, "Calcium channels: unanswered questions," J. Bioenerg. Biomembr., vol. 
35, no. 6, pp. 461-475, 2003. 
 [160]  O. Zhuchenko, J. Bailey, P. Bonnen, T. Ashizawa, D. W. Stockton, C. Amos, W. B. 
Dobyns, S. H. Subramony, H. Y. Zoghbi, and C. C. Lee, "Autosomal dominant 
cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the +¦1A-
voltage-dependent calcium channel," Nat. Genet., vol. 15, no. 1, pp. 62-69, 1997. 
 [161]  H. T. Orr, M. y. Chung, S. Banfi, T. J. Kwiatkowski, A. Servadio, A. L. Beaudet, A. E. 
McCall, L. A. Duvick, L. P. Ranum, and H. Y. Zoghbi, "Expansion of an unstable 
trinucleotide CAG repeat in spinocerebellar ataxia type 1," Nat. Genet., vol. 4, no. 3, 
pp. 221-226, 1993. 
 217   
 [162]  S. M. Pulst, A. Nechiporuk, T. Nechiporuk, S. Gispert, X. N. Chen, I. Lopes-Cendes, S. 
Pearlman, S. Starkman, G. Orozco-Diaz, and A. Lunkes, "Moderate expansion of a 
normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2," Nat. Genet., 
vol. 14, no. 3, pp. 269-276, 1996. 
 [163]  Y. Kawaguchi, T. Okamoto, M. Taniwakiz, and M. Aizawa, "CAG expansions in a 
novel gene for Machado-Joseph disease at chromosome 14q32.1," Nat. Genet., vol. 8 
1994. 
 [164]  A. R. La Spada, E. M. Wilson, D. B. Lubahn, A. E. Harding, and K. H. Fischbeck, 
"Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy," 
Nature, vol. 352, no. 6330, pp. 77-79, 1991. 
 [165]  R. Koide, T. Ikeuchi, O. Onodera, H. Tanaka, S. Igarashi, K. Endo, H. Takahashi, R. 
Kondo, A. Ishikawa, and T. Hayashi, "Unstable expansion of CAG repeat in hereditary 
dentatorubralpallidoluysian atrophy (DRPLA)," Nat. Genet., vol. 6, no. 1, pp. 9-13, 
1994. 
 [166]  J. M. Lamers, P. D. Verdouw, and J. Mas-Oliva, "The effects of felodipine and bepridil 
on calcium-stimulated calmodulin binding and calcium pumping ATPase of cardiac 
sarcolemma before and after removal of endogenous calmodulin," Mol. Cell. Biochem., 
vol. 78, no. 2, pp. 169-176, 1987. 
 [167]  B. del Rio, J. M. G. Pedrero, C. Martinez-Campa, P. Zuazua, P. S. Lazo, and S. Ramos, 
"Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via 
calmodulin," J. Biol. Chem., vol. 279, no. 37, pp. 38294-38302, 2004. 
 [168]  F. Radogna, L. Paternoster, M. De Nicola, C. Cerella, S. Ammendola, A. Bedini, G. 
Tarzia, K. Aquilano, M. Ciriolo, and L. Ghibelli, "Rapid and transient stimulation of 
intracellular reactive oxygen species by melatonin in normal and tumor leukocytes," 
Toxicol. Appl. Pharmacol., vol. 239, no. 1, pp. 37-45, 2009. 
 [169]  A. Seto-Ohshima, E. Lawson, P. C. Emson, C. Q. Mountjoy, and L. H. Carrasco, "Loss 
of matrix calcium-binding protein-containing neurons in Huntington's disease," The 
Lancet, vol. 331, no. 8597, pp. 1252-1255, 1988. 
 [170]  A. V. Panov, C. A. Gutekunst, B. R. Leavitt, M. R. Hayden, J. R. Burke, W. J. 
Strittmatter, and J. T. Greenamyre, "Early mitochondrial calcium defects in 
Huntington's disease are a direct effect of polyglutamines," Nat. Neurosci., vol. 5, no. 8, 
pp. 731-736, 2002. 
 [171]  I. H. Page, A. C. Corcoran, H. P. Dustan, and T. Koppanyi, "Cardiovascular Actions of 
Sodium Nitroprusside in Animals and Hypertensive Patients," Ciculation, vol. 11, pp. 
188-198, 1955. 
 [172]  J. H. Tinker and J. D. Michenfelder, "Sodium nitroprusside: pharmacology, toxicology 
and therapeutics," Anesthesiology, vol. 45 1976. 
 218   
 [173]  E. A. Kowaluk, P. Seth, and H. L. Fung, "Metabolic activation of sodium nitroprusside 
to nitric oxide in vascular smooth muscle," J. Pharmacol. Exp. Ther., vol. 262, pp. 916-
922, 1992. 
 [174]  Y. Yoshioka, a. Yamamuro, and S. Maeda, "Nitric oxide at a low concentration protects 
murine macrophage RAW264 cells against nitric oxide-induced death via cGMP 
signaling pathway," Br. J. Pharmacol., vol. 139, pp. 28-34, May2003. 
 [175]  I. D. G. Duarte, B. B. Lorenzetti, and S. H. Ferreira, "Peripheral analgesia and 
activation of the nitric oxide-cyclic GMP pathway," Eur. J. Pharmacol., vol. 186, no. 2, 
pp. 289-293, 1990. 
 [176]  F. Murad, "The nitric oxide-cyclic GMP signal transduction system for intracellular and 
intercellular communication," Recent Prog. Horm. Res., vol. 49, pp. 239-248, 1993. 
 [177]  E. Southam and J. Garthwaite, "The nitric oxide-cyclic GMP signalling pathway in rat 
brain," Neuropharmacology, vol. 32, no. 11, pp. 1267-1277, 1993. 
 [178]  A. Kyrola, G. Blelloch, and C. Guestrin, "GraphChi: Large-scale graph computation on 
just a PC," in Proceedings of the 10th conference on Symposium on Operating Systems 
Design & Implementation 2012. 
 [179]  J. C. Saeh, P. D. Lyne, B. K. Takasaki, and D. A. Cosgrove, "Lead Hopping Using 
SVM and 3D Pharmacophore Fingerprints," J. Chem. Inf. Model., pp. 1122-1133, 2005. 
 [180]  E. Cohen, J. Bieschke, R. M. Perciavalle, J. W. Kelly, and A. Dillin, "Opposing 
activities protect against age-onset proteotoxicity," vol. 313, no. 5793, pp. 1604-1610, 
2006. 
 [181]  T. Hidvegi, M. Ewing, P. Hale, C. Dippold, C. Beckett, C. Kemp, N. Maurice, A. 
Mukherjee, C. Goldbach, S. Watkins, G. Michalopoulos, and D. H. Perlmutter, "An 
autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and 
reduces hepatic fibrosis," Science, vol. 329, no. 5988, pp. 229-232, July2010. 
 [182]  S. Karve, M. E. Werner, R. Sukumar, N. D. Cummings, J. A. Copp, E. C. Wang, C. Li, 
M. Sethi, R. C. Chen, and M. E. Pacold, "Revival of the abandoned therapeutic 
wortmannin by nanoparticle drug delivery," Proceedings of the National Academy of 
Sciences, vol. 109, no. 21, pp. 8230-8235, 2012. 
 [183]  K.-D. Schultz, K. Schultz, and G. Schultz, "Sodium nitroprusside and other smooth 
muscle-relaxants increase cyclic GMP levels in rat ductus deferens," Nature, vol. 265, 
pp. 750-751, Feb.1977. 
 [184]  Hideaki Karaki, Koichi Sato, Hiroshi Ozaki, and Kazuyasu Murakami, "Effects of 
sodium nitroprusside on cytosolic calcium level in vascular smooth muscle," Eur. J. 
Pharmacol., vol. 156, pp. 259-266, Nov.1988. 
 219   
 [185]  Y. Yoshioka, T. Kitao, T. Kishino, a. Yamamuro, and S. Maeda, "Nitric Oxide Protects 
Macrophages from Hydrogen Peroxide-Induced Apoptosis by Inducing the Formation 
of Catalase," The Journal of Immunology, vol. 176, no. 8, pp. 4675-4681, Apr.2006. 
 [186]  M. H. Lee, M. H. Jang, E. K. Kim, S. W. Han, S. Y. Cho, and C. J. Kim, "Nitric oxide 
induces apoptosis in mouse C2C12 myoblast cells," Journal of Pharmacological 
Sciences, vol. 97, pp. 369-376, 2005. 
 [187]  H. j. Chae, H. s. So, S. w. Chae, J. s. Park, M. s. Kim, J. m. Oh, Y. t. Chung, S. h. 
Yang, E. t. Jeong, H. m. Kim, R. k. Park, and H. R. Kim, "Sodium nitroprusside 
induces apoptosis of H9C2 cardiac muscle cells in a c-Jun N-terminal kinase-dependent 
manner," International Immunopharmacology, vol. 1, no. 5, pp. 967-978, May2001. 
 [188]  H. J. Kwak, K. M. Park, S. Lee, H. J. Lim, S. H. Go, S. M. Eom, and H. Y. Park, 
"Preconditioning with low concentration NO attenuates subsequent NO-induced 
apoptosis in vascular smooth muscle cells via HO-1-dependent mitochondrial death 
pathway," Toxicol. Appl. Pharmacol., vol. 217, no. 2, pp. 176-184, Dec.2006. 
 [189]  C. Stefanelli, C. Pignatti, B. Tantini, I. Stanic, F. Bonavita, C. Muscari, C. Guarnieri, C. 
Clo, and C. M. Caldarera, "Nitric oxide can function as either a killer molecule or an 
antiapoptotic effector in cardiomyocytes," Biochim. Biophys. Acta, vol. 1450, pp. 406-
413, 1999. 
 [190]  M. Kuhn, D. Szklarczyk, A. Franceschini, M. Campillos, C. von Mering, L. J. Jensen, 
A. Beyer, and P. Bork, "STITCH 2: an interaction network database for small 
molecules and proteins," Nucleic. Acids. Res., vol. 38, no. Database issue, p. D552-
D556, Jan.2009. 
 [191]  S. Ayvaz, J. Horn, O. Hassanzadeh, Q. Zhu, J. Stan, N. P. Tatonetti, S. Vilar, M. 
Brochhausen, M. Samwald, and M. Rastegar-Mojarad, "Toward a complete dataset of 
drugÇôdrug interaction information from publicly available sources," Journal of 
biomedical informatics, vol. 55, pp. 206-217, 2015. 
 
 
